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ABSTRACT 
Gram negative and positive bacteria have evolved toxins to aid in their ability to 
colonize host organisms. Some gram-positive bacteria produce exotoxins called 
superantigens that hyper-stimulate the immune system by crosslinking the variable region 
of the beta chain (Vβ) of T cell receptors with the antigen presenting major 
histocompatibility complex II molecule on the surface of antigen presenting cells. This 
hyper-stimulation leads to overproduction of cytokines, which can result in toxic shock. 
In addition, the action of the superantigens has been implicated in many diseases 
including necrotizing pneumonia and endocarditis. Gram-negative bacteria produce 
lipopolysaccharide (LPS), also called endotoxin, as a major constituent in their outer cell 
walls. LPS binds to the host protein called MD-2 and the LPS:MD-2 complex associates 
with cell surface homodimeric Toll-like receptor 4 (TLR4). This tri-molecular interaction 
can lead to massive stimulation of cytokines from TLR4+ antigen presenting cells, 
resulting in endotoxic-mediated septic shock. This process has also been suggested to 
play a role in asthma. A lack of therapeutics for both exotoxin and endotoxin induced 
shock and implicated diseases, as well as an interest in further understanding these 
molecular interactions, guided my studies and development of high affinity agents to 
neutralize these toxins. 
In chapter two, directed evolution was used to engineer a high affinity antagonist 
against the superantigen Staphylococcal enterotoxin C3 (SEC3). I used a previously 
error-prone engineered Vβ against SEC3 as a starting template for further engineering. 
Yeast display was used to create two libraries in two different regions of the previously 
engineered Vβ to improve its affinity for SEC3. The mutations from the highest affinity 
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mutant selected from each library were combined to create a single mutant that had 
improved binding to SEC3 over either mutant. The highest affinity Vβ antagonist was 
tested and found to be effective in various rabbit models with SEC3 by the Schlievert 
laboratory.  
Chapter three describes the cross reactivity of the high affinity SEC3 antagonist 
described in chapter two, with allelic variants of SEC3 (SEC1, SEC2, and SEC4), as well 
as the highly homologous superantigen, Staphylococcal enterotoxin B (SEB). Residues 
potentially responsible for the cross reactivity with SEB were mutated and tested for 
binding to SEB and SEC3. The SEC4 secreting bacteria strain MW2 was used in 
necrotizing pneumonia and infective endocarditis rabbit models by the Schlievert 
laboratory that confirmed the in vivo ability of the antagonist to effectively neutralize 
more than one strain of SEC. 
In chapter four, MD-2 was expressed on the surface of yeast and shown to bind 
MD-2 specific monoclonal antibodies and to its ligands, LPS and TLR4. To test the 
platform, alanine mutants were engineered at residues identified from previous studies 
that tested for binding to LPS as well as TLR4. The alanine mutants behaved as 
anticipated based on the previously published literature. Based on the alanine mutant 
results, six yeast display libraries were engineered in MD-2 in these regions, and a 
seventh library was made using error-prone PCR. Ligand studies of the MD-2 mutants 
allowed identification and insight into the role of critical residues in MD-2 stability and 
ligand binding. 
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CHAPTER 1 
 INTRODUCTION  
 
Innate and Acquired Immunity 
Bacteria live within and around us in a delicate balance. The bacteria inside of us, 
specifically the bacteria in our gut, often plays a symbiotic function that can be altered by 
certain food intake, lack thereof, or antibiotics. Bacteria can break through our 
anatomical barriers of epithelial skin and mucus linings through lacerations in the skin, 
surgery, or spreading of infections such as pneumonia and appendicitis. The immune 
system keeps this balance in place and returns the balance if it is upset. Our bodies 
maintain the balance through the two branches of the immune system, innate and 
adaptive immunity.   
Innate immunity is considered a more “nonspecific” defense and includes such 
components as phagocytic cells and pattern recognition receptors (PRRs).  PRRs are 
located on the surface of immune cells to recognize and eliminate foreign organisms.  
Phagocytic cells include macrophages, neutrophils, and dendritic cells, which circulate 
through blood and tissues recognizing and ingesting microbes that bind to PRRs located 
on their surface (1). PRRs recognize common microbial surface structures that are not 
found on host cells. These targeted microbial structures include flagellin and components 
of pathogen cell walls, which are often essential to the survival of the pathogen. These 
common microbial structures, called pathogen-associated molecular patterns (PAMPs), 
bind to PRRs of innate cells thereby stimulating signaling pathways that lead to release of 
pro-inflammatory cytokines and, in some cases, phagocytosis of the microbe. There are 
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also soluble PRRs, such as mannose binding protein (MBP) and lipopolysaccharide 
binding protein (LBP) in addition to cell associated receptors, such as toll-like receptors 
(TLRs) (2). Because particular microbial patterns are sensed by PRRs, the innate immune 
system does not target all “non-self” antigens, but rather specific classes of microbial 
antigens. For instance, TLRs are able to recognize microbial lipids, carbohydrates, 
nucleic acids, and proteins. One of these PAMPs is lipopolysaccharide (LPS), also known 
as endotoxin, which is recognized by the TLR4. LPS and TLR4 will be further discussed 
below and is a topic of Chapter 4.  
Unlike innate immunity, adaptive immunity is able to respond more efficiently 
after each successive encounter with a microbe, and as such has also been referred to as 
acquired immunity. Adaptive immunity is considered more specific than innate 
immunity, and involves response times that are longer. Adaptive immunity is highly 
specific, highly diverse, and has the hallmark of memory. Memory is conferred by long-
lived B and T cells, the major cell types in the adaptive immune system, promoting a 
faster and stronger response upon secondary exposure to a pathogen.   
B cells recognize antigens via their surface antibodies, also called 
immunoglobulin (Ig), receptors. The Ig receptors are composed of four polypeptide 
chains, including two identical light chains and two heavy chains, with each containing 
one variable region domain and one (light chain) or more (heavy chain) constant region 
domain(s) (Figure 1.1A). The four chains assemble to form a ‘Y’ shape with each light 
chain linked to a heavy chain by a disulfide bond and the heavy chains linked to each 
other by disulfide bonds. Variable regions of the light and heavy chains each contain 
three hypervariable regions called complementarity determining regions (CDRs). Based 
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on proteolytic cleavage experiments, the region that recognizes antigen containing the 
entire light chain attached to the heavy chain variable region and first constant domain is 
known as the fragment antigen binding (Fab). The remaining heavy chain constant 
domains constitute the Fc fragment (because this fragment was found to be readily 
“crystalizable”).  Once antigen binds to the Ig receptors, B cells are activated, divide, and 
differentiate into memory and effector cells.  The effector cells include plasma cells, 
which secrete large amounts of soluble forms of the Ig receptor, known as antibodies.   
T cell receptors are heterodimers composed of a α and a β chain (or less often, a γ 
and δ chain). Each chain contains one variable (Vα or Vβ) and one constant (Cα or Cβ) 
region, structurally similar to the Fab fragment of the antibody (Figure 1.1B). The V 
regions recognize antigen and contain three CDRs, similar to B cell antibodies. The V 
regions also contain a fourth loop called the hypervariable (HV) region, but the function 
of this loop remains unknown. Like antibodies, the CDRs are positioned at the end of a 
series of beta strands that form the framework regions (FR). Each chain contains a 
transmembrane domain and the TCR associate with six different subunits of the signal 
transducing complex called CD3.  
Stem cells from the bone marrow migrate to the thymus where they differentiate 
into mature T cells for export to the peripheral lymphoid organs (e.g. lymph nodes). 
During differentiation, the TCR genes undergo rearrangement to generate a diverse 
repertoire with unique antigen specificities. T cells undergo a process called positive 
selection in which there is selection for TCRs that bind to peptide-MHC, followed by 
negative selection (tolerance) in which there is selection against TCRs that bind too 
strongly to self antigens. Negative selection helps to prevent the export of T cells that 
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induce autoimmune reactions in the host. Two main types of T cells emerge from this 
selection, T helper cells (TH) and cytotoxic T lymphocytes (CTLs). TH cells also express 
the co-receptor CD4 on their surface, while CTLs cells express the co-receptor CD8.   
αβ T cells recognize antigens as peptides presented by major histocompatibility 
complex (MHC) molecules on the surface of cells. There are two classes of MHC, I and 
II. Class II MHC is recognized by CD4+ TH cells, while class I MHC is recognized by 
CD8+ CTLs. MHC class I molecules are expressed on the surface of all nucleated cells, 
while MHC class II molecules are only expressed on antigen presenting cells (APCs), 
which include macrophages, dendritic cells, and B cells. MHC class I molecules are 
composed of an α chain (domains α1, α2, and α3) and a noncovalently associated 
subunit, β2 microglobulin. The α1 and α2 domains form a peptide binding cleft that 
accommodates a peptide of 8 to 10 amino acid residues. MHC class I molecules usually 
display peptides that arise from the cytosol. If the peptide is foreign, an activated CD8+ 
CTL that expresses an appropriate αβ TCR that binds to it will be triggered to destroy the 
target cell. MHC class II molecules consist of a α (α1 and α2 domains) chain and β (β1 
and β2 domains) chain. The α1 and β1 domains form a cleft that accommodates a peptide 
of 10 to 30 amino acid residues. MHC class II molecules most often display peptides 
derived from extracellular sources, such as bacteria. When CD4+ T cells bind to an 
antigen peptide in the context of an MHC class II molecule, they release cytokines that 
help activate cells of both innate and acquired immunity. 
 
Activation of the Immune System by Microbes 
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Our immune system has evolved molecules and mechanisms in innate and 
adaptive immunity to identify and destroy foreign microbes. Though our immune system 
is under tight control, severe bacterial infections may lead to over-stimulation of our 
immune system, while other bacteria have evolved specific mechanisms that over-
stimulate our immune systems. For example, gram-positive bacteria produce toxins 
known as superantigens (SAgs) that usurp the important cellular interactions between Vβ 
and MHC class II molecules in our adaptive immune system by binding to these 
molecules and causing inappropriate cell activation and cytokine release. In the case of 
severe gram-negative bacterial infections, the bacterial LPS that is normally a signal of 
foreign microbes can hyperstimulate the innate system in a severe infection through 
TLR4 over-activation. The goal of bacteria is to multiply and by inducing dysregulation 
of the host immune system through these virulence factors, whether the function of the 
toxin or not, likely help the bacteria evade host defenses to reproduce. 
 
TLR4, MD-2, and LPS 
TLRs are type I transmembrane proteins that share a common structural motif. 
The extracellular region consists of repeating segments of 24-29 amino acids each that 
are known as leucine rich repeats with the motif xLxxLxLxx (L=leucine or isoleucine, 
x=any amino acid). The intracellular domains consist of Toll/IL-1 receptor (TIR) 
domains, which are involved in proximal signaling (Figure 1.2A). Despite their 
conserved intracellular and extracellular structures, the 10 human TLRs discovered to 
date collectively bind a wide range of microbial products from viruses, bacteria, fungi 
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and protozoa (3,4). The first TLR to be identified in humans was the 841 amino acid 
protein TLR4 (5).  
TLR4 binds to LPS in complex with the protein called myeloid differentiation 
factor 2 (MD-2). MD-2 is a 160 amino acid glycoprotein with an N-terminal secretion 
signal. It consists of two beta sheets forming a deep hydrophobic cavity (6). Crystal 
structures of MD-2 with LPS variants have aided in understanding how the two 
molecules interact. MD-2 was able to accommodate 5 of 6 acyl chains of LPS in its 
hydrophobic pocket, leaving the phosphorylated glucosamine backbone of the LPS 
extending from the pocket (7). MD-2 is essential for LPS-mediated activation of TLR4, 
as MD-2 deficient mice were unable to respond to LPS (8). 
LPS is found on the outer membrane of most gram-negative bacteria. It consists 
of the bacterial cell membrane-anchored toxic fatty acid (lipid A) common to all gram-
negative bacteria, a core oligosaccharide region, and a complex polysaccharide coat (O 
antigen) that varies among species (Figure 1.2B). Bacteria with an O antigen coat appear 
as smooth colonies and therefore this type of LPS is referred to as smooth-LPS. Bacteria 
with LPS that lacks the O antigen appear rough, and therefore are called rough-LPS. 
While the lipid A portion and phosphates of LPS are integral to binding MD-2 and TLR4, 
LPS both with and without O antigen are able to bind MD-2 (9). Only recently has the 
core oligosaccharide region of a single specific LPS strain been shown to play a role in 
MD-2 binding (10). The LPS produced by bacteria vary not only in presence or absence 
of the O antigen, but may also vary in phosphate patterns, number of acyl chains, and 
lipid A composition (4). 
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LPS Induced TLR4 Activation 
Although the molecular details of TLR4 activation are not yet completely 
understood, a recently solved crystal structure of the TLR4:MD-2:LPS complex has aided 
in the present model (7). LPS is delivered to TLR4 either through bacterial cell lysis or 
by removal from the surface of gram-negative bacteria by the soluble PRR called LPS 
binding protein (LBP). LBP catalyzes LPS delivery to cluster of differentiation 14 
(CD14) (Figure 1.3). LPS bound to CD14 (membrane bound or soluble) is then delivered 
to MD-2 (or MD-2 may first be bound to TLR4, and the LPS is delivered to this complex 
by CD14). The MD-2:LPS complex binds to cell surface TLR4, which is thought to 
dimerize with a second TLR4, thus forming a dimer of trimers when the TLR:MD-2:LPS 
complex is formed. As seen in other TLR structures, the two TLR4 molecules interact at 
the C-terminus with the N-termini directed away from each other. The ternary crystal 
structure indicated that not only are there direct contacts between TLR4 and MD-2, but 
also direct contacts between TLR4 and LPS (7). The dimerization is thought to be 
required for signaling through the TIR domain, leading to activation of transcription 
factors such as nuclear factor κB (NF-κB), and the release of inflammatory molecules 
such as IL-1 and TNFα. LPS introduced by bacteria in humans typically allows the innate 
system to control an infection, but systemic accumulation of LPS from a severe bacterial 
infection can cause an overwhelming hyper-inflammatory response known as systemic 
inflammatory response syndrome (SIRS), leading to septic shock.   
 
Bacterial Superantigens 
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Bacterial SAgs are exotoxins that activate T cells leading to massive cytokine 
release. Some SAgs can also be produced by viruses and mycoplasma. Bacterial SAgs are 
primarily produced by the gram-positive strains Staphylococcus aureus and 
Streptococcus pyogenes. There are more than forty different SAgs produced by these two 
species of bacteria and they are classified into five major groups I-V based on primary 
sequence homology (Figure 1.4)(11). Over 15 staphylococcal SAgs have been identified, 
including toxic shock syndrome (TSS) toxin-1 (TSST-1), the staphylococcal enterotoxins 
(SEs) A-E, G-J, S-T, and the staphylococcal enterotoxin-like toxins (SEl) K-R, and U 
(12,13). Enterotoxin-like toxins are so named because the enterotoxicity of these toxins is 
unproven. SAgs of S. pyogenes include the exotoxins SpeA, C, G-M, streptococcal 
superantigen (SSA), and mitogenic exotoxins (SMEZ) (14).  
SAg protein sizes range between 20-30 kilodaltons. These toxins share a general 
structure consisting of two globular domains (Figure 1.5). The C-terminal domain 
contains a β-grasp motif that is structurally similar to the Ig-binding motifs of 
streptococcal protein G and L. The OB-fold is a common protein fold found in other 
bacterial toxins, such as cholera toxin and pertussis toxin (15-17). The strong structural 
homology between SAg genes suggests that they evolved from each of these two 
domains (18). Also within the N-terminal domain is a flexible disulfide loop that is 
implicated in emetic activity (19). Despite their conserved structural homology, the SAgs 
possess a wide range of sequence homology. The most distant SAgs share less than 10% 
amino acid sequence identity. In contrast, the most similar, excluding allelic variants, are 
SEA and SEE which share 83% amino acid sequence identity (20). Several toxins are 
known to have allelic variants, including SEC, SEB, SpeA and SMEZ.   
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Though some SAg genes are chromosomal, the majority of SAg genes are located 
on mobile gene elements: pathogenicity islands (21), plasmids (22,23), transposons, and 
phages (24,25). Most streptococcal SAgs are carried by bacteriophages (26-28). 
Expression levels of different SAg genes varies, but they are often low under in vitro 
conditions. Genes that upregulate expression have been identified. For example, the 
expression of exotoxin S. aureus genes is controlled by the accessory gene regulator (agr) 
(29), which is activated by quorum sensing through localized high cell densities. Some of 
the SAgs shown to be under agr system regulation include SEB (30), SEC (31), and SED 
(23). The staphylococcal accessory regulator (sar) gene (32) has also been identified as a 
regulator of gene expression. The agr and sar systems are known to increase expression 
of most SAgs during the post-exponential phases (33). The agr system does not appear to 
play a role in SEA expression in S. aureus, and the toxin was expressed throughout the 
exponential phase of S. aureus growth (34).   
 
T Cell Activation by Superantigens  
The term ‘superantigen’ was given to these unique toxins because of their ability 
to stimulate an uncharacteristically large proportion of T cells (35). While conventional 
antigens may stimulate one in 10,000 T cells, SAgs are capable of stimulating up to 30 
percent of all T cells (1, 37, 38). SAgs can stimulate this high proportion of T cells 
because they bind the Vβ region of the T cell receptor (TCR), not the conventional VαVβ 
regions of the TCR (Figure 1.6). The high frequency of TCR binding and T cell 
stimulation is due to the fact that there are approximately 40 different Vβ regions in the 
human genome, and SAgs often bind to multiple Vβs (36). In contrast, classical antigens 
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require recognition mediated by the regions encoded by five variable element genes (Vβ, 
Dβ, Jβ, Vα, and Jα) of the TCR (37). Despite their highly conserved structural folds, 
SAgs have developed a variety of binding methods to both TCR and MHC class II 
molecules (38,39). Crystal structures of SAgs bound in complex with MHC class II, TCR 
Vβ domains, or both have greatly aided in understanding SAg induced T cell activation 
(38,39). The discussion below will focus on SEB and SEC as they are discussed in 
Chapters 2 and 3 of this thesis. 
Each SAg binds to one or to both of two independent binding sites on MHC class 
II molecules. There is a low-affinity site (KD~10-5M) on the more conserved MHC class 
II α1 chain and a high affinity (KD~10-7M), zinc-dependent site on the polymorphic β1 
chain (39,40). SAgs such as SEC3, SEB and TSST-1 (Figure 1.6B and D), bind 
exclusively to the low affinity α-chain, through the SAg N-terminal OB-domain (41-43). 
This interaction can be peptide dependent or independent. SEB and SEC3 bind 
independently of the peptide (44,45), while TSST-1 engages the MHC bound peptide 
(42). Unlike SEC and TSST-1, SEA binds to the high affinity site on the MHC class II β 
chain in addition to the low affinity site on the α chain (46). Still other SAgs such as 
SpeC, SpeH, and SEH bind exclusively to the β-chain (17,47,48) (Figure 1.6C). 
The extensive range of SAg diversity is also seen in their variable binding to 
TCRs. The affinities of SAgs for the Vβs are quite low, in the range of one to 100 
micromolar (40). This affinity is similar to that of a classical TCR:peptide:MHC 
interaction (49). SAg binding to TCRs does not possess as many variations in orientation 
as SAg binding to MHC, but the residue contact variation is extensive. The SAg interacts 
with the TCR by primarily binding to the Vβ domain of the TCR, resulting in stimulation 
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of a defined T cell repertoire dependent on which Vβs the SAg binds. There is great 
diversity in the number as well as which Vβs an SAg may bind. Even the two SAgs with 
highest sequence homology, SEA and SEE, bind different Vβ repertoires (20). The SAg 
binds the Vβ region between the N-terminal and C-terminal domains. Specific regions of 
the Vβ domain may contact the exotoxins; these include the CDR1, CDR2, hypervariable 
region 4 (HV4), and framework 3 (FR3) (50-53). These regions are seen as loops in 
crystal structures. The structures of many SAgs have been solved in complex with TCRs, 
including SEC, SEB, SpeA, SpeC, TSST-1, SEK, and SEH (54-60). Binding between the 
SAg and the CDR2 loop is a requirement for all bacterial SAgs, while varying selection 
in binding to other CDRs plays a role in Vβ specificity and cross-reactivity (38). The 
more extensive and residue specific the interactions between the SAg and Vβ, the more 
specific the Vβ repertoire. SEB and SEC for instance, engage in conformational binding 
dependent on the TCR backbone mostly interacting with CDR2, but also the HV4 loop 
(39). This allows these two SAgs to interact promiscuously with Vβs that may have great 
sequence variability, but maintain a conserved conformation. SEC3, for instance, 
interacts with human Vβs 12, 13.1, 13.2, 14, 15, 17, and 20 (61). 
Two different SAgs in ternary complexes with MHC class II and a TCR have 
been crystalized. Mycoplamsa arthritidis mitogen (MAM) was the first and the SAg SEH 
was the second (62,63). Though these crystal structures are informative, as discussed 
above, the orientation of binding of these SAgs to MHC and TCR differ from other SAgs. 
Hence, complexes have been modeled using individual SAg:TCR and SAg:MHC class II 
structures. SEC3, modeled in complex with mouse Vβ8.2 and HLA-DR1 (43), indicated 
that SEC3 acts as a wedge between the MHC class II and TCR (Figure 1.6B). This 
	   12	  
interruption causes the MHC:TCR to hinge open disrupting binding between the MHC α 
chain and the TCR β chain. This wedge interaction was also seen for SEB (39,41,64). 
Binding between the MHC and TCR are stabilized by the MHC β chain and Vα CDR2 
loop (65). This stabilization is likely what compensates for the weak interactions between 
SEC3 for MHC and TCR, as the MHC:SEC3:Vβ ternary complex was not measurable by 
surface plasmon resonance, while including the TCR Vα chain allowed a half-life 
measurement of 7.6 seconds for the MHC:SEC3:TCR (65). This ternary complex half-
life falls, in the range of MHC:peptide:TCR complexes (~1-60 seconds) (49).   
  
Bacterial Illness and Disease 
Bacteria are capable of causing a range of serious infections, dependent in part on 
the location. Bacteria can enter the bloodstream through compromised skin barriers such 
as lacerations of the skin (e.g. through surgery). Bacterial infections can also lead to 
colonization of secondary sites such as in pneumonia and appendicitis. There are 
approximately 750,000 cases of sepsis per year; 60% of the diagnosed cases are caused 
by gram-negative bacteria and the remaining 40% by gram-positive bacteria (66). Severe 
sepsis by either gram-positive or gram-negative bacteria can lead to septic shock. Septic 
shock leads to SIRS, vasodilation, intravascular coagulation, myocardial suppression, and 
multiple organ failure (11,67). The mortality rate from septic shock in intensive care units 
has been estimated to be 60% (68). Although the initial stimulus of cytokine release 
stems from adaptive immune responses for gram-positive bacteria and innate immune 
responses for gram-negative bacteria, the same manifestation of cytokine amplification 
and systemic dysregulation leading to septic shock is seen in both. 
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Diseases Associated With Gram-Negative Bacteria and LPS 
Septic shock caused by gram-negative bacteria is known as endotoxic shock. LPS 
from lysed bacteria or removed from bacteria cell walls by the endogenous protein LBP, 
is monomerized with the help of CD14, which delivers it to MD-2, finally forming a 
ternary complex with TLR4, LPS:MD-2:TLR4. Since LPS is an evolutionarily selected 
essential component of the outer membrane of gram-negative bacteria, it is not easily 
mutated to bypass TLR4 recognition. TLR4 activation by LPS releases cytokines such as 
IL-1 and TNF-α. These cytokines activate the innate immune system to destroy the 
foreign invaders, but when high levels of bacteria and therefore LPS are present, 
endotoxic shock and widespread vasodilation, hypoperfusion, and myocardial 
dysfunction occur often leading to death.   
TLR4 activation by MD-2 and LPS is also believed to play a role in asthma.  LPS 
has been shown to exacerbate asthma in humans (69), likely through the activation of 
TH2 cells and subsequent production of IgE and allergy related inflammatory cytokines 
(70). Low levels of LPS have been shown to induce TH2 cells, while high levels of LPS 
induce TH1 activation (71). In addition to MD-2 binding to LPS, the structurally 
homologous house dust mite allergen Derp2 has been shown to also bind LPS thereby 
potentially also having functional homology to MD-2 (72). Derp2 is implicated in asthma 
through molecular mimicry of MD-2 (73). Thus, MD-2 may provide adjuvant activity 
when LPS is present, activating TLR4 and allergen pathways.  
 
Diseases Associated with Gram-Positive Bacteria and Superantigens 
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Septic shock caused by gram-positive bacteria enterotoxins, such as 
Staphylococcus aureus and Streptococcus pyogenes, is known as toxic shock syndrome 
(TSS) (52). The symptoms of gram-positive septic shock were first reported as TSS in 
1978 by Todd et al (74). It was later determined that gram-positive bacteria cause these 
symptoms by exotoxin-induced overstimulation of the immune system, leading to a 
massive release of cytokines such as IL-1, IL-2, IL-6, interferon-γ (IFN-γ), and TNF-α 
(i.e. cytokine storm or cytokine avalanche). This over amplification of cytokines sends 
the immune system into dysregulation and the body into toxic shock. These exotoxins, 
accomplish this as described above, by stimulating T cells independently of the antigen 
specificity of the T cell (75).  
Staphylococcal TSS is classified into non-menstrual and menstrual associated 
TSS. Most cases of staphylococcal TSS are caused by the SAg TSST-1 (toxic shock 
syndrome toxin) (76,77). The finding that TSST-1 and SEB, but not SEA, were shown to 
efficiently transcytose epithelial mucosa may play a role in TSST-1’s ability to cause 
TSS (78). TSS came to public attention in the early 1980’s when the peak incidence of 
TSS was reported between 6.2 and 12.3 cases per 100,000 (79). In 1982, TSS 
development was associated with the use of high absorbency Rely tampons (80). The 
combination of removing Rely tampons from stores, decreasing absorbency of tampons, 
and the FDA requiring tampon labeling in 1982 contributed in a decline to 1 per 100,000 
cases by 1986 (79,81). Non-menstrual TSS can be caused by any staphylococcal 
infection. SAgs implicated in non-menstrual TSS include SEB, SEC3, and TSST-1 (82-
84). The mortality rate of non-menstrual infection is higher, around 5%, versus menstrual 
TSS with a mortality rate of 3% (79). Streptococcal TSS is usually caused by group A 
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streptococci (GAS) and is often secondary to GAS soft tissue infections. In 60% of cases 
the bacteria is identified in the blood, which is known as bacteremia (85). The mortality 
rate of streptococcus TSS is higher than staphylococcal TSS reaching up to 80% 
mortality rates in association with myositis (11). The SAgs SpeA and SpeC are both 
implicated in streptococcal TSS (86).   
SAgs are also responsible for many other illnesses and diseases. Staphylococcus 
is a common cause of food poisoning in the United States. Although the bacteria may be 
killed by heat or pH treatment, the toxins are resistant to these conditions (87). S. aureus 
can grow in a wide range of temperatures, pHs, and salt concentrations, enabling the 
bacteria to survive in many niches. Furthermore, 30-50% of the population are carriers of 
S. aureus, and thus can contaminate food if proper protocols are not followed (87). SAgs 
are known to be extremely potent pyrogens with potencies of picogram per ml 
concentrations (11,40). Thus, ingestion of even small amounts of toxin or toxin 
producing bacteria in food can result in the symptoms of food poisoning. These 
symptoms include nausea, vomiting, diarrhea, and abdominal cramping. The onset of 
staphylococcal food poisoning is often rapid, but short lived, resolving within 24-48 
hours. The mechanisms involved in the ability of SAgs to cause food poisoning are 
distinct from their ability to cause TSS and other diseases (19,88,89). 
In addition to food poisoning, SAgs can cause necrotizing pneumonia, which may 
involve airway inflammation, permanent airway destruction, and mortality (90,91). These 
exotoxins are also implicated in the pathophysiology of nasal polyps, which can lead to 
chronic severe inflammatory airway disease, and have even been implicated in the 
pathogenesis of asthma (92-94). The pathogenesis of these SAgs may be further 
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enhanced by the presence of IgE antibodies to S. aureus exotoxins in nasal polyp tissue 
(95). S. aureus has also been linked to heart diseases and the exotoxins have been 
specifically implicated in rheumatic heart disease (RHD) and Kawasaki Disease (KD) 
(96), the two leading causes of acquired heart disease in children and young adults of the 
developing world. This is especially important since KD is increasing in frequency (97). 
The major causes of death in patients who suffer from these diseases involve the 
cardiovascular system, including symptoms of congestive heart failure, myocarditis, 
dilated cardiomyopathy, ischemic heart disease, coronary artery aneurysms, myocardial 
infarction and vasculitis (98-100). In addition to S. aureus being the leading cause of KD 
and RHD, it has been cited as the third leading cause of endocarditis, accounting for 20% 
of cases in one hospital based study in the US (101). The development of a mouse model 
of KD has further supported the hypothesis that this disease is caused by exotoxins (102). 
It should also be noted that these exotoxins are implicated in numerous autoimmune 
disorders including diabetes mellitus, multiple sclerosis, and rheumatoid arthritis, as well 
as other abnormal immunologic states such as psoriasis, and atopic dermatitis (40,103). 
Another gram-positive bacteria that secretes SAgs, S. pyogenes, has also been implicated 
in several cardiovascular and pulmonary diseases (104).  
 
Treatment and Therapeutics 
Antibiotics and Antibiotic Resistance 
The first treatment given to patients with a bacterial infection are antibiotics. The 
goals of administering antibiotics are to prevent bacterial growth or to directly kill the 
organisms. Yet, even if the bacteria are killed, endotoxin or exotoxin may still be present 
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at toxic levels since conventional antibiotics cannot eliminate these molecules. In 
addition, some antibiotics may even cause an increase in the release of LPS by promoting 
the lysis of bacterial cells. Furthermore, there is at least one known mechanism of 
resistance for each existing class of antibiotics, indicating that current antibiotics alone 
will not adequately address the problems associated with bacterial infections, including 
toxins (105). Despite the obvious need for novel antibiotics, the FDA approved only five 
new antibiotics between 2003 and 2007, and two new antibiotics between 2008 and 2011 
(106). Antibiotic resistance is a concern for both gram-positive and gram-negative 
bacteria. 
The emergence of methicillin-resistant Staphylococcus aureus (MRSA) since the 
1960’s has further complicated its treatment (107). MRSA was historically associated 
with exposure to hospital and healthcare associated (HA-MRSA) risk factors such as the 
young or immunocompromised, but there has recently been an increase in MRSA cases 
identified in persons without healthcare associated risk. These cases, called community 
associated MRSA (CA-MRSA), may be on the increase due to the prevalence of MRSA 
in the population (e.g. a recent study identified, for every patient in whom MRSA is 
identified in a clinical specimen, up to ten additional patients are carrying the pathogen 
asymptomatically (108)). Vancomycin, known as the drug of ‘last resort,’ has 
effectiveness against MRSA, but in the last decade vancomycin-resistant Staphylococcus 
aureus (VRSA) has been identified (109-111). Although the number of cases are still 
low, twelve in the United States since 2002 (112), there has been an increase in the 
number of MRSA isolates that have higher vancomycin minimum inhibitory 
concentrations (MIC). Patients infected with these MRSA strains have poorer outcomes 
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than when treated with vancomycin against MRSA isolates with lower MICs (113). This 
emergence of resistance to antibiotics is of great concern and emphasizes the need for 
novel treatments and antibiotics. 
There has also been an increase of infections caused by gram-negative bacteria 
since the late 1950’s, especially in hospitalized patients (114). Antibiotic resistant strains 
of gram-negative bacteria are also increasing in number. Based on incidence of 
morbidity, mortality, and multidrug resistance, the following gram-negative bacterial 
strains were identified by the Antimicrobial Availability Task Force as high-priority 
pathogens: Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacteriaceae 
(115). In addition, multidrug resistant gram-negative bacteria have been identified in 
many studies. In surgical patients with gram-negative infections, Pseudomonas and 
Acinetobacter were the most common pathogens identified (116). An increase in certain 
classes of drug resistant gram-negative bacteria such as class C β-lactamases that 
hydrolyze a broad spectrum of antibiotics has also been observed (117).  
An antimicrobial that is being pursued in clinical trials is polymyxin B. It acts by 
disrupting bacterial cell membranes and binding to the lipid A portion of LPS, thus 
inactivating the endotoxin (118). Although polymyxin B is protective in sepsis models, it 
is also toxic to the kidneys, complicating its use in patients (119). In an attempt to 
circumvent the toxicity, polymyxin B has been used by immobilization on a column 
followed by passage of a patient’s plasma to remove LPS. Animal trials (rats and dogs) 
have been successful, with increased survival in the later of 83% versus the control 
12.5% when challenged with E. coli (120,121). This method of LPS removal has been in 
use in Japan since 1994, yet clinical trials thus far have shown variable results. One 
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clinical trial from 2005, showed no statistical difference in survival (28% versus 29%), 
although the trial was not powered to detect differences in mortality (122). A more recent 
clinical trial in 2009 showed more positive results with a 28-day mortality of 53% for the 
control group and 32% in the polymyxin B group (123). Although there are many 
antibiotics in the pipeline for MRSA, there are few for gram-negative bacteria and most 
do not have novel mechanisms of action, perhaps indicating that they will be subject to 
the same challenges of emerging resistance as are current antibiotics (115).   
Exotoxins have been identified in MRSA isolated from infected patients 
(124,125), and enterotoxin genes have been found to be carried by VRSA strains (112). 
MRSA strains of greatest concern include strain USA 200 that produces TSST-1, 
USA300 that produces SE-like Q and a new SAg called SE-like X (126), and USA400 
that produces SEB and/or SEC3. SAgs have been shown to contribute directly to severe 
lung infection caused by CA-MRSA (126).   
 
Therapeutic for Bacterial Infection and Toxins: IVIG 
The main treatment for acute bacterial infections consists of antibiotics and 
symptom focused supportive therapy including fluids, blood transfusion, vasopressors to 
treat low blood pressure, and organ support (127). One adjuvant therapeutic for 
endotoxins and exotoxins has been intravenous immunoglobulin (IVIG) (128-130). IVIG 
consists of pooled polyvalent, polyspecific IgG isolated from plasma from donors; among 
the immunoglobulins, there may be antibodies that bind to bacterial cell wall components 
and SAgs. 
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Most individuals have some antibodies to SAgs, but studies have shown that a 
lack of circulating protective antibodies against staphylococcal and streptococcal SAgs is 
a key risk factor for TSS (131,132). Similarly, studies with LPS have shown a correlation 
between circulating antibodies to LPS and reduced morbidity and mortality (133,134). 
IVIG was shown to neutralize SAg activity in both S. aureus as well as GAS isolates 
(135). The same study showed that IVIG was able to inhibit streptococcal SAgs more 
effectively than staphylococcal SAgs, leading to the hypothesis that higher amounts of 
IVIG may be necessary to treat staphylococcal infections (135). Despite some variability 
among studies, IVIG treatment for sepsis and septic shock is generally regarded to have 
some benefit (136).   
IVIG is not an ideal treatment as it requires high doses (1-2gms/kg body 
weight/day), its efficacy is effected by variability of antibody titers dependent on 
preparation and lots, it has a high cost, and a limited supply (137,138). The advantage of 
IVIG is that it has broad application to treat diverse bacterial infections but specific toxin-
targeted therapeutics might prove to be more effective and provide a more widely 
available source than with IVIG.   
  
Active Immunization 
 Vaccination against some toxins has been used for decades and has been highly 
effective. Toxoids are bacterial toxins whose toxicity has been inactivated by chemical 
treatment, heat treatment, or mutations, while their immunogenicity is maintained. 
Successful toxoids used as vaccines against bacterial toxins include pertussis, diphtheria, 
tetanus, and cholera. The toxoids are used as vaccines against toxins because they are 
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capable of inducing an immune response that allows for the formation of memory B cells 
against the toxin without resulting in illness.   
 
Vaccination Against Superantigens 
Toxoids have been effective for the toxins listed above, but SAgs represent a large 
family with varying levels of homology. Due to this variation, it is unlikely that a single 
toxoid would be effective against most of the SAgs. SAgs of concern due to presence in 
MRSA strains, as well as their prevalence in TSS cases, include SEB, SEC3, and TSST-1 
(82-84). In addition, these SAgs appear to be expressed at much higher transcriptional 
and translational levels than other SAg genes (139). Toxoids have been created against 
multiple staphylococcal SAgs including SEA (140,141), SEB (142-144), SEC (145,146), 
TSST-1 (147-149), as well as streptococcal SAgs SpeA (150,151) and SpeC (152).   
Most toxoids are made by chemical methods, such as formaldehyde, or heat 
inactivation of the toxins. In the case of SAgs, treatment with formaldehyde leads to loss 
of emetic and diarrhea inducing properties, but not complete loss of superantigenicity 
(153,154). Therefore, SAg toxoids have been generated by mutating residues in the MHC 
and/or TCR binding regions. These vaccines were found to be effective in animal models 
that included mouse, pig, rabbit, rhesus monkey, and even cow (in the vaccination of the 
SAg SEC, which causes bovine mastitis) (145). Despite the proven efficacy in some 
animal models, there is risk in human use of these vaccines as animal models may not 
accurately predict potential side effects. Mice MHC for instance, have much lower 
affinities for SAgs than human MHC alleles (155). Also, due to polymorphisms in MHC 
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class II in humans, SAg toxoid mutations in MHC binding regions may pose particular 
risks in individuals with different MHC alleles.   
An SEB vaccine, STEBVax, completed its phase I clinical trials March 2014 and 
the study results are not yet available. STEBVax is a toxoid with mutations in the MHC 
II binding domain of SEB. It was tested in non-human primates and three doses of 20µg 
of the recombinant SEB were required for 100% protection when challenged 6 weeks 
after vaccination with aerosolized SEB (142). The estimated incapacitating dose of SEB 
by aerosol exposure (or ED50) for humans is 0.0004µg/kg and the estimated lethal dose 
(or LD50) is 0.02 µg/kg (156). Testing effectiveness by a pulmonary route is appropriate, 
as pulmonary physical protection is challenging and aerosol versions of SAgs may 
threaten to incapacitate large populations. SAgs are listed as bioterrorism category B 
(second highest priority after category A) agents as defined by the Centers for Disease 
Control and Prevention (157). Vaccines against SAgs of greatest concern such as SEB, 
SEC3, and TSST-1 may be reasonable and useful for individuals at risk of exposure such 
as military or hospital personnel. Widespread adoption of such a vaccine may be more 
difficult, and thus development of effective therapeutics for only those patients verified to 
have the corresponding SAg-positive S. aureus infection may be more useful. 
 
Active Vaccination Against LPS 
 J5 is a mutant strain of E. coli 0111:B4 that lacks its O-antigen. Immunization 
with heat killed J5 bacteria, or antisera elicited by the vaccine, induced protection in 
animal models (158). One study using anti-J5 intravenous IgG found no reduction in 
mortality in patients with gram-negative induced septic shock and another study showed 
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that a pooled anti-J5 sera given as prophylactic treatment to prevent sepsis in patients 
undergoing surgery was also ineffective (159,160). Subsequent studies in rats with J5 
anti-sera found that affinity purified IgG antibody was highly protective, and that 
protection was related to the amount of antisera administered (161). Due to reactogenicity 
findings for the whole bacteria vaccine (162), J5 LPS was purified from bacteria as well 
as detoxified by de-O-acylation (dLPS) (163). A vaccine consisting of detoxified J5 LPS 
and the adjuvant outer membrane protein (OMP) from group B meningococcus was 
developed, and this progressed to phase 1 clinical trials (164). Although the vaccine was 
safe, the initial response was modest, with only a 3-4 fold increase in antibody levels over 
baseline. Furthermore, there was a lack of response to repeated vaccination at 12-months 
(165). These findings indicated that this vaccine will likely only be applicable to those at 
high risk, such as individuals undergoing surgery. The J5 dLPS/OMP vaccine in 
combination with synthetic oligodeoxynucleotide containing an unmethylated CpG motif 
to boost immune response was in phase I clinical trials, but the trial was terminated in 
2013 (166).   
A number of LPS vaccines have shown promising results in animal studies, but 
they have not proceeded to clinical trials. Recently, an oral LPS vaccine was studied in 
mice. It was found to significantly increase survival to 87% versus 50% in control mice 
(167). Another study used a mutant of the rough form of LPS from Pseudomonas 
aeruginosa and found that it was 100% protective when challenged with P. aeruginosa 
wild-type strain if the immunizing dose was given 3 times in 50ug/mouse doses (168). A 
third study encapsulated LPS with liposome, which reduces the toxicity of LPS. Chickens 
immunized with this agent produced anti-LPS antibodies and the vaccine was protective 
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against E. coli challenge (169). Additional experiments are required before these vaccines 
proceed to human trials.  
 
Immunosuppressants and Cytokine Antagonists 
Once the host has interacted with microbes and their exotoxins or endotoxins 
there is widespread activation of the immune system leading to release of pro-
inflammatory cytokines as well as other molecules. Accordingly, one therapeutic 
approach has been to inhibit these cytokines and thus their cascade. This strategy is 
challenging as there are multiple cytokines produced as well as multiple signaling 
pathways. Strategies have included antibodies targeting cytokines and anti-inflammatory 
molecules. 
One strategy consists of using antibodies against the key cytokines involved in 
inflammation: TNF-α, IFN-γ, and IL-1. TNF-α is a critical mediator of septic shock and 
has been shown to be involved in lethality of TSS (170-174). Administration of anti-TNF 
monoclonal antibodies (mAbs) to baboons protected against gram-negative sepsis, but 
only if administered two hours before the live bacteria (175). Several clinical studies for 
sepsis have tested TNF-α mAbs including the antibody afelimomab and the mAb Bay 
times 1351, but without a statistically significant improvement in survival (176,177). In 
addition to TNF-α mAbs, soluble TNF-α receptors which bind to TNF-α have also been 
studied in sepsis models. Despite effectiveness in gram-negative and gram-positive 
animal models of sepsis (178,179), human studies with soluble TNF receptors failed to 
show significant improvement in survival and in some studies even resulted in an 
increase in mortality in comparison to control subjects (179,180).  
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Several human clinical studies have examined IL-1 receptor antagonists, and 
although there was a trend for increased protection as seen for other cytokine antagonists, 
none of the results were statistically significant (181-183). Another set of 
immunosuppressant studies used high dose steroids in order to suppress the immune 
system that becomes dysregulated during sepsis. This method proved unsuccessful in 
several clinical trials and even worsened outcomes in some studies for those with renal 
dysfunction (184,185). Interestingly, subsequent clinical trials showed a benefit with low-
dose corticosteroids (186,187). 
Cytokine antagonists have also been used in SAg models of toxic shock. Use of 
TNF-α antibodies V1q and TN3-19.12 for passive immunization resulted in 100% 
survival when delivered before the SAg SEB (172,188). Only TN3-19.12 was tested for 
protection when administered following the SAg, and this resulted in no survival benefit. 
Antibodies against IFN-γ failed to protect mice from the effects of SAg activation 
(188,189). It is important to note that these studies used the D-galactosamine sensitized 
murine model that amplifies the lethal effects of TNF. Although useful and has proven 
informative in many experiments, there are other more biologically relevant animal 
models, as mice are much more resistant to the effects of SAgs than rabbits or humans 
(190).   
SAg induced cytokine proliferation has been inhibited by several drugs including 
some antimicrobials that are believed to have anti-inflammatory properties independent 
of their antimicrobial function. Some of these drugs that were tested in vitro include the 
antibiotic doxycycline (which was tested in an in vivo mouse endotoxin model and found 
to be effective) (191,192), chlorogenic acid (193), the oxygenated diterpene triptolide 
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derived from a Chinese medicinal herb (194), and the antimicrobial tigecycline (195). 
There are several drugs that have been tested in vitro and in vivo in murine models 
against SAg induced septic shock. The anti-inflammatory dexamethasone resulted in 86% 
mouse survival against SEB (196). Pentoxifylline is an anti-inflammatory agent that 
inhibits endotoxin induced released of TNF-α (197). In a SAg induced septic shock 
model it significantly increased the survival rate against SEB (80%) and TSST-1 (100%) 
(198). However, if pentoxifylline was administered 4.25 hours after the SAg, mice were 
not protected. A third drug, pirfenidone, showed 100% survival if administered within 3.5 
hours of the SAg SEB (199). All three of these drugs used an LPS-potentiated murine 
model of SAg induced shock and also showed reduced levels of serum pro-inflammatory 
cytokines TNF-α, IFN-γ, and IL-1. Another drug, rapamycin, has also been shown to 
protect mice in an SEB induced toxic shock model (200). The mouse model consisted of 
a ‘two-hit’ model where two low doses of SEB were administered, one intranasally and 
the second SEB dose 2 hours later intraperitoneally. In this study, 100% survival was 
observed even when rapamycin was administered 24 hours after SEB, but decreased to 
20% by 32 hours. This study also showed in vitro reduction of pro-inflammatory 
cytokines TNF-α, IFN-γ, and IL-1. Several of the above described drugs, including 
rapamycin (200), dexamethasone (196,201), and pentoxifylline (198), that showed 
potential in blocking SAg mediated cytokine activation, are approved by the FDA for 
treatment of other indications. Pirfenidone, which also showed potential in blocking SAg 
cytokine activation, is approved in Europe and presently in multiple clinical trials in the 
United States (202). These drugs have potential for safe clinical use as they have already 
been in use for many years and have established safety records.   
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One drawback to targeting cytokines is that once they are released their signal is 
amplified rapidly, quickly leading to release of other cytokines and small molecules. 
Hence, targeting specific cytokines may leave others free to continue the amplification 
signal. Furthermore, suppression of certain mediators are known to have negative effects 
on the immune system as some of the studies resulted in an increase in mortality due to 
patients becoming susceptible to other pathogens (180). A further drawback of cytokine-
directed therapeutics is that they do not target the upstream cause of the cytokine 
activation. In the case of exotoxin or endotoxin activation, the toxins will continue to 
activate the immune system until they are removed from the system. 
 
Monoclonal Antibodies 
 Monoclonal Antibodies Targeting LPS, TLR4, and MD-2 
LPS mAbs for the purpose of treating or preventing sepsis have targeted the 
different components of LPS including the toxic lipid A, the core region, or the O-
antigen. It is important to note that like SAgs, the presence of circulating antibodies to 
LPS was found to be an important factor in survival from sepsis (133,134,203,204). Anti-
lipid A mAbs were developed by two biotechnology companies, the mouse monoclonal 
E5 by Xoma and the human monoclonal HA-1A by Centocor. Both mAbs were tested in 
clinical trials of sepsis, but no significant improvement in survival was found for either 
(205-210). Among other possibilities, the mAbs may have been unsuccessful because the 
lipid A portion of LPS is buried within the outer membrane of gram-negative bacteria or 
bound by MD-2 and therefore may not be accessible to antibodies. Another mAb, WN1 
222-5, was developed against the core regions of LPS. The murine mAb was reactive 
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against many different gram-negative bacteria including all clinical isolates of E. coli 
tested, and some species of Citrobacter, Enterobacter, and Klebsiella (211). The mAb 
WN11 222-5 has since been developed into a human chimera version SDZ 219-800 and 
was protective in a murine D-galactosamine-sensitized mouse model of sepsis, but it was 
unable to provide protection in a peritonitis model (212). This mAb has not entered 
clinical development. The third region of LPS consists of the O-antigen and is the most 
variable of the three regions, varying dramatically between species. Due to the large 
number of gram-negative bacteria, it seems impractical to create directed monoclonal O-
antigen specific antibodies against each. Despite this hurdle, several vaccines have been 
designed targeting the O-antigen due to its lack of toxicity (213-215). 
Rabbit antibodies were elicited against the ectodomain of TLR4 by fusing the N-
terminal portion of mouse TLR4 ectodomain to the Fc domain of human IgG1 (216). The 
anti-TLR4 antibodies inhibited LPS and gram-negative bacteria both in vitro and in vivo. 
One of their in vivo experiments consisted of injecting E. coli at a low (2x105 colony 
forming units, CFU) and high (2x109 CFU) innocula. At the high inoculum, when the 
anti-TLR4 antibodies were injected 1 hour after the bacteria, survival was 30% versus 
10% for the control. The low inoculum had improved results with 75% survival if treated 
with anti-TLR4 antibodies up to 13 hours after the bacteria versus 30% survival for the 
control (216). Another group developed a TLR4 antibody by fusing the extracellular 
portion of mouse TLR4 with mouse MD-2 linked to human IgG Fc fragments (217). The 
antibody was able to significantly block LPS mediated IL-6 production in vitro. Neither 
of these antibodies has been humanized and thus further development is required before 
clinical evaluation. 
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There have been several TLR4:MD-2 antibodies tested in vitro and in vivo as 
inhibitors of endotoxemia. The mAb 5E3 was selected from greater than 500 hybridoma 
clones screened from rats immunized with a soluble mouse TLR4:MD-2 fusion protein in 
combination with TLR4:MD-2 transfected CHO or HEK293 cells (218). In vivo it was 
found to reduce proinflammatory cytokine release as well as protect mice from lethal 
LPS induced endotoxemia. If the mAb 5E3 was administered within 4 hours of the lethal 
dose of LPS, survival was 100%; after 7 hours, survival was 40%, and after 8 hours there 
was no protection (218). Another mAb Sa15-2, also designed against mouse TLR4:MD-
2, was shown to protect D-galN sensitized mice if given in high enough doses within 2 
hours of LPS administration (219). One of the problems with these mAbs and other MD-
2 antibodies that have been developed, is that they are against mouse MD-2, not human 
MD-2. A group has generated eleven mAbs to human MD-2, but these antibodies have 
not progressed into studies beyond one of the mAbs being used for detection of MD-2 in 
sera of sepsis patients (220). 
Antibodies to CD14 and LBP, the other molecules that interact with LPS before it 
binds to TLR4 and MD-2 have been generated. An anti-mouse LBP antibody was able to 
protect mice from LPS/D-galN induced endotoxic shock (221). Another murine anti-LBP 
antibody was developed by another group and was able to protect LPS challenged mice 
when the mAb was administered at the same time, but failed to protect if given only 15 
minutes after LPS (222). Several anti-CD14 mAbs have been developed and these 
yielded partial protection in rabbits and primates as well as in humans (223-226). The 
most promising anti-CD14 mAb is IC14 and it was tested in a phase I sepsis clinical trial. 
The mAb did not decrease mortality in comparison to a placebo, but the sample size was 
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small (227). A phase II clinical trial using mAb IC14 in sepsis and pneumonia treatment 
to determine efficacy has been completed, but results have not been released. 
  
Monoclonal Antibodies Targeting Superantigens  
 Monoclonal antibodies have been developed for several SAgs (228-231), and 
many have also been studied in SAg animal models. One study generated mouse mAbs 
against TSST-1 and used a rabbit model with a pump to continuously administer SAg, 
thus mimicking bacterial infection. They found that mAb 8-5-7 prevented death in 6 of 7 
rabbits, while only 1 of 7 control rabbits survived (232). The antibody was later tested 
with the same model except an S. aureus strain that secreted TSST-1 was used. Passive 
immunization with the antibody was found to protect 5 of 5 animals while 0 of 3 survived 
without the antibody (233). Most animal models have focused on TSS, but one study 
used a mAb to prevent TSST-1 induced arthritis in a mouse model. The panel of 7 mAb 
failed to prevent S. aureus induced arthritis (234).  
 As described above, a potential drawback is that most of these antibodies were 
developed in mice or other animals and therefore require further engineering to be 
humanized for human use. Recently, there have been several human or murine-human 
chimeras engineered. A murine-human chimeric antibody called HuMab-154 was 
developed against SEB with an affinity for SEB of 0.29nM (235). It was also found to 
cross-react with SEA, SEC1 and SED based on ELISA experiments. Although it was able 
to protect mice in vivo when administered prior to administration of SAg, only 13% 
survival was observed when the mAb was administered 1 hour post exposure. Another 
group designed human chimeric antibodies from mouse antibodies that bound to spatially 
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distinct regions of SEB; when used in combination, these mAbs acted synergistically in 
their ability to inhibit SEB in vitro (236). The affinity of these antibodies were also in the 
subnanomolar range, and in vivo testing showed that preincubation of SEB with either 
mAb resulted in 66% survival, while 100% survival was seen when both mAbs were 
administered (237). The group also demonstrated a combination treatment of their 
antibodies with other therapeutics. They used the same mouse model and administered a 
single mAb in combination with the anti-inflammatory drug Lovastatin, which protected 
100% of mice. Another group selected human monoclonal antibodies from a phage-
display library using the recombinant SEB vaccine (STEBVax described above in 
vaccines) (238). The mAbs were shown to cross react with the homologous SAgs SEC1 
and SEC2. Although the mAbs were effective in vitro, even with preincubation of the 
mAb and SAg, the best mAb only protected 68% of mice in an SEB-mediated toxic 
shock model. 
 Although the mAbs discussed above show some promise, there is also a concern 
that mAbs may present SAg to T cells via Fc receptor interactions, thereby contributing 
to excessive activation (232,239,240). This phenomenon has only been described in vitro 
and it is unclear whether it would occur in vivo. Another hurdle is that mAbs are selected 
against a single SAg. While cross-reactivity for other SAgs has been described, the 
affinities are often reduced and effectiveness has not been tested in vivo. Furthermore, the 
humanized mAbs thus far engineered were all engineered for SEB binding. There are 
many other SAg targeted mAbs that still require humanization or development. Finally, 
as discussed elsewhere, it is important to use the appropriate animal model for in vivo 
efficacy studies. 
	   32	  
 
Toxin Peptide Antagonists 
LPS Peptide Antagonist 
Cathelicidins are antimicrobial peptides that play a role in mammalian innate 
immunity (241). LL-37 is the C-terminal portion of the human cathelicidin known as 
human cationic antimicrobial protein. It has a wide variety of functions, but the most 
important in regard to gram-positive and gram-negative bacteria are its antimicrobial 
activity and its ability to inhibit LPS activity. LL-37 performed comparably to polymyxin 
B in vivo in a rat model of gram-negative sepsis, with the advantage of not being toxic 
(242). Due to the many roles LL-37 plays in the immune system it is the focus of 
numerous clinical studies, but none of them involve LL-37’s ability to neutralize LPS. 
 
Superantigen Peptide Antagonist 
Neutralization of SAg activity has generally been achieved with mAbs by 
inhibiting their binding to the cellular receptors, the MHC class II molecule and/or the 
TCR. Peptides were designed based on a conserved SAg region consisting of SEB 
residues 150-161 by one group and residues 113-124 by another group (243-245). 
Although this region does not contact the TCR Vβ or MHC, the peptides were tested for 
in vivo efficacy in a D-galactosamine sensitized mouse model of septic shock, or a ‘two-
hit’ mouse model in which D-galactosamine and LPS are administered. In these models, 
both peptides were found to inhibit the activities of several SAgs, and one of the peptides 
was effective even when administered three hours after SAg (244). The mechanism of 
action of these peptides was unknown, although it was hypothesized that the peptide 
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interferes with SAg binding of a co-receptor that is required for cell activation. However, 
a later study failed to reproduce the work, showing that both peptides were unable to 
inhibit SEB in vitro or in vivo in a HLA class II transgenic mouse model (246). Recently, 
another peptide that inhibited SAgs SEA, SEB, and SEC was identified (247), and shown 
to be effective in the ‘two-hit’ LPS and D-galactosamine sensitized mouse model.  The 
explanation for the differences in these studies, and the molecular mechanism of 
inhibition remain to be determined.  
 
Soluble Receptors as Potential Therapeutics for Exotoxins  
There are various examples of soluble receptors that have shown efficacy by 
inhibiting the binding of a ligand to the cognate membrane receptor. These include a 
soluble TNF receptor that reduces TNF-mediated inflammatory reactions (248,249), a 
soluble CD4 receptor as a therapy for HIV-1 infection (250), a soluble B lymphocyte 
receptor that suppresses the immune system in vivo (101), a soluble antagonist against IL-
15 to treat inflammatory arthritis (251), and finally a soluble receptor antagonist against 
anthrax toxin (252,253).  
The strategy our laboratory has taken is to engineer high affinity TCR Vβs against 
the SAgs (35,55,254). By using the Vβ as our antagonist, we directly compete with the 
Vβs found on TCRs that the SAg binds. The engineered Vβ therefore blocks the SAg’s 
binding to host TCR Vβs, preventing SAg ‘presentation’ as was a concern in some mAb 
studies. The dissociation constants (KD) for SAgs with its respective Vβ chain are of low 
affinity, in the micromolar range (50,53). This low dissociation constant requires that to 
be used as a soluble neutralizing agent, the Vβ must be engineered to have considerably 
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greater affinity for the SAg. Our laboratory has engineered Vβs with improved stability 
and solubility, as well as higher affinity mutants against multiple SAgs using yeast 
display (discussed below) to screen libraries.  
SEC3 was the first SAg that our laboratory engineered a TCR against. Error prone 
PCR was used to create a random library in TCRs, which was screened for higher affinity 
binders using the TCR Vβ high affinity SEC variant SEC3-1A4 (35). Clones were 
selected, tested for SEC3-1A4 binding, and sequenced. More than half (8 of 14) clones 
were truncated consisting of only the Vβ portion of the TCR. These clones also had 
higher levels of surface expression than the full-length TCRs. The truncated Vβ was used 
in a second round of random PCR mutagenesis yielding seven unique sequences. 
Mutations from several mutants were combined to yield L2CM with a KD of 
approximately 10nM (35). The high-affinity soluble Vβ L2CM was able to neutralize 
SEC3 in vitro, while the wild-type Vβ was unable (35). Though the Vβ L2CM was able 
to neutralize SEC3 in vitro, based on evidence with Vβ mutants against SEB, its affinity 
was judged to be too low to be optimal in the neutralization of SEC in rabbit models (55).  
We have also engineered high affinity single-chain TCR Vβ domains against 
other SAgs including D10 against TSST-1 (254), G5-8 against SEB (55), and KKR 
against SpeA (255). All of the Vβs first required random PCR mutagenesis to stabilize 
expression of the Vβ on the surface, followed by engineering of the Vβ hypervariable 
regions, such as the CDR loops that bind to SAgs. In addition to engineering a Vβ against 
a single SAg, single-chain tandem Vβs to neutralize two SAgs (256), as well as 
nanomolar SAg cross-reactive Vβs have been developed (255). 
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Another group designed an inhibitor that binds to two distant functional sites of a 
SAg. The chimera is composed of the DRα1 domain of the MHC class II molecule linked 
via a flexible linker to the Vβ domain of the T cell receptor (257,258). The group 
engineered these bi-specific chimeras against SEB, SEC3, and TSST-1. Their bi-specific 
chimera against SEC3 used a variation of the high affinity Vβ L2CM (excluding 2 
mutations that were not located at the SAg:Vβ interface) constructed in our laboratory 
and discussed above. One of the potential concerns from this study was that the Vβ 
L2CM was not used as a control when testing the DRα1-L2CM chimera in vitro. Another 
concern is that our laboratory did not see neutralization with the wild-type Vβ in an IL-2 
release assay while their laboratory did for their chimeras that used wild-type Vβs (257). 
Although the strategy of targeting the SAg regions that bind the MHC and TCR is 
logical, further experimentation is necessary to address the concerns. 
As discussed above, the Vβ L2CM affinity was deemed too low to proceed with 
animal models. Thus, Chapter 2 discusses the directed engineering of L2CM to improve 
its affinity for SEC3. There are numerous advantages to using high affinity Vβs as 
therapeutics. One advantage is that the high affinity Vβ G5-8 can be used as a model, as 
it was engineered to pM affinity for SEB and shown to be effective in animal models 
(55). As is the case for all the Vβs engineered in our laboratory, by maturing the portion 
of the TCR that the SAg binds, we are directly competing with the protein the SAg would 
bind. Since the TCR, and Vβ in particular for most SAgs, is the ‘trigger point’ of the 
cascade, we are blocking the impetus of SAg activation. Furthermore, since only part of 
the Vβ is used and it is soluble, our protein will not lead to inappropriate activation, as is 
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one concern with mAbs. Since the Vβs target a foreign molecule, the SAg, they should 
not cause inappropriate suppression or activation of the immune system as may be seen 
with other therapeutics, such as immunosuppressants. The small size of the Vβ is another 
advantage and may allow the protein access to tissue where mAbs are too large. There are 
also potential disadvantages to using this method. One potential disadvantage is that the 
protein may have a short half-life. Methods have been developed to overcome this, such 
as PEGylation. Another concern is that the Vβ may already have reached a limit in 
affinity for SEC3. Since L2CM was engineered using random PCR mutagenesis, and our 
laboratory had made progress in site-directed libraries, we believed that there were still 
regions of Vβ interaction with the SAg with potential for improvement. Finally, since the 
Vβ was developed using a mouse Vβ, there is concern that in humans there may be an 
anti-mouse response, as has been seen against mouse antibodies. The same rabbits that 
were treated with G5-8 when exposed to SEB were again administered SEB and G5-8 
one month after initial exposure, with no difference in results (55). Though there are 
advantages as well as potential pitfalls, the advantages were substantial enough to 
proceed with L2CM affinity maturation. 
 
Soluble Extracellular TLR4 Pathway Proteins as Potential Therapeutics  
  Key components involved in activation of TLR4 signaling include LPS, MD-2 
and the receptor itself, TLR4. A protein called RP105 acts as a soluble receptor mimic of 
TLR4. Unlike TLR4, RP105 lacks an intracellular and hence signaling domain, yet its 
extracellular domain is homologous to that of TLR4’s (259). RP105 forms a complex 
with MD-1, an MD-2 homolog that shares approximately 20% sequence identity (260). 
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The RP105:MD-1 complex directly interacts with TLR4 preventing LPS from binding 
(261). It has been tested in vitro as well as in vivo in mice challenged with LPS. In vitro 
RP105 was able to inhibit TLR4 signaling in HEK 293 cells and RP105:MD-1 was 
shown to directly interact with TLR4:MD-2 (259,262). In vivo RP105-deficient mice 
were associated with significantly more TNF production than wild-type mice. The crystal 
structure of bovine RP105:MD-1 has been solved and reveals that although the 2:2 
stoichiometry is the same as TLR4:MD-2, that the binding interfaces of the complexes 
differ (260).  
 LPS is another key player in TLR4 activation. E5531 is a lipid A analogue that 
was synthesized from Rhodobacter capsulatus (263). It functions as an LPS antagonist 
and was shown to be effective in vivo as well as in vitro (264,265). A second generation 
LPS antagonist was developed and called E5564 or eritoran (266). The crystal structure 
of eritoran in complex with MD-2 and TLR4 was solved and suggested that eritoran 
binds within the MD-2 pocket acting as an LPS antagonist (267). A phase II clinical trial 
with eritoran showed a trend toward reduced mortality with survival of 56.3% versus 
33.3% in the control group when the high risk of mortality subjects were subgrouped 
(268). A phase III clinical trial in sepsis, known as ACCESS trial, was completed but 
results have not been posted, and was designed based on the phase II results to enroll 
patients with a high risk of mortality (269). The results of the phase II trial were not 
statistically significant. It remains to be seen if the phase III trial will benefit patients at 
high risk, and whether other therapeutics can be designed for patients who are not high 
risk.  
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 As indicated, MD-2 is another key player that may serve as a target for inhibiting 
TLR4 activation by LPS. Curcumin is a phenolic natural product that has anti-
inflammatory, anti-carcinogenic activity, and has been shown to bind MD-2 preventing 
LPS activation of TLR4 (270). The MD-2 binding site of curcumin was shown to overlap 
with the binding site of LPS through molecular modeling and by competitive ELISA 
(271). In an animal model of endotoxemia, mice pretreated with curcumin had 
significantly lower levels of TNF-α than the control group (272). In addition to curcumin 
acting as an MD-2 antagonist, the house dust mite allergen Derp2 has been suggested as a 
MD-2 mimic by presenting LPS to TLR4 and inducing activation (72). These molecules 
may be useful in future studies attempting to neutralize LPS activity through MD-2 
modulation. 
 In Chapter 4, yeast display (discussed below) is used to study MD-2 as a potential 
soluble LPS therapeutic. As discussed above in selecting Vβ proteins to neutralize SAgs, 
there are advantages and disadvantages to targeting MD-2. Mouse knockout experiments 
have demonstrated that MD-2 is essential to LPS activation of TLR4, making it a suited 
target for modulation (8). MD-2 is the key protein required for LPS activation of TLR4 
and therefore we are targeting the inflammatory response at its impetus rather than using 
a non-specific treatment. Similarly as for the Vβs, we are mutating the protein that binds 
the toxin, LPS, and therefore are directly competing for the same binding sites as the host 
MD-2. Though we are engineering MD2 analogs to compete with lipid ligands and have 
reduced TLR4 interaction, or vice versa, the prior would be more desirable because in 
that case our protein will remove the LPS from the system rather than block its 
interaction. The recent crystal structure of the ternary complex provides new insight to 
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potential regions of interaction not previously identified through mutagenesis studies (7). 
Though the recent crystal structure of the TLR4:MD2:LPS complex reveals that TLR4 
and LPS make some contacts, MD-2 makes extensive contacts with both TLR4 and LPS 
(7). Thus, MD-2 is in the unique structural orientation to be engineered as a dominant 
negative with reduced binding to one protein, and increased binding for the other. This 
intimate interaction with both is also a potential disadvantage, as a mutation that may 
provide benefit in binding to TLR4 or LPS may unintentionally effect binding of the 
other protein. MD-2 is already high affinity (low nanomolar) for both TLR4 and LPS and 
may be at a limit in maturation with either. The high affinity interaction of MD-2 may 
also lead to unintended stimulation if MD-2 binds with high affinity to LPS, but is still 
able to bind to TLR4 (or vice versa). Though flow cytometry experiments successfully 
probed for MD-2 on the surface of yeast, this protein has not been previously studied 
using yeast display, possibly leading to unforeseen obstacles with it or its ligands in the 
system. Finally, like the Vβs, MD-2 may have pharmacokinetic issues such as a short 
half-life, though there are methods such as PEGylation to overcome this issue. 
 
Engineering Proteins by Yeast Display 
 There are several methods of combinatorial library screening that have been 
developed. The most utilized method is phage display, which consists of a protein 
expressed as a polypeptide fusion to a bacteriophage coat protein. Shortcomings of phage 
display include a lack of post-translational modifications that are required by some 
eukaryotic proteins, lack of eukaryotic chaperones to assist in protein folding, and 
minimal ability to use quantitative approaches to selections. Advantages include the 
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ability to make large libraries (1010 to 1011). Recently, a mammalian cell based antibody 
display platform was described, but its use is limited, as it is designed specifically for 
antibody library display, and mammalian cell display is limited by smaller libraries and 
slower growth characteristics (273).  
 Yeast display has the advantage of eukaryotic chaperones and ability for post-
translational modifications for eukaryotic protein selection (274,275). Yeast display 
allows libraries of 109 mutants, and provides a quantitative selection approach involving 
high-speed fluorescence activated cell sorting (FACS). The most common approach to 
yeast display consists of the yeast mating agglutinin Aga2p protein fused to a protein of 
interest (Figure 1.7). The Aga2p construct is disulfide bonded to the yeast surface 
through the yeast surface protein Aga1. Both Aga1 and Aga2p are under the control of a 
galactose inducible promoter. Epitope tags, such as an N-terminal hemagglutinin epitope 
and a C-terminus c-myc epitope, can be included to flank the protein of interest. These 
epitopes or the protein of interest can be detected using fluorescently labeled ligand or 
antibodies to confirm protein expression and folding on the surface of the yeast. In 
addition to detection, fluorescently labeled ligand or antibodies can be used to select 
yeast with protein mutants that are folded properly on the yeast surface or for protein 
mutants with improved ligand binding, using FACS. Thus, individual clones with a single 
mutant protein can be selected from a library of clones without the need for subcloning or 
protein purification.   
 Our laboratory has successfully used yeast display to stabilize and engineer high 
affinity single-chain antibodies (276), MHC class I (277), MHC class II (278), and TCR 
molecules (279-281). The first TCR to be expressed on the surface of yeast was mutants 
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from the single-chain TCR 2C clone (Vβ8.2-linker-Vα3.1, scTCR) (282). The 2C scTCR 
was displayed poorly on the yeast surface, therefore an E. coli mutator strain was used to 
construct a random library with the goal of determining if individual mutations would 
allow display. After three rounds of fluorescence activated cell sorting (FACS) mutants 
were analyzed and multiple mutations were identified that increased surface expression 
of the protein (282). Based on this data, it was subsequently shown that the level of yeast 
surface display correlates with protein stability and secretion (282,283). Our laboratory 
has used this strategy to engineer numerous other Vβs targeting SAgs (that are discussed 
above in the soluble receptor section).  
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Figure  1.1  Structure  of  antibodies  and  T cell  receptors.  (A)  A 
schematic representation of an antibody molecule and (B) a schematic 
representation and crystal structure of a T cell  receptor.  The arches 
represent the Ig-fold motif. Abbreviations: V (variable), C (constant), 
H (heavy), L (light), Fab (fragment of antigen binding), S-S (disulfide 
bond). RCSB PDB accession code 2XNA.!
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Figure 1.2 Endotoxin, TLR4 and MD-2. (A) TLR4 (green) contains 
many Leucine-rich repeats, spans the cell membrane and has an interior 
signaling TIR domain. TLR4 is in complex with MD-2 (red) and LPS 
(yellow). (B) LPS is composed of a toxic hydrophobic lipid A region 
(yellow),  a  core  polysaccharide  chain  (orange),  and  may  have  a 
hydrophilic O-antigen polysaccharide chain. When endotoxin has little 
or  no O-antigen it  is  called  rough LPS.  RCSB PDB accession code 
3FXI.!
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Figure  1.5  Superantigen  staphylococcal  enterotoxin  C3  (SEC3). 
SEC3 is  composed  of  two domains,  an  N terminal  (green)  and  a  C 
terminal (blue) domain. The smaller N terminal domain is of similar size 
and  topology to  the  OB fold,  present  in  many toxins.  The  !3 helix 
(yellow) separates the two domains and contains many of the residues 
that vary between SEC allelic variants. SEC contains a cysteine loop 
(orange) that is 16 residues in length, which is almost twice as long as 
most  SAg  cysteine  loops,  except  for  SEB  which  is  similar  in  size. 
Unlike most other group II members, SEC3 possesses a Zinc binding 
motif (magenta). The V" domain of the TCR binds at the top surface 
between the two domains and the MHC binds at the bottom of the N 
terminal domain. RCSB PDB accession code 2AQ3.#
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Figure 1.6 Modeled MHC:SAg:TCR variations in binding. The TCR 
!  chain is red and the "  chain orange. The MHC class II "  chain is 
green  and  the  !  chain  aqua.  (A)  Depicts  the  traditional  MHC:TCR 
interaction. (B) SEC3 (blue) binding to the V! chain of the TCR (40). 
(C) SpeC (yellow) completely disrupts MHC and TCR binding and acts 
as a bridge between the two. (D) TSST-1 (gray) binds to MHC:TCR in a 
similar orientation as SEB. Figures (A), (C), and (D) (36).#
A!
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Figure 1.7 Yeast cell surface display. A gene of interest (such as a V! 
region) is generated by PCR and cloned into the yeast display vector. The 
protein is displayed on the surface of yeast via an Aga2 fusion protein. 
Expression can be detected using the epitope at the N-terminus of the 
TCR, a hemagglutinin (HA) tag, and at the C-terminal of the TCR, a c-
myc epitope tag. Mutated libraries of the gene are designed, engineered, 
and  screened  for  increased  affinities  using  fluorescent-labeled  ligand 
(such as biotinylated-SEC) (274).!
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CHAPTER 2 
ENGINEERING A Vβ  T CELL RECEPTOR REGION AS A HIGH-AFFINITY 
SEC ANTAGONIST1 
 
Introduction 
The gram-positive bacterium Staphylococcus aureus is responsible for a wide 
spectrum of diseases, with infections that can target skin and mucous membranes, heart, 
lungs, bones, and blood (284,285). Among the major factors associated with severity of 
S. aureus illnesses is a class of secreted exotoxins called superantigens (SAgs). The 
mechanism of superantigenicity is now understood at both biochemical and structural 
levels. The activity requires SAg binding to the Vβ region of the heterodimeric T cell 
receptor (TCR) and simultaneously to class II products of the major histocompatibility 
complex (MHC II). The major systemic effects of SAgs that result from these interactions 
are fever, hypotension, and skin rash production (14).  
The potent hyperactivation of the immune system makes staphylococcal SAgs 
capable of incapacitation and lethality, and appears responsible for their involvement in 
multiple illnesses. While first defined for their ability to cause food poisoning (11), and 
perhaps best known to the public as the direct cause of toxic shock syndrome (TSS) due 
to a tampon related outbreak in the 1980’s (286), in recent years SAgs have been 
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  O.	  N.,	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  and	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increasingly implicated in several other related illnesses, including necrotizing 
pneumonia, purpura fulminans, and infective endocarditis (67,92,287). Supporting a 
possible role of SAgs, a recent analysis of Methicillin-Susceptible S. aureus (MSSA) 
endocarditis showed that the TSST-1 gene was among only a few genes that was 
significantly associated with isolates derived from endocarditis patients, in distinct 
contrast to isolates from soft tissue infections (288). In the study, over 90% of the MSSA 
strains that caused endocarditis in patients from North America, Europe, and Australia 
expressed the TSST-1 gene. 
Methicillin-resistant S. aureus (MRSA) producing SAgs pose added problems in 
management of staphylococcal illnesses, due to their increased difficulty in treatment 
(289) associated with antibiotic resistance and SAg toxicity. Staphylococcal enterotoxin 
C (SEC), is one of the SAgs that has been identified as important, due to its secretion by 
multiple MRSA strains and its implication in several SAg mediated diseases. For 
instance, a recent study with a rabbit model showed that SAgs play an important role in 
the lethality associated with pulmonary infections caused by community-associated 
(CA)-MRSA (287), including the highly-studied CA-MRSA USA400 strain MW2 that 
secretes SEC4 (290).  
One therapeutic for SAgs is IVIG, but it has several drawbacks including cost, 
limited supply, and variability of antibody titers depending on lots (137,138). Vaccines 
are another potential strategy to prevent diseases associated with SAgs, and presently 
there is a vaccine against SEB in phase I clinical trials. However, vaccination would 
require separate vaccines to be developed against each SAg as well as the potential need 
for multiple doses to maintain antibody titers (142). Monoclonal antibodies have also 
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held promise as therapeutics, but none has been developed against SEC for human use. 
Our laboratory has used the soluble form of the toxin’s receptor as a potential therapeutic, 
as was developed for anthrax toxin (253). The dissociation constants (KD) for SAgs with 
their respective Vβ chain are of low affinity, in the micromolar range (50,53). This low 
dissociation constant requires that to be used as a soluble neutralizing agent, the Vβ must 
be engineered to have considerably greater affinity for the SAg. Our lab has developed 
high affinity antagonists using TCR Vβ regions against SEB (55), TSST-1 (254), and a 
first generation Vβ against SEC (L2CM) was generated by using random mutagenesis 
(35). Four allelic variants of SEC have been identified (SEC1-4), and crystal structures 
have been solved for SEC2 and SEC3, including both in complex with the mouse 
Vβ8.2Cβ (50), and SEC3 in complex with the class II MHC molecule HLA-DR1 (43). In 
addition, the structure of SEC3 in complex with our first generation high affinity SEC3 
antagonist Vβ (L2CM) has been solved (54). These three-dimensional structures allow a 
semi-rational design to improve the affinity of the SEC antagonist L2CM against the 
toxin.  
In this chapter, a rational design approach combined with directed evolution using 
yeast display (275) was used to improve the affinity of the first generation Vβ8 against 
SEC3 (35). The highest affinity soluble Vβ was effective at neutralizing SEC3 activity in 
vitro. This Vβ was also effective at neutralizing activity of SEC3 in vivo in two different 
rabbit models as well as in several different rabbit models of disease using live bacteria 
that secrete SEC. The high affinity soluble Vβ was used to show that SEC is involved in 
infective endocarditis in a rabbit model, a finding further supported by the use of an 
isogenic MW2 SEC knockout (MW2ΔSEC). These results suggest that the soluble high-
	   52	  
affinity Vβ antagonist may be useful as a therapeutic for diseases in which SEC is 
implicated.  
 
Materials and Methods 
Yeast Display Libraries and Cloning 
The gene encoding the mouse Vβ8TCR mutant called L2CM (35) was cloned into 
yeast display vector pCT302, which contains an N-terminal hemagluttinin (HA) tag and a 
C-terminal c-myc tag (Figure 2.1A) (275). Libraries of mutants in L2CM were 
constructed in the CDR2 (residues 52-56) and HV4 (residues 70-74) regions by site-
directed mutagenesis using overlapping degenerate primers (with NNS codons) (Table 
2.1). The vector pCT302:G5-9 was digested with NheI/BglII and run on a 1% agarose gel 
to separate the plasmid from the insert G5-9 and the plasmid pCT302 was excised and gel 
purified. The PCR products were transformed along with the NheI/BglII digested plasmid 
pCT302 into the yeast strain EBY100 (275), which inserts the PCR product into the 
plasmid by homologous recombination (277,278). The resulting HV4 library contained 
7x105 and the CDR2 library 1.7x106 independent transformants and were grown in 
selective media (SD-CAA) for 48 hours. Ten clones were picked from each library and 
sequenced to ensure the presence of diversity in the library. 
 
Fluorescence Activated Cell Sorting (FACS) of Libraries 
Expression of AGA2p fusions were induced by growth of yeast cells in medium 
containing galactose at 20°C for 32-48 hours. After induction, yeast-displayed Vβ 
proteins were selected by Fluorescence Activated Cell Sorting (FACS) on a MoFlo high-
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speed cell sorter (Cytomation). There were 5x107 cells from each library sorted for the 
first sort and 1x107 cells for the second, third, fourth, and fifth sorts. Between the top 
0.25% and 2% of cells were selected from each sort to obtain the most fluorescent as well 
as a sufficient number of cells to grow for each following sort. Yeast cell libraries were 
selected by using either equilibrium or off-rate based methodology. The first two sorts of 
both libraries consisted of equilibrium sorting where each yeast library was incubated 
with 100pM biotinylated-SEC3 (Toxin Technology, Sarasota, FL) in phosphate buffered 
saline (PBS) for 1 hour on ice. Cells were washed with 0.5 ml PBS-0.05% bovine serum 
albumin (PBS-BSA) and then incubated with Streptavidin-phycoerythrin (SA-PE) (BD 
Biosciences) at a 1:1000 dilution. Following each sort, the cells are grown in selective 
SD-CAA media, and then induced in galactose containing media for the following sort. 
The third, fourth, and fifth sorts consisted of off-rate selection. This was performed by 
incubation of yeast libraries with biotinylated-SEC3 (10nM for sort 3 and 0.1nM for sort 
4 and 5) under equilibrium conditions, followed by washing with PBS-BSA, incubation 
with non-biotinylated SEC3 in ten-fold molar excess (100nM for sort 3, and 1nM for sort 
4 and 5) in PBS at 25°C for various times depending on sort, followed by SA-PE 
staining. The top 0.25% fluorescent clones were selected from the fifth and final sort and 
plated on selective media. 
 
Selection and Analysis of Vβ Mutants By Flow Cytometry 
Eight clones were selected from the CDR2 library plate and seven clones from the 
HV4 library plate and grown in glucose containing media at 30°C. Protein expression 
was induced by culturing in galactose containing media at 20°C for 32-48 hours. 
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Plasmids were rescued from the clones and sequenced by the UIUC sequencing facility. 
Cells (5.5x105 for each clone) were incubated with various concentration of biotinylated-
SEC3, anti c-myc antibody (Invitrogen), or anti-hemagglutinin (anti-HA) antibody 
(Covance HA.11) for one hour on ice. After washing, SEC3 stained cells were incubated 
with SA-PE (1:1000 dilution), anti-c-myc stained celled were incubated with goat-anti 
chicken (1:100 dilution) (Invitrogen), and anti-HA stained cells were incubated with 
goat-anti-mouse antibody (1:200 dilution) (Invitrogen). Individual clones were also 
analyzed for off-rate binding to biotinylated-SEC3. Off-rate analysis of clones was 
performed as described above for sorting, except that the second incubation with 
unlabeled SEC3 was performed at either on ice or 25°C. Samples at various time points 
were analyzed and percent bound biotinylated-SEC3 (mean fluorescence units (MFUs) of 
samples at specific time point/MFUs at time point zero x 100) was plotted against time. 
C-myc and HA tag expression were used to estimate surface expression of clones. Cells 
were analyzed on a Coulter Epics XL flow cytometer on the live yeast cell population.   
 
Cloning of Highest Affinity Clone Mutations Into A Single Gene 
Mutations from clone CD6 (residues N24K, N28S, H29Y, N30D, G42E, and an 
insertion of the amino acid F between residues 29 and 30) and clone HV7 (residues P70L, 
S71T, H72W, E73R, N74T) were combined by sequential site directed mutagenesis steps 
using QuickChange as described by the manufacturer (Stratagene, La Jolla, CA) into a 
single pCT302 plasmid. Clone CD6 was used as the template. The first site directed 
mutagenesis primers CD6-HV7a (FWD and REV) (Table 2.1) introduced mutations 
P70L, S71T, and single nucleotide changes in residues 72 and 73. After sequencing to 
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confirm the correct mutations, the second primer CD6-HV7b (FWD and REV) (Table 
2.1) was used to introduce residues H72W, E73R, and N74T. The final clone containing 
all mutations from clones CD6 and HV7 was named L3 (Figure 2.2) and transformed into 
EBY100 cells. The clone was titrated with various concentrations of biotinylated-SEC3 
in comparison to the template L2CM and the two mutants CD6 and HV7.  
 
Cloning, Expression, and Purification of Soluble Vβ Proteins 
The Vβ mutant L3 was subcloned as an NheI-BglII fragment from the pCT302 
vector into a pET28 expression vector (Novagen) for expression in bacteria (Table 2.1). 
The Vβ proteins used in the in vitro and rabbit experiments were expressed in BL21 
(DE3) Escherichia coli using the pET28 expression vector. The Vβ protein was then 
refolded in vitro from 600mgs of inclusion bodies by solubilizing in 1.1gms guanidine-
HCl and 2.5ul β-mercaptoethanol for one hour at 37°C. The solubilized inclusion bodies 
were then centrifuged to pellet insoluble debris and the supernatant was added dropwise 
over 3 minutes into 400ml of stirring denaturant buffer (7.5M urea, 50mM Tris pH 8.0, 
2nM reduced glutathione, 2nM oxidized glutathione) at 4°C. The mixture stirred for four 
hours after which 2.6 liters of dilution buffer (200mM NaCl, 40 mM Tris pH 8.0) was 
added dropwise. The refolding protein was allowed to stir for an additional 24 hours after 
the dilution was stopped, and 2ml of Ni agarose resin slurry (50%) (Qiagen) was added 
for 24 hours. The Ni beads were isolated by filtration and the protein was washed, 
followed by elution with 500 mM imidazole. The protein was then purified by gel 
filtration high-performance liquid chromatography (HPLC) (BioCad Sprint) using a size 
exclusion Superdex 200 column (Pharmacia) in PBS (pH 7.4) as described previously 
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(55). Protein preparations were examined by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and mass spectrometry. For mass spectrometry analysis, 
purified protein was equilibrated with ammonium acetate buffer and then analyzed at the 
UIUC Mass Spectrometry Laboratory by Electrospray Ionization on a Quattro II mass 
spectrometer using Masslynx software. Endotoxin presence in the purified Vβ 
preparations was in the range of 200-2000 EU/mL, but prior to in vivo use, the Vβ 
preparations were passed over a polymyxin B column to remove endotoxin, which 
reduced the levels to 20-200 EU/mL. 
 
Binding of Soluble Vβ to SEC3 
Binding of soluble Vβ to biotinylated-SEC3 was examined by enzyme-linked 
immunosorbent assay (ELISA) and Surface Plasmon Resonance (SPR). For the titration 
ELISAs, Vβ protein was immobilized on flat bottom 96-well plate wells (1 μg/ml) and 
the background was blocked by PBS + 0.5% BSA. After washing, various concentrations 
of biotinylated-SEC3 were titrated into the wells, followed by streptavidin-conjugated 
horseradish peroxidase (BD Biosciences), and finally substrate to yield a colorimetric 
read-out at an absorbance of 450 nm wavelength. Competition ELISAs were also 
performed, where Vβ is immobilized on the flat bottom 96-well plate at 5 ug/ml and the 
background blocked with PBS +0.5% BSA. After washing, 20nM SAg SEC3 is added as 
well as serial diluted Vβ. Readout of binding is detected as described above for titration 
ELISAs. 
The affinities and kinetic parameters of Vβ:SEC3 interactions were determined by 
SPR analysis using a BIAcore 3000 instrument by our collaborator Eric Sundberg as 
	   57	  
described previously (35,55). Briefly, the SAg was immobilized by standard amine 
coupling to a CM5 sensor chip at a density of 500 response units (RU). Serial dilutions of 
Vβ protein was injected for up to 3 minutes at a flow rate of 25 ml/min and allowed to 
dissociate for up to 10 minutes prior to regeneration of the binding surfaces. 
 
T Cell Assays 
T cell hybridoma line M6-16 cells that expresses a TCR with the mouse Vβ8.2 
region (291) were maintained in RPMI 1640 supplemented with 10% heat inactivated 
FCS, 5mM HEPES, 2mM L-glutamine, 100 U Penicillin, 0.1 mg/ml streptomycin, 4x10-
6M β-mercaptoethanol (KF media). MHC class II-positive B-cell line LG-2 cells (105 
cells/ml) were maintained in RPMI 1640 supplemented with 10% FBS, 25mM HEPES, 
2mM L-glutamine, 100 U penicillin, 0.1 mg/mL streptomycin, 1mM sodium pyruvate, 
and 100uM non-essential amino acids (R10 media). Cells were only used in assays when 
viability reached or was greater than 90%. In assays, the TCR expressing M6-16 cells (5 
x 105 cells/ml) were stimulated with 35nM SEC3 in the presence of MHC class II-
positive B-cell line LG-2 cells (105 cells/ml) in 96-well round bottom plates. Soluble Vβ 
proteins (L3, L2CM, or negative control mTCR15) were added at various concentrations 
to a final volume of 200ul per well and incubated at 37°C, 5% CO2 for 20-24 hours. Since 
evaporation of outer wells of 96-well plates was a concern based on previous 
experiments, the outer wells of the 96-well plate were filled with media only to prevent 
concentration change of internal wells. Parafilm was also placed between the wells and 
the lid to prevent evaporation. After 20-24 hours, cells were centrifuged for 5 minutes at 
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1200 rpm, and supernatants were collected. IL-2 levels in supernatants were measured by 
ELISA. 
 
Construction of S. aureus MW2 Isogenic SEC Knockout Mutant 
The SEC knockout mutant was constructed and tested by our collaborator Patrick 
Schlievert and Wilmara Salgado-Pabon. For the construction of an MW2 sec4-deletion 
plasmid, the sequences upstream (618 bp) and downstream (549 bp) of sec4 were PCR 
amplified with primer sets EcoRI-UPsecF/f1-UPsecR and f2-DNsecF/AvaI-DNsecR 
respectively (Table 2.1). The fragments were spliced together by overlapping 
amplification with the primer pair EcoRI-UPsecF/AvaI-DNsecR, digested with EcoRI 
and AvaI, and inserted into pJB38 (292). The resulting plasmid, pJB38-Δsec4 (pWSP4) 
was electroporated into RN4220 and moved into MW2 by transduction with 
bacteriophage ϕ11. The sec4 deletion was introduced following the pKOR1 protocol 
(293) and confirmed by PCR. Loss of the plasmid in the Δsec4 clones was confirmed by 
streaking on Todd Hewitt plates containing chloramphenicol (10μg/ml). 
 
Bacterial Strains 
CA-MRSA USA400 strain MW2 was originally obtained in the Upper Midwest 
from a young patient who succumbed to necrotizing pneumonia. The strain of low 
passage is maintained in the lyophilized state in the Schlievert laboratory. MW2 produces 
the SAgs SEC (77 ug/ml), SE-like Q (30ng/ml), SEA (0.15 ng/ml), SE-like H (0.075 
ng/ml), SE-like K (0.075 ng/ml), SE-like L (0.075 ng/ml), and SE-like X (0.1 ng/ml). 
Studies by the Schlievert laboratory of MW2 and other S. aureus strains reported findings 
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(139) show that SEC is expressed at orders of magnitude higher levels than the other 
genes in certain strains and thus is likely to be more involved in the diseases caused by 
SAgs (139). Other S. aureus strains that are known to cause infective endocarditis include 
MSSA MN8 and CA-MRSA c99529. MSSA MN8 includes a SAg profile of TSST-1 
(20ug/ml), SEC (1ug/ml), SEl-Q (0.2ug/ml), SEl-K (0.075 ng/ml), SEl-L (0.075 ng/ml), 
and SEA (0.075 ng/ml) (unpublished data). The profile of CA-MRSA c99529 includes 
SEB (75 ug/ml), but the production of other SAgs by this strain has not been determined. 
SAg levels were determined by quantitative Western immunoblots by the Schlievert 
laboratory. This method of toxin quantification has been reported previously (294). The 
strain MNPE (USA200 MSSA) was isolated from an influenza death that had developed 
pulmonary TSS (295). The strain expresses detectable SAgs SEC3 and TSST-1, and 
though not produced at high enough levels to be purified and detected, PCR analysis 
showed that MNPE also carries the genes of SAgs SEA, SEl-G, SEI, SEl-K, SEl-L, SEl-
M, SEl-N, SEl-O, and SEl-P (296). 
 
Animal Studies 
All animal experiments were performed by our collaborator Patrick Schlievert 
according to protocols approved by the Laboratory of Animal Care and Use Committee 
of the University of Minnesota and University of Iowa. 
 
Endotoxin Enhancement Studies 
New Zealand White (NZW) rabbits were injected i.v. with 5ug/kg of the SAg 
SEC in PBS either alone or in combination with 100ug/kg soluble Vβ L3 in PBS, 
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followed 4 hours later with i.v. injections of 0.15 ug/kg/ml endotoxin (Salmonella 
typhimurium). SAgs have been shown to amplify the effects of endotoxin through 
synergistic release of TNF-α (297,298). Temperatures were monitored for 4 hours after 
injection. The rabbits were monitored for up to 48 hours for signs of fever, diarrhea, and 
death. The p value were determined by Fisher’s Exact Test (n=9 per group). 
 
Miniosmotic Pump Studies 
In this model, dutch belted rabbits receive continuously released SEC3 from 
subcutaneously implanted miniosmotic pumps (Alza, Palo Alto, CA) (299). Young adult 
rabbits (approximately 1-2 kg, both sexes) were anesthetized with ketamine and xylazine, 
and incisions were made on the left flanks. A subcutaneous pocket was made in each 
rabbit large enough to accommodate the miniosmotic pump. The miniosmotic pumps are 
loaded with 200ug SAg and implanted in the pocket. The rabbits were sutured, allowed to 
wake, returned to their cages and monitored for temperature on day 2, and TSS symptoms 
and death over 8 days. In this model, the maximum fever occurs on day 2. Soluble 100ug 
Vβ or the control PBS was administered intravenously once daily for 7 days. 
 
Necrotizing Pneumonia Studies 
NZW rabbits (approximately 2kg each) were anesthetized with ketamine and 
xylazine and incisions were made in the nape of the neck and then in the trachea. The 
animal is placed on its left side to insert a catheter through the trachea into the left 
bronchi. 1.8x109 bacteria are injected, the trachea sealed and the incision sutured. The 
animal is allowed to wake and is then returned to its cage and monitored. This model of 
	   61	  
necrotizing pneumonia was previously described by Strandberg (287). Two species of 
bacteria were tested in separate experiments. The first experiment used SEC4-secreting 
USA400 CA-MRSA strain (MW2) and the second used the SEC3 and TSST-1 secreting 
USA200 MSSA strain (MNPE). Following bacteria administration, rabbits (n=4 per 
group) were administered either the control PBS (pH 7.4) or Vβ.  In the MW2 strain 
necrotizing pneumonia experiment, rabbits were administered an I.V. of 500ug Vβ L3 
once daily and temperatures were monitored daily over four days. In the MNPE 
necrotizing pneumonia experiment, rabbits were administered an I.V. of the Vβ L3 and 
the Vβ D10V mixed at 100ug/ml in PBS given to rabbits twice daily for three days. The 
Vβ D10V was expressed and purified by Ningyan Wang in our laboratory using the same 
method as described above. Survival of rabbits challenged with bacteria were monitored 
over 7 days and CFU/lung were determined by manual scraping of lung tissue, followed 
by plating upon premature death or day 7.  
 
Soluble Vβ Endocarditis Studies 
NZW rabbits were anesthetized and underwent surgery to insert catheters through 
the left carotid arteries to the aortic valves, where the catheters remained for 2 hours. The 
experiments consisted of two groups of rabbits (n=4 per group). Either the control PBS 
(pH 7.4) or 100 ug of Vβ L3 was injected intravenously through the marginal ear vein of 
the NZW rabbits (approximately 2 kg each), followed by the SEC secreting microbe CA-
MRSA USA400 strain MW2 in the range of 8.9x107 to 1x108 bacteria. The rabbits were 
administered either the control PBS or 100 ug of Vβ L3 twice a day for up to four days. 
The rabbits were examined daily for survival and upon premature death or on day four 
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for vegetations. CFU of aortic vegetations were determined by manual scraping of the 
cardiac tissue, followed by plating. The p values were calculated using unpaired two-
tailed t tests. 
 
MW2 SEC Knockout Endocarditis Studies 
NZW rabbits were anesthetized and underwent surgery to insert catheters through 
the left carotid arteries to the aortic valves, where the catheters remained for 2 hours. The 
experiments consisted of two groups of rabbits (n=6 per group). Either the SEC secreting 
microbe CA-MRSA USA400 strain MW2 or the SEC4 knockout MW2 strain was 
injected in the range of 2.4x107 to 3.5x107 bacteria. The rabbits were examined daily for 
survival and upon premature death or on day four for vegetations. Two of the rabbits that 
were infected with MW2 were used for histopathology and therefore their CFU/aortic 
vegetations could not be measured. p values were determined using a two-tailed unpaired 
t test. 
 
Results 
Yeast Display and Engineering of High-Affinity Anti-SEC Vβ Mutants 
To engineer soluble, high-affinity SEC antagonists, we used a mouse Vβ8 gene 
cloned as an AGA-2 fusion in the yeast display vector pCT302 (Figure 2.1A) (275). 
Previously in our laboratory, random mutagenesis was used to affinity-mature the wild 
type Vβ8 against SEC, resulting in the mutant called L2CM (35). However, our more 
recent studies have shown that site-directed mutagenesis approaches could yield 
significantly higher affinities (e.g. in the 50 to 200 pM range) for Vβ mutants against the 
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SAg SEB, providing more potent in vitro and in vivo neutralizing agents (55). To 
accomplish this with the SEC system, L2CM was used as the starting template for a 
directed evolution strategy with specific site-directed libraries of mutants (Figure 2.2).   
Based on alanine scanning mutagenesis (300) and crystal structures (50,54), Vβ 
residues at the interfacial regions of the Vβ:SEC complex were mutated to generate two 
libraries, one in hypervariable region 4 (hereafter termed HV library) and one in 
complementarity determining region 2 (hereafter referred to as CD library) (Figure 2.1B). 
Site-directed mutagenesis of residues 70 through 74 (NNS codons) in HV yielded a 
degenerate library size of 7x105 mutants. This library was subjected to five rounds of 
sorting and expansion using biotinylated-SEC/ SA-PE and equilibrium or off-rate based 
selections. The first two rounds consisted of successive equilibrium sorts with 100 pM 
biotinylated-SEC, collecting the top 0.5% of the fluorescent population in the first 
selection and the top 2.0% in the second selection. The third, fourth and fifth sorts were 
based on off-rate selections in which the libraries were incubated with biotinylated-SEC 
under equilibrium conditions (4°C for 1 hour), followed by washing and incubation with 
non-biotinylated SEC in ten-fold molar excess at 25°C. Yeast populations that retained 
bound biotinylated-SEC after various times (i.e. with longer off-rates; third sort, 1.5 hour, 
fourth and fifth sorts, 2 hour) were selected.  
After the fifth sort of the HV library, cells were plated, and seven colonies were 
analyzed individually, along with the template Vβ L2CM, for binding to various 
concentrations of SEC3 (Figure 2.3A). All seven clones exhibited a higher level of 
binding compared to L2CM, as exhibited by their increased MFU at 0.1nM and 1nM 
biotinylated-SEC3 staining in comparison to L2CM. Clone HV7 and HV2 showed the 
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greatest increase, as indicated by MFUs (Figure 2.3A). To examine binding further, the 
dissociation properties of the biotinylated-SEC3 bound to each yeast clone was examined 
by incubation with excess unlabeled SEC3, followed by washing at various times, 
incubation with SA-PE, and analysis by flow cytometry.  All seven HV clones exhibited 
higher levels of bound SEC3 after ten min (Figure 2.4), consistent with the higher 
binding affinities.  
Plasmids from the seven colonies were rescued and sequenced. Four unique 
sequences were identified among the seven mutants (Figure 2.2 and Figure 2.5A). All 
four mutants contained the same mutations at two of the five positions in the HV4 region: 
S71T and H72W, suggesting that these mutations were important for improved affinity. 
The selection of histidine in L2CM previously from an error prone PCR library, as a 
substitution for the wild type glutamine at position 72, had suggested this region could be 
optimized for SEC binding. The strong preference for tryptophan at position 72 among 
the HV clones is consistent with the notion that it can be optimized even further by 
substitution with a bulky aromatic side chain (Figure 2.6A). Another preferred mutation, 
P70L, was identified in three of the four unique mutants. Further evidence for strong 
selection of these mutations at the SEC3 binding level (as opposed to a nucleotide 
preference) is that both the S71T and P70L mutations were encoded by different 
degenerate codons (tryptophan has only a single codon in an NNS library) (Figure 2.5A). 
There were also weak preferences for asparagine (2/4) at position 73 and glutamic acid at 
position 74 (2/4).  
After identifying unique sequences, one representative plasmid of each unique 
clone (HV2, HV3, HV6, and HV7) was retransformed into EBY100 cell and titrated at 
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various concentrations of biotinylated-SEC3 in comparison to L2CM. Mean fluorescence 
units were normalized for each and graphed (Figure 2.7A). In addition, each unique clone 
was tested for off-rate binding at 0 minutes, 10 minutes, 30 minutes, and 60 minutes in 
comparison to L2CM (Figure 2.7B). Percent remaining bound after each time point was 
calculated and graphed. Mutant HV7 had the most improved binding affinity (Figure 
2.7A), as was suggested by the initial binding analysis (Figure 2.3A). In the off-rate 
analysis, HV7 retained the greatest percent biotinylated-SEC3 bound at every time point 
tested indicating that it had the most improved off-rate (Figure 2.7B) among the HV 
library tested clones, which was suggested by the initial off-rate analysis (Figure 2.4).  
 In the second library, in CDR2, site-directed mutagenesis of residues 52 through 
56 (NNS codons) yielded a degenerate library size of 1.7x106 mutants. This library 
underwent the same sorting strategy as described for the HV library above, although in 
this case a positive population was first identified after the fourth sort. After the fifth sort, 
cells were plated, and eight colonies were induced and stained with 0.1nM, 1nM, and 
10nM biotinylated-SEC3 followed by SA-PE (Figure 2.3B). All eight CDR2 clones 
showed improvement in the mean fluorescence units when stained with 0.1 nM 
biotinylated-SEC3, compared to the L2CM template (Figure 2.3B). In contrast to the HV 
clones, seven of the clones did not show a significant change in the dissociation rate after 
10 minutes compared to L2CM, whereas one clone (CD6) had a modest improvement 
(Figure 2.4), This suggests that the improvement in binding affinity is largely due to 
faster on-rates. 
The plasmids of the eight clones were rescued and sequenced, showing that all 
eight were identical, except that one clone (CD6) contained an additional mutation. 
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Unexpectedly, the sequences revealed that there were no mutations in the CDR2 region, 
but that there were mutations in or near the CDR1 region, at positions 24, 28-30, and the 
CD6 mutation at position 42 (Figure 2.2 and Figure 2.5B). The origin of these mutations 
is almost certainly due to the original vector that was used to clone the PCR products that 
contained the HV4 and CDR2 libraries within L2CM. The pCT302 vector that was 
digested for insertion of the L2CM CDR2 library contained the high-affinity Vβ mutant 
called G5-9, developed against SEB (55). Thus, during the homologous recombination 
step involving yeast transformation of the libraries, there was likely a low frequency of 
recombination between undigested pCT302/G5-9 and the PCR-amplified library of 
L2CM. The prevalence of the G5-9/L2CM chimera in the SEC-selected library suggests 
that other CDR2 mutations in the library were not preferred above the A52V and S54N 
mutations of L2CM, and that the CDR1 of G5-9 provided some improvement above 
L2CM in SEC binding (as it did with SEB). In fact, the recent crystal structure of a 
related SEB-binding mutant called G5-8 predicts that the N28Y mutation of this Vβ 
provides a several-fold improvement in affinity and that it contacts residue Asn60 that is 
conserved between SEB and SEC (301) (Figure 2.7B).  
CD1 and CD6 were selected as representative clones and retransformed into 
EBY100. They were titrated at various concentrations of biotinylated-SEC3 in 
comparison to L2CM (Figure 2.7C). CD1 titrated similarly to L2CM, while CD6 had an 
improved binding affinity. In addition, each unique clone was tested for off-rate binding 
in comparison to L2CM as was described for the HV library clones. As was seen in the 
initial analysis (Figure 2.4), CD6 had a slight improvement in off-rate (Figure 2.7D), 
while CD1 had no improvement in comparison to L2CM.  
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Binding Analysis of Mutations From Two Clones Combined Into A Single Clone 
As clones HV7 and CD6 had improved binding, and we have shown previously 
that such mutations can yield synergistic binding when combined (35,302), the HV7 and 
CD6 mutations were introduced into a single mutant called L3 (Figure 2.2). Yeast display 
titrations were performed with L2CM, the two higher affinity clones CD6 and HV7, as 
well as the mutant with combined mutations L3 (Figure 2.8). When the histogram data 
were graphed, the titrations with SEC showed that mutant L3 had an affinity that was 
improved slightly above that of both HV7 and CD6 (Figure 2.9), and thus L3 was used 
for further studies as a soluble Vβ protein and for neutralization of SEC. 
 
Expression and Purification of Soluble Vβ Proteins 
 To produce soluble protein for neutralization studies, the gene that encodes Vβ L3 
was cloned into a pET28 expression vector and transformed into E. coli (BL21 DE3). The 
Vβs L2CM and mTCR15 (which is the wild-type Vβ with stabilizing mutation G17E) 
(Figure 2.2) were also transformed into E. coli BL21 cells and expressed for use as 
controls in soluble Vβ assays. The expressed Vβ proteins aggregated into inclusion 
bodies, which were denatured and refolded by dilution. The proteins were selected using 
Ni-beads followed by elution from the beads and purification on a size-exclusion column. 
The L3 protein eluted as a monomer on gel filtration chromatography (Figure 2.10A) and 
exhibited the expected sizes by SDS-PAGE and mass spectrometry (calculated size based 
on amino acid sequence, 14,566 daltons; size observed on mass spectrometry, 14,563 
daltons) (Figure 2.10B and Figure 2.11). The protein yield averaged 2 mgs per liter of 
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inclusion bodies. The protein yield of L2CM was 2 mgs per liter of inclusion bodies and 
the protein yield of mTCR15 was 5 mgs per liter of inclusion bodies. 
  
Binding Analyses of Soluble Vβ Proteins 
 To ensure proper folding, the Vβs L3 and L2CM were analyzed for their ability to 
bind SEC3 by ELISA. In the titration ELISA, Vβ was plated on flat bottom 96 well plates 
followed by serial titration of biotinylated SEC3 (b-SEC3), followed by streptavidin-HRP 
and substrate. A properly folded, immobilized Vβ protein binds to the soluble b-SEC3 
yielding a titration curve (Figure 2.12A). Competition ELISAs were also performed; in 
this case, purified soluble L3 competed with plate bound L2CM for binding to 20nM b-
SEC3. Unbound, soluble b-SEC3 will bind to plate-bound L2CM which can be detected 
by streptavidin-HRP, and the percent competition by L3 can be measured. In this format, 
L3 was also able to outcompete L2CM for binding to SEC3 (Figure 2.12B). The refolded 
L3 protein was determined to be active by these ELISAs and used for in vitro as well as 
in vivo studies. 
 L3 protein, as well as the template Vβ L2CM, were further examined using 
surface plasmon resonance (SPR) to measure the affinity and kinetics of their interactions 
with SEC3 (Figure 2.13). Our collaborator Eric Sundberg measured the affinities (KD 
values) of L2CM and L3 to be 10 nM and 2 nM, respectively. L3 also exhibited an 
approximate 7-fold improvement in off-rate, suggesting that both the HV4 and CDR1 
mutations increase the stability of the complex with SEC3. The half-life (t1/2) of the 
complex at 25°C is thus predicted to be approximately 20 min, perhaps predictive of 
ability to block the SAg activities of the SEC in neutralization assays in vitro and in vivo. 
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In Vitro Neutralization of SEC3-Mediated Activation of T Cells 
 To analyze whether the higher affinity mutant L3 had improved ability to 
neutralize SEC3, compared to L2CM or the wild type Vβ, we monitored the release of 
IL-2 by a T cell line that expresses the Vβ8 TCR region. In this assay IL-2 is secreted 
when the Vβ8-positive T cell line is incubated with SEC (35 nM) and a human class II 
MHC positive B-cell line called LG-2. The soluble high-affinity Vβ proteins L3, L2CM, 
and mTCR15 (282) were added at various concentrations, and after approximately 24 
hours supernatants were assayed for IL-2 levels using a capture ELISA. The wild-type 
VβTCR (mTCR15), which has an affinity for SEC3 of 3 μM, was ineffective at 
neutralizing the activity of SEC3 (Figure 2.14). In contrast, L2CM was able to 
completely neutralize SEC3 activity with an IC50 of 400 nM, and L3 was able to 
completely neutralize SEC3 activity with an IC50 of 40 nM. Thus, L3 exhibited 
approximately 10-fold improved inhibitory properties, consistent with its 7-fold enhanced 
lifetime of dissociation compared to L2CM. Accordingly, L3 was produced in quantities 
to examine its in vivo effects in rabbit models. 
 
Neutralization of SEC3 by the Soluble Vβ L3 in an Endotoxin Enhancement Rabbit 
Model 
 It has not been possible to determine the levels of circulating SAg (including 
SEC) in animal models as the levels are below the detection limits of known assays 
(Western blots, sensitive ELISAs). Their potent toxicity, and most likely their permeation 
into tissues is also associated with this inability to detect the toxins in blood. Thus, to 
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determine whether Vβ L3 could neutralize SEC in vivo, our collaborator Patrick 
Schlievert examined the ability of Vβ L3 to neutralize SEC3 in an endotoxin 
enhancement rabbit model. NZW rabbits were injected with 5ug/kg SEC3 followed by 
either PBS or the soluble Vβ L3 at 100ug/kg. After 4 hours, each rabbit was injected i.v. 
with 0.15 ug/kg of endotoxin (LPS), which is 100 times the half-maximal lethal dose 
(LD50) in rabbits pretreated with 5ug/kg SEC3 (the LD50 of LPS alone is 500 ug/kg). 
After 48 hours, none of the nine rabbits that received PBS only survived, while eight of 
the nine rabbits that received the soluble Vβ L3 survived (Figure 2.15). The ability of the 
L3 protein to prevent death in this model was highly significant (p<0.001). 
 
Neutralization of SEC3 by the Soluble Vβ L3 In A Miniosmotic Pump Rabbit Model 
 In a bacterial infection, SAg is thought to be produced continuously by the 
bacteria. To simulate this, a miniosmotic pump has been used by the Schlievert 
laboratory in a rabbit model. The pump releases approximately 200ug of SEC3 over an 
eight day period. In this model, either PBS or 100ug of Vβ L3 was administered 
intravenously daily (n=3 per group). The second day body temperatures of the rabbits that 
received the control PBS averaged 39.6°C, which was significantly greater than the 
rabbits that received the Vβ L3, which were 38.7°C (Figure 2.16A). Although these 
values differ only by a degree, the difference is significant, with a p value <0.05. Two of 
the three rabbits that received the Vβ L3 survived, while none of the three rabbits that 
received the control PBS survived (Figure 2.16B). 
 
Neutralization of SEC4 Secreted by MW2 In A Necrotizing Pneumonia Rabbit Model  
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To examine the ability of Vβ L3 to neutralize SEC secreted from bacteria, the 
Schlievert laboratory used a necrotizing pneumonia rabbit model. This model is 
appropriate because SEC is implicated as playing a role in the development of 
necrotizing pneumonia (287). NZW rabbits were administered 2x109 bacteria of the SEC-
positive strain CA-MRSA USA300 MW2, intrabronchially. Although other SAg genes 
are present in this strain, it is important to note that SEC is secreted at more than 2500-
fold higher concentrations than other SAgs in MW2 (methods), suggesting that among 
the SAgs one might expect SEC to have the most significant hyper-inflammatory effect. 
Treatment consisted of i.v. injection of 500ug Vβ L3 or PBS daily. Temperatures were 
measured daily, as was survival. Three of the four rabbits that were given MW2 followed 
by the control PBS died over the four days (Figure 2.17B). The control treated rabbits 
had an increase in body temperature that peaked on the second day (Figure 2.17A). All 
four of the rabbits that received the Vβ L3 survived and their temperatures remained 
normal (Figure 2.17). Thus, Vβ L3 was able to neutralize the SEC4 secreted by MW2 
and survival of the treated rabbits was significant with p<0.05. 
 
Neutralization of SEC by the Vβ L3 In USA400 CA-MRSA Infective Endocarditis 
To examine the ability of Vβ L3 to neutralize SEC4 secreted by bacteria in an 
infective endocarditis rabbit model, the Schlievert laboratory used strain MW2 (303). In 
this model, rabbits were anesthetized prior to insertion of catheters through the carotid 
arteries to the aortic valves, allowing the catheters to damage the aortic valves for 2 
hours; the catheters were then removed and the animals closed. This treatment results in 
damage to the aortic valves that mimics the effects of damaged heart valves caused by 
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congenital and rheumatic heart disease, intravenous drug use, or valve prostheses. 
Infective endocarditis was modeled by injecting approximately 108 SEC-secreting 
bacteria USA400 strain MW2 into the marginal ear vein, allowing for formation of 
vegetations at the valve sites for up to 4 days, similar to that observed in infective 
endocarditis. Rabbits were examined daily for survival and for vegetations upon death or 
on day four upon euthanasia. It is important to note that in studies to date, MW2 has the 
greatest ability to cause infective endocarditis among various strains tested including 
MSSA MN8 and CA-MRSA c99529 (Methods).   
Two of the four rabbits treated with the control PBS, but not L3, died before the 
4th day (one within 24 hours and the second at 48 hours). The rabbit that died at 24 hours 
developed a single vegetation with 1.3x107 colony-forming units (CFU/aortic 
vegetations) (Figure 2.18C). The relatively rapid death of this rabbit likely accounts for 
the smaller vegetation size compared to the other rabbits. The other rabbits exposed to 
MW2 developed multiple large vegetations (Figure 2.18A, B, and D) with an average of 
6.2x107 CFU/aortic vegetations (Figure 2.19A).  
One of the 4 rabbits that was administered Vβ L3 died at 72 hours. In contrast to 
the control (PBS) rabbits, this and all three of the other Vβ L3-treated rabbits had either 
no or only small vegetations (Figure 2.18E-H). In addition, the average number of 
organisms from the Vβ L3-treated rabbits was 340 CFU/aortic vegetations (Figure 
2.19A). Although significant (p value of 0.013) these data were skewed somewhat 
because the one Vβ-treated rabbit that died at 72 hours had 4.7x106 CFU when the aortic 
valve surface was dissected and analyzed (Figure 2.19B), but this was still below that of 
any of the control rabbits.  
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To further examine the role of SEC produced by strain MW2, an isogenic SEC 
knockout mutant of MW2 (MW2ΔSEC) was made by Wilmara Salgado-Pabon and 
Patrick Schlievert. Using the same protocol described above to model infective 
endocarditis, following the 2 hour catheterization and closing of the animals, the rabbits 
were infected with approximately 3x107 CFU of either the SEC4 secreting MW2 strain or 
the MW2ΔSEC strain (n=6 per group). Rabbits were examined daily for survival and for 
vegetations upon death or on day four upon euthanasia. 
The SEC secreting MW2 strain formed vegetations in all 6 rabbits, with an 
average number of CFU of 107 per vegetation (Figure 2.19B). In contrast, the isogenic 
MW2ΔSEC mutant failed to form detectable vegetations in any of the 6 rabbits, and there 
were no CFU detected (Figure 2.19B). Furthermore, these rabbits had no signs of illness, 
and no bacteria could be isolated from the region of the heart valves. The distinct 
difference in vegetation formation for the wild type versus isogenic strain further 
supports our conclusion that the SAg SEC plays a role in the development of MW2-
mediated infective endocarditis. 
 
Neutralization of SEC3 by the Soluble Vβ L3 and Neutralization of TSST-1 by the 
Soluble Vβ D10V In A Necrotizing Pneumonia Rabbit Model 
 To examine the ability of Vβ L3 to neutralize SEC secreted from a strain that 
secretes more than one SAg, the Schlievert laboratory used a necrotizing pneumonia 
model in which NZW rabbits were intrabronchially administered 2x109 bacteria of the 
CA-MSSA USA200 strain MNPE, which secretes SEC3 and TSST-1. Treatment 
consisted of either an i.v. injection of 100 ug/ml mixture of Vβ L3 and Vβ D10V or PBS. 
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D10V is a human Vβ that has been engineered for picomolar binding to the toxin TSST-1 
((254) and Dr. Ningyan Wang, unpublished data). The treatment was given twice daily 
for three days. Survival of rabbits challenged with bacteria were monitored over 7 days 
and CFU/lung was determined upon premature death or day 7. All four rabbits that were 
given MNPE followed by the control PBS died on the first day (Figure 2.20A). One of 
the four rabbits that received treatment of Vβs L3 and D10V died on the second day and 
the remaining three survived the full course of the 7 days (Figure 2.20A). Despite the one 
rabbit that died on the first day for the Vβ treatment group and the high CFU/lung in that 
rabbit, the average CFU/lung was significantly lower for the Vβ treated rabbits (mean 
6.8x104 CFU/lung) than for the control PBS treated rabbits (mean 6.7x109 CFU/lung) 
(Figure 2.20B). The Vβs were able to neutralize the SAgs secreted by MNPE and 
survival of the rabbits treated was significant with p<0.05. It remains to be seen whether 
either of the Vβ used alone in this model would provide protection for the rabbits 
exposed to MNPE. 
 
Discussion 
Exotoxin genes have been identified in many cases of MRSA infection (124,125), 
and have been found to be carried by VRSA strains (112). In addition to the emergence 
of antibiotic resistant strains, SAgs secreted by S. aureus and group A streptococci have 
been shown to contribute to multiple illnesses including TSS, necrotizing pneumonia, 
purpura fulminans, and extreme pyrexia syndrome (67,287,304). Clinical and 
epidemiological features also implicate SAgs in diseases such as atopic dermatitis and 
Kawasaki syndrome (305). A recent study showed that the SAg TSST-1 gene was among 
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the few genes significantly associated with isolates derived from endocarditis patients, in 
distinct contrast to isolates from soft tissue infections, further supporting a possible role 
of SAgs (288). Despite advances in acute care and antibiotics, mortality rates due to 
bacteria remain high. Neither the treatment of symptoms nor the use of antibiotics are 
able to remove SAgs already secreted by the bacteria within the host. Thus, SAgs can 
continue to cause TSS or contribute to disease even in the case of an effective antibiotic. 
Hence, I have focused my effort here on developing an agent that targets one of the 
toxins, Staphylococcal enterotoxin C (SEC) that is secreted by various strains of bacteria 
including antibiotic resistant strains. 
Our lab has shown previously that a soluble form of an engineered Vβ protein 
(G5-8) could neutralize the lethal effects of the SAg SEB in two animal models, the LPS 
enhancement model and in the miniosmotic pump model (55). The G5-8 Vβ mutant had a 
binding affinity of 48 pM, which was superior in various in vitro assays to earlier 
generation mutants with affinities in the nanomolar range. Thus, here I further engineered 
a lead Vβ against SEC, called L2CM (35), to improve its affinity and its neutralizing 
potential. L2CM was originally engineered by random mutagenesis, and with improved 
strategies for site directed mutagenesis I focused on libraries within the Vβ loops nearest 
to the SEC binding interface, HV4 and CDR2. Furthermore, the crystal structure of 
L2CM in complex with SEC3 had been solved serving as a tool in a rational design 
approach to improve Vβ binding to SEC3 (54). 
The selection for the improved Vβ mutants had a strong preference for several 
HV4 residues, including a tryptophan at position 72. Although speculative without a 
crystal structure, it is possible that this mutation improved binding either through 
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aromatic ring stacking (e.g. with tyrosine 90 in SEC3, Figure 2.6A) or through additional 
buried hydrophobicity. The observation that no improved mutations were found in CDR2 
suggests that the A52V and S54N mutations of L2CM are already optimal for binding to 
SEC. Recent studies have suggested that the G53R mutation of the SEB-reactive G5-8 
prevents high-affinity binding to SEC3 because the unique tyrosine of SEC3 at position 
26 occupies the pocket that Arg53 is inserted into in SEB (255,301) . In contrast, 
previous extensive structural and binding analyses of A52V and S54N have shown that 
these mutations act through multiple mechanisms, pre-configuring the Vβ surface for 
binding and also increasing the contacts with SEC3 (54). In addition, the key CDR1 
mutation Tyr28 that was derived originally from the SEB-reactive Vβ G5-9 and was 
introduced into L3 has been shown in the G5-8 structure to contact Asn60, a residue 
shared between SEB and SEC3 (Figure 2.6B) (301). Although each of these mutations 
may act to enhance binding affinity by only a few fold, I have shown that the additive 
effects can provide significant improvements in neutralization potential. The potency of 
the effects is no doubt also a property of the dissociation lifetimes of the Vβ:SAg 
complexes, with longer lifetimes allowing the inactive complexes to be cleared from the 
system before they can bind to the target cellular Vβ domain of the TCR.  
My highest affinity Vβ L3 was able to not only protect rabbits from the SAg 
SEC3, but also protect in the clinically applicable model of an SEC-secreting strain that 
is antibiotic resistant. In both a necrotizing pneumonia model (Figure 2.17), as well as an 
endocarditis model (Figure 2.19), the Vβ was able to protect rabbits from the bacterial 
strain MW2. I also showed that two different SAgs secreted by a single bacterial strain 
(MNPE) could be neutralized by administering a mixture of high affinity Vβs engineered 
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against each SAg (Figure 2.20). Furthermore, I was able to show that the enterotoxin 
SEC is involved in vegetation formation in a rabbit model of infective endocarditis. This 
conclusion is based on the observation that 1) a potent neutralizing agent against the SAg 
SEC reduced vegetation size and bacterial growth substantially and 2) an isogenic SEC 
knockout mutant of MW2 caused less vegetation formation in rabbits. This represents 
further evidence of the association of this SAg and the illness, and it provides a 
therapeutic strategy that might show efficacy even in cases where antibiotics have 
reduced impact. Although there are no doubt other factors that are important in infective 
endocarditis etiology, our evidence suggests that S. aureus SAgs, and SEC in MW2 in 
particular, may represent a target for treatment of the disease.  
While antibiotics represent the major approach to treatment of infective 
endocarditis (306), the mortality rates in MSSA and MRSA staphylococcal endocarditis 
remain high (307), highlighting the need for the identification and development of novel 
intervention strategies. The success of other receptor based therapies as seen for TNF-α 
receptor and the anthrax receptor (249,253), as well as our promising in vivo rabbit model 
results suggest that utilizing the SAg receptor may be a useful therapeutic. I have also 
demonstrated that more than one Vβ agent can be used concurrently to successfully 
reduce mortality caused by a bacterial strain that secretes several SAgs. Although 
diagnostics may become rapid enough in the future to use targeted therapeutics against 
only the SAg carried by the bacteria, prophylactic use of multiple neutralizing Vβs may 
be of benefit until targeted treatment is an option.  
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Figure 2.7 Flow cytometry based analyses of yeast display clones for 
binding to SEC3. For affinity approximation yeast cells were incubated 
with varying concentrations of biotinylated-SEC3 ranging from 0.01 to 
100nM for the HV (A) and CD (C) library clones versus L2CM. HV7 has 
the greatest improvement in equilibrium binding over L2CM (A)  while 
CD6  had  a  slightly  improved  equilibrium  binding  (C).  Off-rate 
comparisons were made for both the HV (B) and CD libraries (D). All of 
the HV clones had improved off-rates over L2CM (B) while CD6 had a 
slightly  improved  off-rate  over  L2CM  (D).  The  flow  cytometry 
experiments were repeated 3 times, representative results are shown. (321)!
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Figure  2.8  Flow  cytometry  histograms  of  yeast  displayed  clones 
analyzed for SEC3. Flow cytometry histogram of (A) L2CM, the two 
highest affinity clones selected from each library (B) HV7 and (C) CD6, 
and the combined mutant (D) L3 were titrated with 0.01 nM to 100 nM 
biotinylated-SEC3, followed by SA-PE. !
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Figure 2.13 Surface plasmon resonance. Surface plasmon resonance 
traces of serial twofold dilutions (800nM stocks) of (A) L2CM and (B) 
L3 injected at a flow rate of 25ul/min over immobilized SEC3. L2CM/
SEC3 and L3/SEC3 binding parameters for affinity (KD), on-rate (ka) 
and  off-rate  (kd)  are  shown.  (Figure  2.13  represents  the  work  of 
collaborator Eric Sundberg) (321)!
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Figure 2.15 Endotoxin enhancement model. Rabbits were injected i.v. 
with either the superantigen SEC alone or in combination with the TCR 
V!  L3,  followed  4  hours  later  with  LPS.  0/9  rabbits  survived  when 
injected  with  SEC  alone.  L3  is  able  to  neutralize  the  toxin  yielding 
survival of 8/9 rabbits. p value determined by Fisher’s Exact Test (n=9 
per  group).  (Figure  2.15  represents  the  work  of  collaborator  Patrick 
Schlievert). (321)"
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Figure  2.16  Miniosmotic  pump  model.  Rabbits  were  surgically 
implanted with a pump that releases either the superantigen SEC alone or 
in combination with the TCR V! L3. (A) Second day body temperatures 
were significantly reduced and (B) 0/3 rabbits survived when injected with 
SEC alone versus survival of 2/3 rabbits. (A) p value determined by two-
tailed t test (n=3 per group). The error bars represent SEM. (Figure 2.16 
represents the work of collaborator Patrick Schlievert)."
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Figure 2.17 MW2 necrotizing pneumonia study. New Zealand White 
rabbits  (approximately  2kg  each)  were  intrabronchially  administered 
2x109 bacteria of the CA-MRSA USA400 strain MW2, which secretes 
SEC3. Treatment consisted of either I.V. 500ug V! L3 or PBS daily. (A) 
Temperatures  in  rabbits  administered V!  remained low while  rabbits 
that received MW2 only had an increase in temperature. The error bars 
represent SEM. (B) 1/4 rabbits survived when injected with MW2 alone. 
The V!s are able to neutralize the toxin yielding survival of 4/4 rabbits. 
p value of (B) (p<0.05) determined by Log-rank (Mantel-Cox) test (n=4 
per  group).  (Figure  2.17  represents  the  work  of  collaborator  Patrick 
Schlievert). (321)"
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Figure  2.18  Vegetative  growths  in  the  rabbit  model  of  infective 
endocarditis. Two groups of NZW rabbits (n=4 per group) underwent 
surgery to mimic the effects of damaged heart valves. The control group 
of  rabbits  was  administered  PBS  (pH  7.4)  and  the  test  group  was 
administered  100!g  V"  L3,  followed  by  i.v.  injection  of  the  SEC 
secreting CA-MRSA USA400 strain MW2. Rabbits were administered 
either the control PBS or 100!g of V" L3 twice daily for four days. The 
rabbits were examined daily for survival and on day four for vegetations. 
The PBS-treated rabbits developed multiple and large vegetations (A-D). 
The V" L3-treated rabbits had either no or smaller vegetations (E-H). 
(Figure  2.18  represents  the  work  of  collaborator  Patrick  Schlievert). 
(321)#
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Figure 2.20 Necrotizing pneumonia by a TSST-1 and SEC3 secreting 
bacteria. New Zealand White rabbits were intrabronchially administered 
2x109 bacteria of the CA-MRSA USA200 strain MNPE, which secretes 
both TSST-1 and SEC3. Treatment consisted of either an I.V. mix of the 
V! L3 and V! D10V at 100ug/ml or PBS daily. (A) 0/4 rabbits survived 
when injected  with  MNPE alone.  The V!s  are  able  to  neutralize  the 
toxins  yielding  survival  of  3/4  rabbits.  (B)  The  CFU/lung  were 
significantly lower for V! treated rabbits than rabbits administered PBS. 
p  value  of  (A)  determined  by  Log-rank  (Mantel-Cox)  test  and  (B) 
determined by unpaired two-tailed T Test (n=4 per group). (Figure 2.20 
represents the work of collaborator Patrick Schlievert)."
	   98	  
 
!"#$%&'
()&*+,-
%+&.%/0
%12%.&0
.%3&45+
&251.6+
026.&"1
3&$,#+"+
7&251.6
+026,51
(&
& !"#$%&
'(
%)*
+,
-)
.-
(%
"&
)
/&
0,
-&
)*
+,
-)
)
/&
0,
-&
)1
-2
'-
#(
-$
+ )
& & 89:'&;
,#+"+7&
&
<8!=>
'&
?<$,2%&@
;&&
&
ABC&DD8
&ED8&8
88&E!E
&EE8&E
8E&8ED
&!E!&C=
B&
&
&
&
&
&
!F&*+5
-56%+&
&
&
ABC!EE
&!E8&D
E8&!DE
&8!E&!
ED&DD&
C=B&
;'8G8
9:'.5
%&HI9
&&
ABC&DDE
&DE!&E
!8&88!
&DE!&D
DE&!E8
&DED&D
88&!88
&C=B&
;'8G8
9:'.5
%&:JK&
ABC&8!8
&D!E&!
88&E!8
&EDD&D
E!&E!8
&!88&!!
!&?LL&
?LL&?L
L&
?LL&?L
L&E88&
D!E&!D
E&E!E&
E!D&DE
!&8ED&
C=B&
MK@&;,
#+"+7&
&
<8!=>
'&
?<$,2%&@
;&&
&
ABC&DD8
&ED8&8
88&E!E
&EE8&E
8E&8ED
&!E!&C=
B&
&
&
&
&
&
!F&*+5
-56%+&
&
&
ABC!EE
&!E8&D
E8&!DE
&8!E&!
ED&DD&
C=B&
;'8GM
K@.5%H
I9&&
ABC&!!8
&!88&8!
8&E!!&
8!D&D!
D&!8D&
D8!&E8
8&888&C
=B&
;'8GM
K@.5%:
JK&
ABC&8E8
&8ED&E
E!&DED
&DDE&D
EE&?LL
&?LL&?
LL&?LL
&?LL&?
LL&
!8!&DD
E&DD8&
8!8&D!
E&!88&E
!8&C=B&
89N&O&M
KFP"Q&&
<8!=>
'&
89NCM
KF"HI
9&
&
ABC&DE!
&E8D&E
DD&88!
&88E&D
E8&!EE
&888&ED
8&EDE&
E8!&!8
!&&
888&!8
E&!!8&
C=B&
89NCM
KF":J
K&
ABC&DEE
&!DE&D
DD&EDE
&ED!&!
8!&D8!
&DDD&!
!E&D!8
&!DD&E
DD&
88!&8D
!&E!8&
C=B&
89N&O&M
KFP#Q&&
<8!=>
'&
89NCM
KF#HI
9&
&
ABC&DED
&D88&!8
8&EDE&
88E&ED
8&!D!&
DDD&E8
8&!!8&!
88&8!8
&&
E!!&8!
D&D!D&
C=B&
89NCM
KF#:J
K&
ABC&8E8
&8ED&E
E!&DED
&DDE&D
EE&DD!
&888&ED
E&D8!&
!DD&!8
!&
DDE&DD
8&8!8&C
=B&
;=&R<J
!'S&
&
<8!=>
'&
;'(89N
OMKFH
I9&
&
ABC&!EE
&!EE&D
8!&ED8
&DED&D
8!&D8E
&D!8&E
88&8EE
&ED8&8
8E&C=B&
&
&
&
&
&
-K#S('
<J!'S
":JK&
&
ABC&!!!
&EDE&E
!!&8!!
&E!E&D
DE&88D
&E!E&D
!8&D&C=
B&&
<TU=SC
V!"#$#&
&
<TU=S&
&
%#
&:WCX*
.%2H&&
&
AYC&E!8
&8!E&D
EE&!!8
&EDD&8
E8&ED8
&EE!&D
!D&!!8
&E&C=Y&
&&&&P<I?
*@Q&&
&
&
4)CX*.
%2:&
&
&
AYC&D8!
&ED8&E
8D&8D!
&8!8&8!
!&8E!&
88E&E8
E&!!8&
88&R=Y&
&
&
&
&
&
4'C9L.
%2H&
&
&
AYCE8D
&8D!&D
8!&ED8
&DED&!
DE&EDE
&!ED&E
ED&!88
&E88&
!!E&8E
&C=Y&
&
&
&
&
&
'(
)WC9L.
%2:&&
&
AYC&E!8
&8!E&88
8&DDD&
DD8&EE
D&8E!&
8EE&E8
E&D!!&
E8E&E8
&C=B&
&
& " &9%Z%1
%+"6%&2
5351.&
PLL?Q&
0.%3&45
+&2+%"6
,1Z&$,#+
"+,%.&"
+%&.[5\
1&,1&+%3
]&\[%+%
&L^"17
&#".%&"
13&?^D
&5+&8&
# &*+,-%
+.&0.%3
&#7&?2[
$,%_%+6&
;"#5+"
65+7&65
&251.6+
026&GI
'&?J8&`
152`50
6&.6+",1
(&&
	   99	  
 
CHAPTER 3 
CROSS REACTIVITY OF THE HIGH AFFINITY Vβ L3 WITH SEB AND SEC 
ALLELIC VARIANTS2 
 
Introduction 
Four allelic variants of SEC (SEC 1-4) in human isolates have been identified, as 
well as several species-specific SEC variants in other animal and food isolates. Despite 
the few amino acid residue differences in SEC variants isolated from each host animal 
species, each variant is unique to the species whether human, sheep, or cattle (308). 
Known SEC variants share greater than 93% sequence identity with each other and at 
least 65% sequence identity with the phylogenetically related group member SEB (309). 
SEB and SEC share fewer similarities in sequence with other staphylococcal 
enterotoxins, and in fact they have greater sequence homology with several streptococcal 
enterotoxins.  
When recombinant SEC and SEB were used to examine the Vβ repertoire 
stimulated by these SAgs, the same human Vβ regions were identified: 12, 13.2, 14, 15, 
17, and 20 (61). SEC1 and SEB were also able to strongly stimulate T cells with Vβ3, but 
not T cells with Vβ13.1; in contrast, SEC2 and SEC3 strongly stimulate T cells with 
Vβ13.1 (61). The least conserved residues among SEC variants reside at the N-terminus 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  Some	  data	  and	  figures	  in	  this	  chapter	  were	  previously	  published:	  Mattis,	  D.	  M.,	  Spaulding,	  A.	  R.,	  Chuang-­‐Smith,	  O.	  N.,	  Sundberg,	  E.	  J.,	  Schlievert,	  P.	  M.,	  and	  Kranz,	  D.	  M.	  (2013)	  Engineering	  a	  soluble	  high-­‐affinity	  receptor	  domain	  that	  neutralizes	  staphylococcal	  enterotoxin	  C	  in	  rabbit	  models	  of	  disease.	  Protein	  engineering,	  design	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of the SAg, between residues 14 and 26 (Figure 3.1). In this region, SEC1 is nearly 
identical to SEB, but both differ by five residues from SEC2, SEC3, and SEC4. This 
region of variability contacts the TCR and not the MHC molecule, as indicated by 
structural analysis (Figure 3.2).  
Mutational studies of the SAgs have aided in our understanding of residues 
important in Vβ binding. As noted above, the N-terminus contains the greatest diversity 
between the SEC variants. In one study, three of these residues (20, 22, and 26) were 
replaced in SEC1 with the residues from SEC2 (310). Monoclonal antibodies specific for 
SEC2 bound to the mutated SEC1, suggesting that these residues formed the epitope of 
the antibodies. In other studies, single amino acid substitutions were examined. For 
example, residue 26 in the N-terminus region is a tyrosine in SEC2-4 and a valine in SEB 
and SEC1 (Figure 3.1) (61). Tyr26 was identified in the Vβ:SEC crystal structures solved 
by Fields et al. as making contacts with the Vβ (Figure 3.2) (50). When this residue was 
mutated in SEC1 to a tyrosine, the mutant had the same Vβ stimulating profile as SEC2-4 
(61). This indicated that a single amino acid substitution of a tyrosine at position 26 could 
influence binding to the Vβ, and hence the T cell repertoire that was stimulated.   
Crystal structures of Vβ regions in complex with SEC1, SEC2, and SEB have 
contributed to our understanding of how SAgs bind Vβs (50,54,64,301). The CDR2, and 
to a lesser extent the HV4 region, of the Vβ region contact the SAgs SEC and SEB 
(Figure 3.3). In addition to the CDR2 and HV4 region, the CDR1 region of a Vβ was 
engineered to increase its binding to SEB (301). The Vβ mutant was designed to have an 
additional residue inserted into its CDR1 region to mimic the longer CDR1 loop of SpeC. 
This loop extension added enough flexibility and distance in the loop to allow interaction 
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of the Vβ with SEB. The G5-8 CDR1 loop is pictured in yellow in Figure 3.3. This 
extension mutation is also present in the high affinity Vβ called L3, engineered against 
SEC3 and discussed in Chapter 2. In this chapter, I demonstrate that L3 is able to bind 
not only to the SAg that it was selected for, SEC3, but also to SEC 1, 2, and the most 
recent identified variant 4. More unexpectedly, L3 was shown to cross-react with SEB. 
Through mutational analyses, I determined which of the L3 mutations were responsible 
for this cross-reactivity, and I provide a plausible structural explanation for the ability of 
L3, but not other high-affinity Vβ regions, to bind to both SEC and SEB. Identifying 
high-affinity Vβ regions that cross-react with multiple SAgs would have practical 
applications toward the development of a therapeutic that could neutralize more than one 
toxin. 
 
Materials and Methods 
In Vitro Binding of L3 to SEC Allelic Variants  
The ability of the Vβ against SEC3 (L3) to neutralize allelic variants of SEC was 
examined by Olivia Chuang-Smith and Patrick Schlievert. Purified rabbit and human 
lymphocytes were incubated with different concentrations of SEC subtypes (0.1 pg-1 µg 
per well) for 3 days at 37°C in 5% CO2. Experiments used 0.27, 2.7 or 27 µg/well of Vβ 
L3 to neutralize the activity of 0.01 μg/well SEC. Since IVIG has been shown to 
neutralize S. aureus SAg activity (135), it was used as a positive control (1.74, 17.4, and 
174.0 μg/well) in the Vβ L3 experiments. After 3 days, 1 µCi of 3H-thymidine was added 
to each well of lymphocytes. After 24 hours the cellular DNA was collected with a 
MASH II apparatus (Microbiological Associates; Bethesda, MD) and the thymidine 
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uptake was measured using a liquid scintillation counter (model LS, Beckman 
Instruments; Fullerton, CA). Data was collected as counts per minute (cpm) and shown as 
an average of four replicates. SEC variant experiments were also repeated 4 times. 
 
Rabbit Model for SEC and SEB Toxicity 
New Zealand White (NZW) rabbits (approximately 2 kgs each) were injected i.v. 
with 5μg/kg of the SAg SEC3 or SEB in PBS either alone or a mixture of SAg (5ug/kg) 
with 100ug/kg soluble Vβ G5-8 in PBS, followed 4 hours later with i.v. injections of 5 
μg/kg/ml endotoxin (Salmonella typhimurium). SAgs have been shown to amplify the 
effects of endotoxin through synergistic release of TNF-α (297,298). Temperatures were 
monitored at 0, 2, and 4 hours after initial injection. The rabbits were monitored for up to 
48 hours for signs of fever, diarrhea, and death. The p value was determined by fisher 
exact test (n=4 per group). All animal experiments were performed by our collaborator 
Patrick Schlievert according to protocols approved by the Laboratory of Animal Care and 
Use Committee of the University of Minnesota and University of Iowa. 
 
In Vitro IL-2 Assay of L3 Binding to SEB and SEC3  
T cell hybridoma line M6-16 cells that expresses a TCR with the mouse Vβ8.2 
region (291) were maintained in RPMI 1640 supplemented with 10% heat inactivated 
FCS, 5mM HEPES, 2mM L-glutamine, 100 U Penicillin, 0.1 mg/ml streptomycin, 4x10-
6M β-mercaptoethanol (KF media). MHC class II-positive B-cell line LG-2 cells (105 
cells/ml) were maintained in RPMI 1640 supplemented with 10% FBS, 25mM HEPES, 
2mM L-glutamine, 100 U penicillin, 0.1 mg/mL streptomycin, 1mM sodium pyruvate, 
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and 100uM non-essential amino acids (R10 media). Cells were only used in assays when 
viability reached or was greater than 90%. In assays, the TCR expressing M6-16 cells (5 
x 105 cells/ml) were stimulated with 35nM SEC3 or 35nM SEB in the presence of MHC 
class II-positive B-cell line LG-2 cells (105 cells/ml) in 96-well round bottom plates. 
Soluble Vβ proteins (L3 or G5-8), expressed and purified as described in Chapter 2, were 
added at various concentrations to a final volume of 200ul per well and incubated at 
37°C, 5% CO2 for 20-24 hours. Since evaporation of outer wells of 96-well plates was a 
concern based on previous experiments, the outer wells of the 96-well plate were filled 
with media to prevent concentration change of internal wells. Parafilm was also placed 
between the wells and the lid to prevent evaporation. After 20-24 hours, cells were 
centrifuged for 5 minutes at 1200 rpm, and supernatants were collected. IL-2 levels in 
supernatants were measured by ELISA. Briefly, recombinant IL-2 was immobilized on 
flat bottom 96-well plates (1μg/ml) overnight and the background was blocked by PBS + 
0.5% BSA for two hours at room temperature. Wells were washed with 200ul PBS. 
Supernatant (150ul) from cell activation was added to each well for one hour on ice. 
Wells were washed and biotin-rat-anti mouse IL-2 (BD Biosciences) was added for one 
hour at room temperature, wells washed, and followed by streptavidin-conjugated 
horseradish peroxidase (BD Biosciences), and finally substrate to yield a colorimetric 
read-out at an absorbance of 450 nm wavelength.  
 
L3 Site Directed Mutants  
pCT302:L3 was used as a template to create the following mutants with mutations 
at position 53: G53R, G53H, G53N, G53D, G53T, G53S, G53V, G53A. These mutants 
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were made by site directed mutagenesis using QuickChange as described by the 
manufacturer (Stratagene, La Jolla, CA) into the pCT302:L3 plasmid. Final constructs 
were named L3 G53X, where X is the amino acid that was mutated into position G53, as 
listed above. Primers used for each construct are listed in Table 3.1. The final clones were 
sequenced to confirm mutations and transformed into EBY100 cells. The clones were 
titrated with various concentrations of biotinylated-SEC3 and biotinylated-SEB 
(described below). 
 
G5-8 Site Directed Mutants 
Mutations from the HV4 region of clone L3 (P70L, S71T, Q72W, E73R, and 
N74T) were introduced into clone G5-8 by sequential site directed mutagenesis steps 
using QuickChange as described by the manufacturer (Stratagene, La Jolla, CA). Clone 
pCT302:G5-8 was used as the template. The first site directed mutagenesis primers G5-8: 
70 71, 72 (fwd and rev) (Table 3.2) introduced mutations P70L, S71T, and Q72W. This 
mutant was named G5-8: 70-72. After sequencing to confirm the correct mutations, the 
second primer G5-8: 73, 74 (fwd and rev) (Table 3.2) was used to introduce mutations 
E73R and N74T. The final mutant containing the HV4 region L3 mutations in the 
template G5-8 was named G5-8: 70-74. Mutations were also introduced into position 
Arg53 in G5-8. Mutant G5-8 R53G was made using site directed mutagenesis as 
described above (Table 3.2). This mutation at position 53 was also introduced into mutant 
G5-8: 70-74 using the primers G5-8 R53G (fwd and rev) (Table 3.2). The final clones 
were sequenced to confirm mutations and transformed into EBY100 cells. The clones 
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were titrated with various concentrations of biotinylated-SEC3 and biotinylated-SEB 
(described below).  
 
Flow Cytometry of Yeast Display Mutants 
 Cells (5.5x105 for each clone) were incubated with various concentration of 
biotinylated-SEC3 or biotinylated-SEB (Toxin Technologies Sarratoga FL), anti c-myc 
antibody (Invitrogen), or anti-hemagglutinin (HA) antibody (Covance HA.11) for one 
hour on ice. After washing, SAg stained cells were incubated with streptavidin-
AlexaFluor647 (1:200 dilution) (Invitrogen), anti-c-myc stained celled were incubated 
with goat-anti chicken AlexaFluor647 antibody (1:100 dilution) (Invitrogen), and anti-
HA stained cells were incubated with goat-anti-mouse AlexaFluor647 antibody (1:200 
dilution) (Invitrogen). C-myc and HA tag expression were used to estimate surface 
expression of clones. Cells were analyzed on a Coulter Epics XL or Accuri flow 
cytometer and gated on the live yeast cell population.   
 
Surface Plasmon Resonance of Vβs with SAgs 
The affinities and kinetic parameters of Vβ:SEC3 and Vβ:SEB interactions were 
determined by SPR analysis using a BIAcore 3000 instrument by our collaborator Eric 
Sundberg as described previously (35,55). The soluble G5-8 and G5-8 R53G protein was 
expressed and purified by Ningyan Wang in our laboratory. Briefly, The SAg was 
immobilized by standard amine coupling to a CM5 sensor chip at a density of 500 
response units (RU). Serial dilutions of Vβ protein were injected for up to 3 minutes at a 
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flow rate of 25 ml/min and allowed to dissociate for up to 10 minutes prior to 
regeneration of the binding surfaces. 
 
Results 
The Vβ L3 Neutralizes the Four SEC Allelic Variants In Vitro 
The known SEC variants, SEC1-4, share at least 93% sequence identity (Figure 
3.1). The ability of the SEC3-engineered antagonist Vβ L3 to neutralize the other three 
SEC subtypes was examined in the laboratory of Patrick Schlievert by Olivia Chuang-
Smith. Lymphocyte proliferation was induced by treating human peripheral blood 
mononuclear cells (PBMCs) with 0.01 μg/well of SAgs SEC 1-4. The Vβ L3 was then 
added at three different concentrations: 27 ug/well, 2.7 ug/well or 0.27 ug/well. The 
lymphocyte proliferation is significantly reduced at all three of these L3 concentrations 
relative to SAg alone and the reduction in lymphocyte proliferation was dose-dependent 
(Figure 3.4A).  
In addition to testing L3, the ability of IVIG to neutralize the SEC allelic variants 
was tested in comparison, as IVIG has been used as treatment for TSS (discussed in 
Chapter 1). PBMCs exposed to SEC were treated with varying concentrations of IVIG 
ranging from 1.74 ug/well to 174 ug/well. IVIG neutralized the lymphocyte proliferation, 
induced by the SEC variants, but the concentrations of IVIG used were higher than those 
used for Vβ L3 (Figure 3.4B). Furthermore, there was variation in effectiveness of IVIG 
among the different SEC variants. This variation in IVIG effectiveness for the different 
SEC subtypes may occur because the antibodies found in the IVIG sample target 
different regions of the SAgs that may not block SAg:Vβ interaction. The Vβ L3 is 
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engineered to bind to the same location as the host Vβ, and therefore directly interferes 
with the ability of the SAg to activate cell proliferation. This data demonstrates that L3 
serves as an effective neutralizing agent for all four known allelic variants of SEC 
produced by S. aureus. Finally, it is important to note that the Vβ L3 was able to inhibit 
SEC induced lymphocyte proliferation at a lower concentration than IVIG. 
 
In Vivo Vβ G5-8 Protects Rabbits Against SEB, But Not SEC3 
 To verify that the high affinity Vβ G5-8 engineered for SEB (55) is unable to 
neutralize SEC3 in vivo, based on its low affinity for SEC3, our collaborator Patrick 
Schlievert used an endotoxin enhancement model. New Zealand White rabbits were 
injected with 5ug/kg SAg (SEB or SEC3) or a mixture of 100ug/kg soluble Vβ G5-8 with 
5ug/kg SAg. After 4 hours, each rabbit was injected i.v. with 5 ug/kg of endotoxin (LPS), 
which is 100 times the half-maximal lethal dose (LD50) in rabbits pretreated with 5ug/kg 
SAg (the LD50 of LPS alone is 500 ug/kg). Temperatures in the first 4 hours showed 
greater increases in rabbits given only SAg or SEC3 and G5-8 versus rabbits given SEB 
and G5-8 (Figure 3.5A). After 48 hours, none of the rabbits that received only SAg 
survived. 100% of rabbits that were given SEB with G5-8 survived, as was expected 
based on previous experiments (55). None of the rabbits that received SEC3 with Vβ G5-
8 survived (Figure 3.5B). The ability of the G5-8 protein to prevent SEB induced death in 
this model versus SAg alone or G5-8 with SEC3 was significant (p<0.05) using a fisher 
exact test. This experiment demonstrated that even with 65% sequence identity between 
SEB and SEC3, a Vβ affinity matured against one, does not necessarily cross-react with 
the other.  
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L3 Neutralizes Both SEB and SEC3 In IL-2 In Vitro Assays  
To examine whether the Vβ L3, engineered against SEC, also did not cross-react 
with SEB, its ability to neutralize both SAgs was monitored by the release of IL-2 from a 
T cell line that expresses the Vβ8TCR region. In this assay IL-2 is secreted when the 
Vβ8-positive T cell line is incubated with SEB or SEC3 (35 nM) and the human class II 
MHC positive B-cell line LG-2. The soluble high-affinity Vβ proteins L3 and G5-8 were 
added at various concentrations, and after approximately 24 hours supernatants were 
assayed for IL-2 levels using a capture ELISA. The Vβ L3, which was shown to 
effectively neutralize the activity of SEC3 in Chapter 2, was also able to completely 
neutralize SEB activity with an IC50 of 40 nM (Figure 3.6B). In contrast, the Vβ G5-8 
that was developed against SEB was unable to neutralize SEC3 activity (Figure 3.6A), 
although it completely neutralized SEB activity (Figure 3.6B). In conclusion, although 
each Vβ (G5-8 and L3) was engineered for binding to a specific SAg, SEB or SEC3 
respectively, L3 was able to cross-react with the homologous SAg (SEB), while G5-8 
was unable to cross-react with the homologous SAg (SEC3).  
 
Analysis of L3 Vβ Regions for SEB Binding 
To examine L3 mutations responsible for the cross-reactivity with SEB, various 
mutants generated in the yeast display vector were studied for binding to SEC3 and SEB. 
Mutations in L3 originated from one of three sources; the template L2CM, mutations 
from mutant HV7 in the HV4 region, or mutations from mutant CD6 in the CDR1 region 
(Figure 2.2). Yeast displayed Vβs L3, L2CM, HV7, CD6, and G5-8 were incubated with 
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10nM biotinylated-SEB and 10nM biotinylated-SEC3 to study their ability to bind each 
SAg at 10 nM concentration (Figure 3.7). Mutants L2CM, L3, CD6, and HV7 that were 
selected for improved SEC3 binding, all bound SEC3 as seen by the positive peaks 
(Figure 3.7 left-hand column). The SEC3 binding results for the Vβ mutants confirmed 
previously observed and expected results based on original selections with SEC3. As also 
expected, from the in vitro and in vivo results (above), G5-8 did not show binding to 
SEC3, whereas binding to 10nM SEB was observed. The mutants L3 and HV7 were both 
able to bind SEB detectably while L2CM and mutant CD6 did not show detectable 
binding to SEB (Figure 3.7 right-hand column). Thus, one or more of the five mutations 
in the HV4 region of HV7 contributed to the enhanced binding to SEB. As discussed in 
Chapter 2, based on modeling using the crystal structure of L2CM in complex with 
SEC3, we believe that the Trp72 mutation in L3 may interact with Tyr90 in SEC3 (Figure 
2.6A). This residue (Y90) is also conserved in SEB providing a possible explanation for 
the improved interaction of the HV4 region of L3 and SEB (Figure 3.8A).  
Studies have identified the CDR2, and to a lesser extent the HV4 region, as the 
major sites of SAg binding, rather than the CDR1 region (39). However, it was somewhat 
surprising that CD6 did not show a positive peak for SEB binding, as the mutations in 
CD6 originated from G5-9, which binds SEB with similar affinity to G5-8 (low 
picomolar) and was also previously described by Buonpane et al. to bind to SEC3 (2.5 
nM) (55). The only difference between G5-8 and G5-9 is that G5-9 contains a single 
amino acid mutation in the CDR1 region, N30D. It is important to note that the CDR1 
region in G5-8, CD6, and L3 contain a single amino acid extension relative to the wild-
type Vβ between positions 29 and 30. This added residue lengthens the CDR1 loop, 
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likely positioning it in a more favorable contact distance as suggested by the structural 
and mutational analysis by Bonsor et al (301). Their study suggested that the CDR1 
region contributed to SEB binding due to the Tyr28 mutation (also found in L3 and HV7) 
and its pi-stacking interaction with Arg110 of SEB, as well as its hydrogen bonding to 
Asn60 of SEB (301). Residue Arg110 is found only in SEB and not in the SEC variants 
(Figure 3.1 yellow box), whereas Asn60 is found in SEB and all four SEC allelic variants 
(Figure 3.1 yellow box, and Figure 3.8B). As Asn60 is present in both SEB and SEC 
variants, the CDR1 Tyr28 residue in L3 may contribute to SEB binding in a similar 
manner as G5-8, but it was not of sufficient affinity to detect binding of CD6 to 10nM 
SEB.  
 
Residue 53 in Vβ Mutants L3 and G5-8 is a Key Residue for SEC3 and SEB Binding 
The CDR2 region has been identified as a key region of Vβ interaction with SEC3 
as well as SEB (300). Confirming the importance of the Vβ CDR2, Bonsor et al. 
identified mutation G53R in G5-8 as the most significant in contributing to the increased 
Vβ affinity to SEB, using a series of reversion mutants (301). Churchill et al. showed that 
Vβ residues 51-53 in the CDR2 region were important residues in binding to an SEC3 
variant through alanine scanning mutagenesis (300). Many of the same residues, 
specifically the CDR2 residues 51-53 have been identified in crystal structures as 
important in forming contacts between the Vβ and SAg (50,64). Recently, our lab 
showed that position 53 in the CDR2 region was a key amino acid in binding to both SEB 
and SEC, suggesting that the arginine in position 53 of G5-8 can interact favorably with 
Val26 of SEB, but that the Arg side chain is pointed in such a way that it would lead to a 
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steric clash with Tyr26 of SEC3 (255). This was supported by the finding that Arg53 
reverted back to the wild-type Gly in G5-8 (G5-8 R53G) was now able to bind to SEC3 
with an affinity of 35nM (Table 3.3) (255). However, the R53G mutation also reduced 
binding of G5-8 to SEB from 0.24nM to 7nM (255).  
The wild-type glycine residue at position 53 is retained in L3. Due to the large 
size difference between glycine and arginine, we hypothesized that another residue may 
accommodate improved binding to both SEB and SEC3 at this position. Therefore, 
various mutations at position Gly53 were made in the yeast displayed Vβ L3. The amino 
acids D, N, T, S, A, V, R, and H were selected to cover a spectrum of amino acid 
variability and mutated into position Gly53. The mutants were examined with 0.1nM, 
1nM, and 10nM SEB and SEC3. Mutants L3, L3-G53S, and L3-G53A bound SEC3 at all 
three concentrations, and L3 G53V and L3 G53R displayed potential binding in 
comparison to the other Vβ mutants and G5-8 (Figure 3.9A). In contrast, all of the 
mutants except for the charge revertant L3 G53D (compared to Arg53) showed binding 
to 10nM SEB (Figure 3.9B). I suggest that the presence of Y26 in SEC3 may limit the 
size of the side chain at position 53 of the Vβ that can be accommodated, thus limiting 
binding to the mutants G53S and G53A with smaller side chains. Yet, size may not be the 
only limiting characteristic in Vβ SEC interaction at position 53, as G53T which has only 
one additional methyl group than serine did not show binding to 10nM SEC3. SEB, in 
comparison to SEC3, accommodates more side chain diversity at position 53, consistent 
with the extra space available at this site, due the Val26 of SEB (compared to the Tyr26 
of SEC3). Importantly, of the mutations, the Arg53 appeared to bind the best, which may 
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indicate that arginine is forming similar interactions as G5-8 with SEB at this position, 
and explains why Arg53 was highly selected in the screens that yielded G5-8.  
To more fully examine the binding affinities of selected mutants, L3, G5-8, L3 
G53S, L3 G53A, L3 G53V, L3G53V, L3 G53H, and L3 G53R were titrated with a range 
of SEC3 concentrations (Figure 3.10). L3 bound with a BD50 ~3nM. Mutants L3 G53S, 
and G53A bound with an affinity of ~40nM, and mutant L3 G53R bound SEC3 with an 
affinity of ~50nM. As expected, L3 G53H, L3 G53T, L3 G53V, and G5-8 did not bind at 
any of the SEC3 concentrations. Although reduced in binding affinity, binding of L3 
G53R was surprising as arginine is a large and basic residue. Its binding may be 
accommodated by the flexibility of the loops or other entropic effects. L3 retaining the 
highest affinity binding among the mutants may indicate that the fluorescence based 
selection from the constructed libraries likely selected for the optimal residue at this 
position for binding to SEC3. 
 
G5-8 R53G Binding to SEC Can Be Improved By Adding HV4 Region Mutations of L3 
The HV4 region of L3 was identified as playing a role in L3 binding to both SEB 
and SEC3 (Figure 3.7 and discussed above). Since the HV4 region of G5-8 had not been 
engineered, the binding of this region was further explored by creating mutants in G5-8. 
The mutant G5-8/70-72 was created by incorporating L3 mutations P70L, S71T, and 
Q72W into G5-8. The mutant G5-8/70-74 was engineered by incorporating L3 mutations 
E73R and N74T to G5-8/70-72. Based on studies highlighting the importance of the 
CDR2 regions and the study by Wang et al. demonstrating that G5-8 R53G improved G5-
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8 binding to SEC3 (255), this single amino acid mutant was made as well as 
incorporating the mutation R53G to G5-8/70-74. 
Mutants were titrated with 0.1nM, 1nM, and 10nM SEC3 and SEB. Mutants G5-
8/70-72, and G5-8/70-74 showed no binding to SEC3 (Figure 3.11A). As expected, G5-8 
R53G bound SEC3, and the additional HV4 mutations of G5-8/70-74 R53G showed an 
additional improvement in binding (Figure 3.11A). All of the mutants bound detectably 
to SEB at 1nM and 10nM, showing higher levels of binding (MFU) than L3 (Figure 
3.11B). To further examine the binding affinities of the mutants that bound SEC3, the 
clones were titrated with a range of SEC3 concentrations. The G5-8 R53G mutant bound 
to SEC3 with a binding affinity of approximately 30nM (Figure 3.12). When the 
mutations from the HV4 region of L3 and the CDR2 region R53G mutation were 
combined (G5-8/70-74 R53G), the mutant was able to bind SEC3 with an improved 
affinity (2 nM) over the R53G mutation alone, and with an affinity similar to L3.  
In conclusion, I found that mutations in the HV4 region of the Vβ template L2CM 
contributed to improved SEC3 binding from 10nM in L2CM to 2nM in L3 (Chapter 2). 
These same HV4 region mutations also increased the binding affinity of G5-8 R53G from 
30nM to approximately 2nM (Figure 3.12). However, mutants G5-8/70-72 and G5-8/70-
74 did not bind SEC3 at the concentrations tested (Figure 3.11A and 3.12). These results 
suggest that mutation R53G has the greatest effect on SEC3 binding of G5-8, while the 
mutations in residues 70-74 increased binding by about an order of magnitude. Hence, 
the CDR2 loop and its binding to the SAg appears to be most important, while mutations 
in the surrounding loops such as HV4 further stabilize the Vβ and SAg interaction. 
Finally, the ability of G5-8/70-74 R53G to bind with the same affinity as L3 indicates 
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that the mutations that are not shared between G5-8 and L3, likely play a minimal role in 
SEC3 binding. These mutations include several in the CDR2 region as well as in the 
framework region. Furthermore, given the improved binding of G5-8/70-74 R53G to 
SEB, compared to L3 (Figure 3.11), it could be argued that G5-8/70-74 R53G would be 
the best candidate for a dual-neutralizing agent. 
 
SPR Binding Affinities of Vβs for SAgs SEB and SEC3 
 SPR analysis of Vβs L3, L2CM, G5-8, and G5-8 R53G were performed by our 
collaborator Eric Sundberg. The results of the SPR analysis are listed in Table 3.3. The 
results show that L3 is able to bind SEC3 at 2nM affinity and SEB at 4nM affinity. L3 
has ~4.5-fold improved off-rate in SEC3 binding versus SEB binding, while the on-rate 
for SEB binding is more than 2-fold improved over SEC3 binding. 
 
Discussion 
 The ideal antagonist will be capable of neutralizing multiple SAgs. The SEC 
allelic variants share over 90% sequence identity, and therefore it was not surprising that 
the high affinity Vβ L3 engineered for SEC3 binding cross-reacted with high affinity for 
the other three SEC variants. In contrast, SEB and the SEC variants share only about 65% 
sequence identity, and thus cross-reactivity of the Vβ agents, including L3, is less likely. 
Previous studies by our laboratory have shown that the SEB-directed high-affinity Vβ 
called G5-8 did not bind with high-affinity to SEC3, a result that I substantiated here 
through both in vitro and in vivo neutralization studies. As with G5-8, L3 was engineered 
from yeast display libraries selecting for increased binding to the single specific SAg 
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SEC3. However, unexpectedly L3 was shown to cross-react with high-affinity for both 
SEB and SEC3, as determined by in vitro binding and neutralization studies. The 
structural basis of the cross-reactivity by L3, or the lack of cross-reactivity in the case of 
G5-8, was further examined by a series of mutational studies. 
Analysis of various mutants of L3 indicated that the HV4 region was responsible 
in part for the cross-reactivity. Based on the crystal structures of G5-8 in complex with 
SEB and the L2CM in complex with SEC3, sequence aligned overlay models of the Vβs 
and SAgs were constructed. The backbones of the Vβ regions and the SAgs overlay 
almost indistinguishably, except for the disulfide loop of the SAgs (which was disordered 
in the crystal structure) and the CDR1 loop, which is one amino acid longer in G5-8 
(Figure 3.3). The W72 mutation in L3 was previously discussed (Chapter 2) as being 
positioned within range for aromatic stacking with Y90 of SEC3. This region of SEC3 
was well overlapped with SEB and importantly this same residue, Y90 is also present in 
SEB. Thus, I propose that the W72:Y90 interaction could contribute to the cross-
reactivity between L3 and SEB (Figure 3.1 and 3.8A). 
The importance of the HV4 region mutations in L3 to binding SEC3 were further 
confirmed through the analysis of various G5-8 mutants. The L3 HV4 mutations were 
introduced into G5-8 and, based on studies by Wang et al. from our laboratory, I also 
constructed G5-8 mutants with the R53G mutation (Wang et al had shown that this 
mutation enabled G5-8 binding to SEC3 with a KD value of 35nM affinity) (255). Yeast 
display titrations of these mutants showed that neither G5-8 alone nor G5-8 with the L3 
HV4 region mutations was able to detectably bind SEC3 at 100nM. In contrast, I verified 
that G5-8 with the R53G mutation bound with approximately 30nM binding affinity 
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(Figure 3.12 and Table 3.3). Interestingly, the G5-8 mutant with both the R53G mutation 
and the L3 HV4 region mutations bound SEC3 with improved affinity over G5-8 R53G, 
and comparable to yeast displayed L3 (KD value of about 2nM). This suggests that 
although the HV4 region mutations may improve affinity for SEC3, the affinity remains 
below the level to be detected with 100nM SEC3 by flow cytometry. G5-8 consists of 
wild-type residues in the HV4 region and therefore may have potential for further affinity 
improvement in this region.  
Due to the proximity of the CDR loops and HV4 loop to each other, there are also 
potential intramolecular interactions that likely contribute to stability of the mutants. 
Analysis of the G5-8 and SEB complex by Bonsor et al. showed that Tyr28 in the CDR1 
of G5-8 makes contacts with Asn60 and Arg110 of SEB (301). Although CDR1 residue 
Tyr28 is present in both G5-8 and L3, only Asn60 (but not Arg110) is identical in SEC3 
and SEB. As Asn60 in SEB was responsible for a majority of the increase in the complex 
buried surface area in the G5-8 structure (compared to the wild type Vβ8), Asn60 and 
surrounding residues which are also similar in SEB and SEC3, may also contribute to the 
cross-reactivity (Figure 3.8B). Finally, the L3 HV4 residue Trp72 is in proximity to 
interact, potentially, with Tyr28 in the CDR1 region through pi stacking (Figure 3.8B). I 
suggest that this interaction may contribute to stabilization of Tyr28 for binding to 
residue Asn60 in SEC3 and SEB. 
As previously discussed (Chapter 1), MRSA strains are increasing and there are 
few novel treatments. There are bacterial strains, such as MRSA strain USA400 MW2, 
that secrete both SEC and SEB (311). A single therapeutic that could neutralize both 
SAgs would be useful in treating strains that secrete either or both SAgs. L3, or possibly 
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the mutant G5-8/70-74 R53G, may serve as promising, single therapeutics for both, as 
both show very low nanomolar binding to each SAg. Alternatively, these could serve as 
starting point to engineer a cross-reactive Vβ with picomolar affinity to neutralize SEB 
and SEC. For example, it may be possible to focus only on libraries in the HV4 region 
and selection for both SEC and SEB binding. However, based on my results, Vβ position 
53 may play a role in limiting the affinity that can be reached for cross-reactivity for SEC 
and SEB. Nevertheless, the affinity of L3 and G5-8/70-74 R53G for both SEB and SEC 
are as good as most affinity matured antibodies, and it is possible this will be sufficient to 
provide effective neutralization in diseases caused by strains of S. aureus that secrete 
these toxins. 
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DMM, 10/20/10
SEC 1-4 vs SEB
SEC4 ESQPDPTPDELHKSSEFTGTMGNMKYLYDDHYVSATKVKSVDKFLAHDLI
SEC3 ------M-------------------------------------------
SEC2 --------------------------------------M-----------
SEC1 -------------A-K---L-E---V------------------------
SEB ------K--------K---L-E---V----NH---IN---I-Q--YF---
SEC4 YNISDKKLKNYDKVKTELLNEDLAKKYKDEVVDVYGSNYYVNCYFSSKDN
SEC3 --------------------------------------------------
SEC2 --------------------------------------------------
SEC1 ---------------------G----------------------------
SEB -S-K-T--G---N-RV-FK-KDL-D----KY---F-A---YQ----K-T-
SEC4 VGKVTGG---KTCMYGGITKHEGNHFDNGNLQNVLIRVYENKRNTISFEV
SEC3 --------------------------------------------------
SEC2 --------------------------------------------------
SEC1 --------------------------------------------------
SEB DINSHQTDKR-------V-N-N--QL-KYRSIT-RV--FE--K-LL--D-
SEC4 QTDKKSVTAQELDIKARNFLINKKNLYEFNSSPYETGYIKFIENNGNTFW
SEC3 ------------ -------------------------------------
SEC2 --------------------------------------------------
SEC1 --------------------------------------------------
SEB --N--M-------YLT-HY-VK--K-----N-------------E--S--
SEC4 YDMMPAPGDKFDQSKYLMMYNDNKTVDSKRVKIEVHLTTKNG
SEC3 -- ---------------------------S------------
SEC2 -- ---------------------------S------------
SEC1 -- ---------------------------S------------
SEB -- ----------------------M----D-----Y----K-
27 amino acid signal sequence not included above
1 1 0 2 0 2 7
SEC1 M N K S R F I S C V I L I F A L I L V L F T P N V L A
SEC3 M Y K R L F I S R V I L I F A L I L V I S T P N V L A
!" !#" $#" %#" &#" '#"
(#" )#" *#" +#" !##"
!!#" !$#" !%#" !&#" !'#"
!(#" !)#" !*#" !+#" $##"
$!#" $$#" $%#" $&#"
Figure 3.1  Protein sequences  of  superantigens  SEB and SEC 1-4 
allelic  variants.  Nucleotide  sequence of  SEC variants  1-4  and SEB. 
Nucleotides  that  differ  in  SEC 1-3  from SEC4 are  in  red  and  SEB 
nucleotides  that  differ  from  SEC4  are  in  light  blue.  Yellow  blocks 
highlight residues discussed in this chapter: Y26, N60, Y90, R110.!
Figures!
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Figure 3.3 Overlay model of V!s and superantigens SEC3 and SEB. 
Crystal structures of SEC3 (dark blue) in complex with L2CM (marine) 
and SEB (grey) in complex with G5-8 (cyan) were overlaid.  The V! 
regions that interact with the SAgs are colored as follows: G5-8 (yellow) 
and L2CM (orange) CDR1, G5-8 (red) and L2CM (magenta) CDR2, and 
G5-8  (green)  and  L2CM  (forest  green)  HV4.  RCSB  PDB  accession 
codes 2AQ3 and 3R8B."
Vβ G5-8"
Vβ L2CM"
SEC3"
SEB "
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Figure 3.4 The soluble high-affinity V! L3 neutralizes activity of all 
four SEC subtypes. Human PBMCs were incubated in the presence of 
0.01 !g/well SEC with varying concentrations of either (A) the V" L3 or 
(B)  pooled IVIG. L3 neutralized all four allelic subtypes of SEC in a 
dose-dependent manner. IVIG was able to neutralize SEC variants, but 
required more than 6-fold higher concentration than L3. Bars indicate 
level  of  lymphocyte  proliferation  as  counts  per  minute  (CPM)  by 
scintillation counting.  * indicates p < 0.005; #,  p < 0.05.  (Figure 3.4 
represents the work of collaborators Olivia Chuang-Smith and Patrick 
Schlievert).#
A!
B!
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Figure 3.5 LPS enhancement rabbit model of SAgs SEC3 and SEB 
treated  with  soluble  V!  G5-8.  New  Zealand  White  rabbits 
(approximately 2 kg each) were injected I.V. with 5ug/kg SEB or SEC 
or mixtures of V! G5-8 (100ug/kg) mixed with SAg (5ug/kg) (n=4 per 
group). (A) Fevers were measured at 0, 2, and 4 hours. (B) At the 4 hour 
time  point,  all  rabbits  were  given  intravenous  5ug/Kg  of  LPS from 
Salmonella typhimurium. This is 1/100 LD50 of LPS in rabbits. Survival 
of SEB+G5-8 versus each other group was significant with a p<0.05 by 
Fisher  Exact  Test.  (Figure  3.5  represents  the  work  of  collaborator 
Patrick Schlievert)."
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A! Vβ L3"
SEC3"
SEB"
W72!
V91!
Y91!
Q92!
N92!
Y89!
Y89!
N88!
N88!
Y90!
Y90!
B!
SEC3"
SEB"
Vβ L3" HV4!
CDR1!
W72!
Y90!
Y28! N60!
Figure  3.8  Model  of  L3  cross-reactivity  for  SEC3  and  SEB.  (A) 
Model of the L2CM structure with L3 substituted mutations in the HV4 
region, showing aromatic base stacking between L3:W72 and overlay of 
SEB/SEC3 Y90 that may be responsible for improved affinity of L3 as 
well as cross-reactivity with SEB. (B) Expansion of model in (A) with 
the addition of the CDR1 loop of G5-8 with L3 substituted mutation 
N30D in complex with SEB/SEC3. The overlay shows SEB/SEC3 N60 
that may interact with L3:Y28 contributing to the cross-reactivity of L3 
with  SEB.  Models  based  on  RCSB PDB accession  codes  2AQ3 and 
3R8B.!
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SEC Titration (8/3/12 geom)
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Figure 3.10 Titration of L3 mutants at position 53 with SEC3. L3 
bound with an estimated affinity of 3nM, while mutants L3 G53S, L3 
G53A, and L3G53R bound SEC3 by an estimated order of magnitude 
less than L3. Other mutants listed including G5-8 showed no binding to 
SEC3.!
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Figure 3.11 Binding to SEB and SEC3 of yeast displayed V!s with 
mutations at position 53. V! mutants were titrated with 0.1nM, 1nM, 
and 10nM (A) SEC3 and (B) SEB. All mutants were still able to bind 
SEB and had improved MFUs over L3. Only mutants containing the 
R53G mutation were able to bind SEC3."
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SEC Titration (7/26/12 geom)
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Figure 3.12 Titration of G5-8 mutants with SEC3. L3 and mutant 
G5-8: 70-74 R53G bound with an estimated affinity of 3nM. Mutant 
G5-8  R53G  bound  with  ~30nM  affinity.  Other  G5-8  mutants  with 
mutations in the HV4 region did not bind SEC3. !
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CHAPTER 4 
MD-2 MUTATIONAL STUDIES USING YEAST-DISPLAY 
 
Introduction 
Lipopolysaccharide (LPS), endotoxin, is found on the outer membrane of most 
gram-negative bacteria. LPS has three components: a lipid A, a core of polysaccharides, 
and an O-antigen (for a more in depth discussion refer to Chapter 1). The lipid A portion 
is recognized as the ‘toxic’ component of LPS, capable of potently stimulating the innate 
immune system. LPS is able to potently stimulate the innate immune system through 
interaction with Toll-like receptor 4 (TLR4) on the surface of antigen presenting cells 
(APCs) (5). TLR4 activation by LPS releases cytokines such as IL-1, IL-6 and TNF-α. 
While these cytokines activate the innate immune system to facilitate elimination of 
infectious agents, higher levels of gram-negative bacteria, especially systemically, can 
lead to widespread vasodilation, hypoperfusion, and myocardial dysfunction. These can 
result in an overwhelming hyper-inflammatory response known as systemic 
inflammatory response syndrome (SIRS), leading to septic shock. 
LPS is thought to be delivered to an APC subsequent to bacterial cell lysis and/or 
by removal from the bacteria surface by LPS-binding protein (LBP). LBP facilitates LPS 
delivery to CD14, which in turn allows LPS to associate with either myeloid 
differentiation factor 2 (MD-2) directly, or with the complex of MD-2 and TLR4 on the 
cell surface. MD-2 is a 160 amino acid glycoprotein that contains an N-terminal secretion 
signal; it consists of two beta sheets that form a deep hydrophobic cavity (6). Crystal 
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structures of MD-2 with LPS variants have aided in understanding how the two 
molecules interact. The LPS produced by bacteria vary not only in presence or absence of 
the O antigen, but may also vary in phosphate patterns, number of acyl chains, and lipid 
A composition (4). Lipid A and the phosphates of LPS are required for binding to MD-2 
and TLR4, but LPS is capable of binding to MD-2 without the O antigen (9). Only 
recently has the core oligosaccharide region been shown to play a role in MD-2 binding 
(10). MD-2 is able to accommodate five acyl chains of LPS in its hydrophobic cavity, 
leaving the phosphorylated glucosamine backbone of LPS extending from this pocket (7). 
The components CD14, MD-2, and TLR4 are all essential to LPS responsiveness, as 
mouse models lacking any of these three components result in mice hyporesponsive to 
LPS (8,312-314). MD-2 is essential for LPS-mediated activation of TLR4, as MD-2 
deficient mice are unable to respond to LPS (8). 
Although the molecular details of TLR4 activation are not completely understood, 
a crystal structure of the TLR4:MD-2:LPS complex has guided the present model (7). In 
one scenario, the MD-2:LPS complex binds to cell surface TLR4, which is thought to 
dimerize with a second TLR4, thus forming a dimer of trimers (TLR4:MD-2:LPS)2. As 
observed in other TLR structures, the two TLR4 molecules interact at the C-termini with 
the N-termini directed away from each other. The ternary crystal structure shows direct 
contacts between TLR4 and MD-2 and between TLR4 and LPS (7). Dimerization is 
thought to be required for signaling through the TIR domain, leading to activation of 
transcription factors such as nuclear factor κB (NF-κB), and the release of inflammatory 
molecules such as IL-1 and TNFα to recruit local immune defenses to destroy the 
microbial invaders (7,315-317).  
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The response of the innate immune system to the invading gram-negative bacteria 
must be robust to limit the infection, but must also be self-limited to avoid damage to the 
host. When the bacterial infection and hence the amount of endotoxin is large, or the 
immune response is uncontrolled, an exaggerated inflammatory response can lead to 
endotoxic shock. As MD-2 is a key protein required for LPS activation of TLR4, 
mutating MD-2 to modulate its binding to LPS and TLR4 is one strategy to reduce the 
effects of LPS-mediated toxicities. As noted above, mouse models have demonstrated 
that MD-2 is essential for LPS activation of TLR4, making it a suited target for 
modulation (8). Similar to the strategy I used for targeting S. aureus enterotoxin C (refer 
to Chapter 2), the generation of neutralizing agents might be accomplished by mutation 
of a soluble mutant of MD-2 that binds well to LPS, but not to TLR4. Such mutants could 
directly compete for the same binding sites as the host MD-2, but would not activate the 
system through TLR4. 
The potency of LPS in immune system activation makes it capable of 
incapacitation and lethality, and appears responsible for the involvement of LPS in 
multiple illnesses. While perhaps best known as a cause of endotoxic shock, in recent 
years, TLR4 activation by LPS has also been proposed to exacerbate other inflammatory 
conditions such as asthma (69). The detailed mechanisms in the latter process remains to 
be determined, but downstream effects likely involve activation of TH2 cells and 
subsequent production of IgE and allergy related inflammatory cytokines (70). Low 
levels of LPS have been shown to induce TH2 cells, while high levels of LPS induce TH1 
activation (71). The allergen Derp2 from the dust mite has been shown to be structurally 
homologous to MD-2 and to bind to LPS, suggesting that it may act as a ligand in both 
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the innate and adaptive systems (72,73). Thus, further understanding of MD-2 may also 
assist in modulation of MD-2 for treatment of some allergen reactions.  
In our studies, I used a system that allows more rapid analysis of the role of 
specific MD-2 residues in ligand binding. Accordingly, I displayed human MD-2 on the 
surface of yeast, and showed that the displayed protein could bind to MD-2-specific 
monoclonal antibodies (mAbs) and to its ligands, LPS and TLR4. Guided by the structure 
of MD-2 in complex with LPS and TLR4, I generated various alanine mutants to examine 
the role of specific residues in ligand binding. I also generated several libraries of 
mutants that allowed me to use ligand selections to identify key residues and to isolate 
MD-2 mutants improved in either stability (i.e. surface levels) or ligand binding.  
 
 Materials and Methods  
Yeast Display Mutant Cloning 
The gene for MD-2 was synthesized by Genscript and sub-cloned into the yeast 
display vector pCT302 by Adam Chervin, PhD, which contains an N-terminal 
Hemagluttinin (HA) tag and a C-terminal Myc (c-myc) tag, using restriction sites NheI 
and XhoI (275). Mutants of MD-2 were engineered by site directed mutagenesis using 
QuickChange as described by the manufacturer (Stratagene, La Jolla, CA). The following 
mutants were constructed: L54A, F119A, F121A, I124A, F126A, F131A, C95A, D100A, 
D101A, C105A and E92V/S118P. Primers used are listed in Tables 4.1 and 4.2. The 
E92V and S118P mutations were cloned individually into MD-2 and primers used are 
listed in Table 4.4. After verifying mutations by sequencing, plasmids were transformed 
into EBY100 cells and grown in SD-CAA selective media. Expression of the Aga2p 
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fusion was induced by growth of yeast cells in medium containing galactose at 20°C for 
32-48 hours. 
 
Analysis of Yeast Surface Displayed MD-2 with Antibodies 4H1 and 18H10 
Expression of Aga2p fusions on yeast was induced by growth in medium 
containing galactose at 20°C for 32-48 hours. After induction, yeast were stained with 
anti-c-myc mAb 9E10 at 1:100 dilution (Invitrogen) or anti-HA mAb HA.11 at 1:50 
dilution (Covance). The anti-HA stained cells were stained with secondary goat-anti-
mouse antibody at 1:200 dilution (Invitrogen) and the anti-c-myc stained cells were 
stained with secondary goat-anti-chicken at 1:100 dilution (Invitrogen). C-myc and HA 
tag expression were used to estimate surface expression of clones. After induction, the 
surface displayed MD-2 was also analyzed using two anti-MD2 monoclonal antibodies 
(mAbs). Yeast cells (1x106) were incubated with mAb 4H1 at 1:200 dilution (Hycult 
biotech) or mAb 18H10 at 1:100 dilution (Hycult biotech) for one hour on ice. Cells were 
washed with 200ul Phosphate Buffer Saline + 0.5% Bovine Serum Albumin 
(PBS+0.5%BSA) followed by goat anti-mouse Alexafluor 647 (GaM647) at 1:200 
dilution (Invitrogen) on ice for one hour. Cells were washed and analyzed on an Accuri 
C6 flow cytometer.  
 
Human CD14 and TLR4 Protein Construction, Expression, and Purification 
The human soluble CD14 was cloned, expressed, and purified by Stacy Kelley of 
the Tapping Laboratory, as previously described (318). Diana Ranoa of the Tapping 
Laboratory generated the soluble human TLR4 extracellular domain by following the 
	   139	  
hybrid LRR technique first described by Kim et al. 2007 and adopted by Guan et al. 2010 
(267,319). 
 
Binding of Yeast Displayed MD-2 and Mutants to Biotin-LPS and TLR4 
Yeast cells with the Aga2p fusion were induced in medium containing galactose 
at 20°C for 32-48 hours. After 10 minutes of vigorous vortexing, 100nM biotin-LPS 
(biotinylated ultra-pure LPS-EB, InvivoGen; LPS concentration was based on a formula 
weight of biotin-LPS of approximately 10,000) was incubated at a 1:3 molar ratio with 
human CD14 in a 37°C water bath for one hour. Biotin-LPS/CD14 was then added at 
various concentrations to 1x106 yeast cells and incubated at 37°C for one hour. Cells 
were washed and incubated with SA-Alexafluor647 (SA647). After washing, cells were 
analyzed on an Accuri C6 flow cytometer. 
To detect TLR4 binding, 1x106 yeast cells were incubated with various 
concentrations of flag-tagged TLR4, and after washing with PBS+0.5%BSA, the cells 
were incubated with anti-human TLR4 mAb HTA-125 at a 1:200 dilution (eBioscience). 
After one hour on ice, cells were washed and incubated with GaM647. After washing, 
cells were analyzed on an Accuri C6 flow cytometer. Due to its similar size and unrelated 
functionality, yeast displayed protein L3 (discussed in Chapters 2 and 3), was used as a 
negative control in all experiments with MD-2 and MD-2 mutants. 
 
Yeast Display Library Engineering 
Seven libraries of mutants were made in the human pCT302:D101A mutant. One 
library consisted of error-prone PCR-based mutations and six libraries consisted of site-
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directed mutants constructed in the LPS binding region of MD-2. These latter six libraries 
were constructed by site-directed mutagenesis using overlapping degenerate primers 
(with NNS codons) in the following groups of either four residues of MD-2: (S118-F121) 
and (S118/S120/K122/G123), or three residues of MD-2: (L54/G56/K57), (F119-F121), 
(G123/I124/F126), (Y131-C133). The error prone library was generated by amplifying 
the gene MD-2:D101A from the pCT302:D101A plasmid using flanking primers with a 
method of error-prone PCR to give a 0.5% error rate (320). The vector pCT302:scSurv 
was digested with NheI/BglII and run on a 1% agarose gel to separate the plasmid from 
the unrelated insert gene Survivin. The plasmid pCT302 was excised and gel purified. 
The PCR products were transformed along with the NheI/BglII digested plasmid pCT302 
into the yeast strain EBY100 (275), which inserts the PCR product into the plasmid by 
homologous recombination (277,278). The resulting three-codon libraries contained 
between 2.4x106 and 3.3x106 independent transformants. The resulting four-codon library 
MD-2:S118-F121 contained 6.4x105 independent transformants and the other four-codon 
library MD-2:S118/S120/K122/G123 contained 8.5x105 independent transformants. The 
libraries were cultured in selective media (SD-CAA) for 48 hours. Ten clones from each 
library were sequenced to ensure the presence of the expected diversity (sequences not 
shown). 
 
Selection of Vβ Mutant Libraries by Fluorescence-Activated Cell Sorting (FACS) 
Aga2p fusions were induced by growth of yeast cells in medium containing 
galactose at 20°C for 32-48 hours. After induction, yeast-displayed MD-2 proteins were 
selected by FACS on a BD FACS Aria II high-speed cell sorter or analyzed by flow 
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cytometry. Yeast cell libraries (approximately 1x108 cells) were selected using an 
equilibrium based methodology. The LPS libraries were incubated with the described 
concentration of biotin-LPS/CD14 at 37°C, washed, and then incubated with SA647. 
Following each sort, the cells were grown in selective SD-CAA media, and then induced. 
Each of the LPS sorts collected the top 1% of cells. The 1st sort selected with 500nM 
biotin-LPS/CD14, the 2nd sort with 100nM biotin-LPS/CD14, and the 3rd through 5th sorts 
with 10nM biotin-LPS/CD14. Cells from the 5th sorts were plated and grown on selective 
media and 10 clones from each of the 5th sorts sequenced. 
The four-codon library of residues (S118/S120/K122/G123) was sorted a second 
time selecting clones for binding to TLR4. The cells were incubated with the following 
described concentration of TLR4 on ice, washed, incubated with HTA-125, washed, 
incubated with GaM647, washed, and selected by FACS. For the 1st sort, the cells were 
stained with 125nM TLR4 and the top 1% of cells collected, 125nM TLR4 for the 2nd sort 
and the top 0.5% of cells collected, 62.5nM TLR4 for the 3rd sort and the top 0.1% of 
cells collected, 12.5nM of TLR4 for the 4th sort and the top 0.2% of cells collected, and 
12.5nM TLR4 for the 5th and final sort and the top 0.4% of cells collected. Cells from the 
4th and 5th sorts were plated and grown on selective media and sequenced. Clones from all 
of the libraries were analyzed for equilibrium binding to biotin-LPS/CD14 and TLR4. C-
myc and HA tag expression were used to estimate surface expression of clones. Cells 
were analyzed on a BD Accuri C6 flow cytometer. 
 
Results 
Yeast Display Expression and Detection of MD-2 
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To determine whether the yeast display system could be used to examine various 
features of the MD-2 protein, the human MD-2 gene was cloned as an Aga-2 fusion into 
yeast display vector pCT302 (275). Expression of the full-length Aga-2/MD-2 fusion on 
the surface of yeast, as well as a control fusion L3 (discussed in Chapters 2 and 3) that 
contains a T cell receptor Vb domain of similar size to MD-2, (321) was confirmed by 
screening with antibodies for the HA tag at the N-terminus and c-myc tag at the C-
terminus of the protein (Figure 4.1A). To detect the MD-2 protein itself, yeast cells were 
stained with two monoclonal antibodies (mAbs) to human MD-2, 4H1 and 18H10. Both 
mAbs 4H1 and 18H10 bound to the MD-2 fusion on the yeast surface, but not to the L3 
fusion (Figure 4.1B). These results confirm that MD-2 is expressed on the surface and 
they suggest that a substantial fraction of it is folded properly.  
 
Binding of Yeast Displayed MD-2 to LPS  
To examine if LPS binding to yeast-displayed MD-2 could be detected, yeast cells 
were incubated with biotin-LPS. Since CD14 has been shown to facilitate binding of LPS 
to MD-2, I conducted experiments with both the preincubated biotin-LPS/CD14 complex 
and biotin-LPS alone (Figure 4.2A and B). The biotin-LPS demonstrated a positive peak 
(solid line open histogram) in comparison to secondary reagent only (grey filled 
histogram) (Figure 4.2A). The biotin-LPS also showed a minor degree of nonspecific 
binding to the negative control yeast (L3) as seen as a shoulder (dotted line) (Figure 
4.2A). However, this weakly positive shoulder (L3) was eliminated in the presence of the 
preincubated biotin-LPS/CD14 complex (Figure 4.2B dotted line), while the complex 
mixture retained binding to yeast-displayed MD-2 (Figure 4.2B solid line). This result is 
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consistent with the possibility that aggregated LPS, more abundant in the absence of 
CD14, yielded some background association with the yeast. To avoid this, subsequent 
experiments were performed using biotin-LPS preincubated with CD14.  
In order to estimate the approximate affinity of the measured interaction between 
MD-2 and LPS, various concentrations of biotin-LPS/CD14 were incubated with MD-2 
and then examined by flow cytometry. The mean fluorescence units (MFU) for 
histograms were determined at each concentration of LPS, and the background MFU was 
subtracted from these values. In order to estimate the equilibrium binding affinity, the 
concentration of LPS was determined by assuming an average molecular weight of 
10,000gm/mol. Using this approach, the yeast-displayed MD-2 was estimated to bind to 
the biotin-LPS/CD14 with a KD value of 90 nM (Figure 4.2C). This estimate of affinity is 
similar to the KD value of 65 nM described by Kirkland and colleagues for a soluble form 
of MD-2 (322). 
 
Binding of Yeast Displayed MD-2 to TLR4 
To examine if yeast-displayed MD-2 binding to TLR4 could be detected, a TLR4-
extracellular domain-Fc fusion protein was expressed, purified, and the Fc tag removed, 
followed by another round of purification to yield soluble monomeric TLR4-extracellular 
domain (TLR4). Although TLR4 was purified as a monomer, it is possible that the 
monomer preparations may retain divalent forms and consequently the affinity 
calculations are estimates. After titration with various concentrations of TLR4, the TLR4-
specific antibody HTA-125 was used to detect TLR4 binding. The TLR4 demonstrated a 
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positive peak (solid line open histogram) in comparison to the negative control yeast L3 
(dotted line) and the secondary reagent only (grey filled histogram) (Figure 4.3A).  
To estimate the approximate affinity of MD-2 and TLR4, various concentrations 
of TLR4 were incubated with MD-2 and then examined by flow cytometry. The MFU for 
histograms was determined as described above for LPS. The concentration of TLR4 was 
determined by assuming an average molecular weight of 80,000gm/mol. Using this 
method, the yeast-displayed MD-2 was estimated to bind to TLR4 with a KD value of 
100nM (Figure 4.3B). This estimate of affinity is within an order of magnitude of the 
affinity measured by Golenbock and colleagues for soluble MD-2, with an apparent KD 
for TLR4 of 12nM (323). 
 
Ligand Binding Analysis of Yeast-Displayed Alanine Mutants of MD-2 
Several studies have suggested that MD-2 residues in the region F119 to K132 are 
important for LPS binding to MD-2 (324-326). In addition, this region has been shown to 
be in contact with an LPS ligand present in the crystal structure of the MD-2 complex 
((7), Figure 4.4). To examine if the MD-2/yeast display system could be used as a 
platform to more rapidly examine the role of MD-2 residues in ligand binding, various 
MD-2 residues were mutated to alanine: L54A, F119A, F121A, I124A, F126A, and 
Y131A ((7,326,327), Figure 4.4). Each of the mutants was titrated with various 
concentrations of the biotin-LPS/CD14 complex. Such titrations can yield two flow 
cytometry parameters that provide information about the mutant. First, the maximum 
MFU at the highest ligand concentrations can be an indicator of the stability of the 
protein (i.e. higher yeast surface levels are correlated with greater stability of the protein 
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or mutant) (282,283). Second, the concentration of ligand that yields 50% maximal 
binding is correlated with the equilibrium binding affinity (35,328).  
Based on the titrations with LPS, mutants F126A and Y131A showed no 
difference in stability (maximum level of surface display, MFU) or affinity, relative to 
MD-2 (Figure 4.5). In contrast, the two mutants F121A and F119A showed the most 
significant impact on both surface levels and apparent affinity for LPS (Figure 4.5). 
Mutants I124A and L54A showed an intermediate impact on LPS binding, in terms of 
both stability and apparent affinity (Figure 4.5). Consistent with these results, mutants 
F119A and F121A (327), and the double mutant F121A/K122A (324), have been 
reported to reduce LPS binding activity mediated by MD-2. This previous study showed 
that double mutant Y131A/K132A was unable to bind to LPS, although the single-site 
mutant K132A (the single-site Y131A mutant was not tested) was able to partially bind 
LPS (324). Although residues L54, I124, F126, and Y131 were proposed to contribute 
hydrophobic bonds with LPS acyl chains (7), the results here may indicate these 
interactions with LPS play less of a role in stability and affinity of MD-2 in comparison 
to F121 and F119. Both F119 and F121 are located at the opening of the MD-2 pocket 
that LPS inserts into (Figure 4.4), and therefore these residues appear to have more 
potential to impact the interaction with LPS; in contrast, Y131, F126, I124, and L54 are 
located deeper inside of the MD-2 pocket, limiting their potential interactions to a smaller 
region of LPS. In the case of F126 and Y131, this interaction is limited to the tails of the 
LPS lipid chains. 
Another region of the MD-2 molecule, involving residues C95, D100, D101, and 
C105 has been proposed to impact TLR4 binding, but not association with LPS (325). To 
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determine if I could verify and extend these observations by analysis of yeast-displayed 
MD-2, the single-site mutants C95A, D100A, D101A, and C105A were generated. 
Initially, binding of the four mutants was tested at 1000nM TLR4 (Figure 4.7A) and 
100nM biotin-LPS/CD14 (Figure 4.6B). Binding to TLR4 was reduced in all four of the 
mutants (Figure 4.6A). Binding to LPS was also significantly reduced in C95A and 
C105A, but only partially reduced in D100A and D101A (Figure 4.6B). The reduced 
binding to the cysteine mutants was expected, since these residues form a disulfide bond 
in the protein. Hence, reduced binding to LPS and TLR4 in both of these mutants is likely 
due to misfolding of the protein. Mutants D100A and D101A were then titrated with each 
ligand and showed reduced binding to TLR4 (Figure 4.7A), but their binding to LPS 
remained the same as the wild type MD-2 (Figure 4.7B). The observation that maximum 
surface levels were shown to be the same with LPS provided further evidence that these 
two mutants were expressed properly and thus the reduction in TLR4 binding was indeed 
due to a loss of important contacts. 
 
Use of Yeast Display Libraries for Analysis and Engineering of LPS Binding 
To further understand the role that particular residues play in MD-2 function, I 
went beyond single-site alanine mutations and engineered libraries of mutants that would 
contain every amino acid at several positions. Six libraries consisted of site-directed 
mutants constructed in the LPS binding region of MD-2, adjacent to the key residues 
identified from the alanine mutants. These six libraries were constructed by site-directed 
mutagenesis using overlapping degenerate primers (with NNS codons) in the following 
groups of either four residues of MD-2: S118/S120/K122/G123 (called LPS-I library) 
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and S118/F119/S120/F121 (called LPS-II library), or three residues of MD-2: L54/G56/S 
57, F119/S120/F121, G123/I124/F126, and Y131/K132/C133 (Figure 4.8-4.10). The four 
three-codon libraries were pooled (and called LPS-III) prior to selection with a ligand. In 
addition, a random mutagenic library (LPS-EP) generated by error-prone PCR (with a 
0.5% error rate) was also generated in order to determine if any improved LPS-binding 
mutants could be isolated without regard to the specific residues identified by site-
specific analysis. The above libraries were sorted with biotin-LPS/CD14 to isolate 
mutants that retained, or had improved, binding to the ligand. Since this approach focused 
on the interaction of MD-2 with LPS, the D101A mutant, which showed wild-type 
binding affinity for LPS (Figure 4.7B) was used as the template. 
The four-codon libraries, the pooled three-codon library, and the error prone 
library were each subjected to FACS through five successive sorts and the top 1% of cells 
binding to biotin-LPS/CD14 was selected. The first sort of the error-prone and each of 
the two four-codon libraries each sorted 1x108 cells, while 5x107 cells of each of the 
three-codon libraries were combined and sorted together. The selecting concentrations 
were: 500nM biotin-LPS/CD14 for the 1st sort, 100nM for the 2nd sort, and 10nM for the 
3rd through 5th sorts. After the final sort, cells were plated and ten colonies from each 
library were analyzed for binding to biotin-LPS/CD14 and sequenced. Three unique 
mutants from the LPS-I library, two unique mutants from the LPS-II library, three unique 
mutants from the LPS-III library, and three unique mutants from the LPS-EP library were 
identified among these clones (Figure 4.11).  
Stringent selection of yeast display libraries with ligands is an approach to 
identify those residues within a library that represent key contacts or that can compensate 
	   148	  
for other mutations (255). To examine if any mutants from our libraries could 
compensate for the decreased binding of mutation MD-2/D101A to TLR4, the LPS-I 
library (S118/S120/K122/G123) was subjected to FACS through five successive sorts 
with the following concentrations of TLR4: 125nM TLR4 for the 1st and 2nd sorts, 
62.5nM TLR4 for the 3rd sort, and 12.5nM TLR4 for the 4th and 5th sorts. The 4th and 5th 
sorts were plated and eight clones from the 4th sort and 10 clones from the 5th sort were 
sequenced. The 4th sort contained six unique mutants, and the 5th sort a single unique 
mutant (TLR4-selected), that was also identified in the 4th sort (Figure 4.11).  
 
Preliminary LPS Binding Analysis of LPS Sorted Library-Derived Mutants 
The three unique error-prone mutants, the three unique LPS-I 
(S118/S120/K122/G123) library mutants, the two unique LPS-II library mutants, and the 
two full-length LPS-III library mutants were tested for binding to biotin-LPS/CD14 at 
three concentrations (Figure 4.12). All mutants except for LPS-III library mutants 
showed improved mean fluorescence over MD-2. The two unique full-length mutants 
identified from LPS-III library showed no difference in total MFU relative to MD-2 
(Figure 4.12D). The lack of consensus between sequences, the lack of improvement in 
fluorescence, and selection of truncated sequences may indicate that the LPS-III library 
mutants were not preferred over the wild-type residues present in MD-2. For these 
reasons, the three codon LPS-III library mutants are not further discussed in the ligand 
binding analysis. 
 
Binding of Library-Derived Mutants to LPS and TLR4  
	   149	  
Representatives of each of the mutants from the biotin-LPS/CD14 and TLR4 
selected libraries were examined for binding to both LPS and TLR4. To verify that these 
mutants could bind biotin-LPS/CD14 and TLR4, they were titrated with biotin-
LPS/CD14 and TLR4 (Figure 4.13). As discussed above, these titrations provide two 
parameters of interest, the maximum MFU at the highest ligand concentrations as an 
indicator of the stability of the protein (282,283) and the concentration of ligand that 
yields 50% maximal binding as an indicator of the equilibrium binding affinity (35,328).  
In comparison to MD-2, the mutants did not differ significantly in their binding 
affinities for biotin-LPS/CD14, with the exception of the TLR4-selected mutant 
(T84N/D101A/S118A/S120D/K122P) (Figure 4.13A). This mutant did not reach 
saturation levels of binding to biotin-LPS/CD14, suggesting that it may have a reduced 
binding affinity relative to MD-2. However, the maximum MFU and hence stability of all 
the mutants was improved over MD-2 regardless of the ligand used for selection. The 
relative improvements in stability, confirmed using both the biotin-LPS/CD14 and TLR4 
ligands, appeared to correspond to the origin of the library that yielded the mutants: LPS-
EP mutants had the most improved stability, followed by LPS-II, and then LPS-I mutants 
(Figure 4.13).  
The TLR4-selected mutant showed the most significant increase in yeast surface 
display, with a 3-fold higher MFU than the next highest group of mutants, from the LPS-
EP library (Figure 4.13B). The large improvement in maximum MFU with minimal 
changes in binding affinity suggested that improvements in protein stability are likely 
responsible for the selection of these mutants. Nevertheless, the retention in binding to 
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each of the ligands verifies that these mutants have selected residues that maintain, or 
possibly improve, the requisite contacts. 
 
Sequences of Library-Derived Mutants 
The sequences of selected mutants revealed the amino acid positions within the 
libraries had either maintained the wild-type residues or evolved toward highly restricted 
side chains. From the ten sequenced mutants of library LPS-I there were three unique 
sequences (Figure 4.11). Six of the ten contained the mutations 
S118P/S120R/K122P/G123K, two of the ten contained the same mutations except the 
glycine at position 123 was mutated to an arginine (G123R), and two of the ten contained 
an S120K mutation rather than the S120R mutation (S118P/S120K/K122P/G123R).  
The LPS-II library yielded one clone of ten that contained the mutations 
S118P/F119Y/S120V, along with the wild-type residue F121. The other nine clones 
contained the mutations S33Y/S118P/F121W along with the wild-type residues F119 and 
S120 (Figure 4.11). The LPS-III library yielded three unique mutants. Three mutants 
contained the mutations L54R/G56N/S57P (Figure 4.11). Two other mutants contained 
mutations Y131F/K132L/C133P and mutation S118P. Mutation S118P may have been 
introduced from a replication error in the F119-F121 library or from contamination from 
another library. A single mutant had a premature stop codon at position 123 and 
contained the mutations F121L/K122N. Four other clones contained frame-shift 
mutations or early stop codons resulting in poorly expressed mutants as seen by HA and 
c-myc staining (data not shown). Four clones were selected from the fourth sort to 
determine if the frame-shift or truncations were carried through the sorting process. Of 
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the four clones analyzed, none of them contained truncations and none of the four shared 
the same mutations (data not shown). The error-prone library LPS-EP yielded three 
unique clones, all containing the mutations S118P and E92V. Seven of the ten sequenced 
clones contained only these two mutations (Figure 4.11). Two clones also contained 
mutation H155R and one clone also contained mutations V113I and L146F. 
Although the LPS selected clones retained some wild-type residues in the 
degenerate library positions, there were clearly strong preferences for certain mutations at 
other positions. For example, all of the LPS-selected clones contained the S118P 
mutation (Figure 4.11). Other LPS-selected mutations that predominated among clones 
included the LPS-EP mutation E92V and the LPS-I mutation K122P. In addition, all of 
the clones in the LPS-I library preferentially selected a positive-charged residue at 
position 120 (S120R or S120K) and position 123 (G123K or G123R). The LPS-II library 
had less improvement in stability than either the LPS-EP or LPS-I libraries, and showed 
preference for either wild-type residues at positions F119 and F121, or a large 
hydrophobic residue (Figure 4.11). These are the same residues that when mutated to 
alanine had decreased stability and affinity to biotin-LPS/CD14 (Figure 4.5), suggesting 
that the wild-type phenylalanine or a similarly large hydrophobic residue, such as 
tyrosine or tryptophan, is preferred at these locations.  
In comparison to LPS-selected mutants, the TLR4-selected mutant showed both 
similarities and a distinct pattern of residue selection. All of the TLR4-selected clones 
contained the mutation K122P, which was also present in all clones from the same library 
(LPS-I) selected with biotin-LPS/CD14. Although the S118P mutation present in all LPS-
selected mutants was not selected in the 5th and final sort of the TLR4-selected mutant, it 
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was present in four of the six clones from the 4th sort. Most strikingly, there was a strong 
preference for negative-charged residues in positions S120 and G123 in the TLR4-
selected clones. This preference is in contrast to the LPS-selected mutants that contained 
positive-charged residues at these two positions (Figure 4.11). 
 
Role of Selected Mutations in Yeast Display Surface Levels and Ligand Binding 
To examine the influence of several selected mutations on surface display and 
binding, I generated the individual mutants S118P and E92V, and the double mutant, in 
the wild-type MD-2, without the D101A mutation. All of the mutants had increased 
maximum MFU in biotin-LPS/CD14 and TLR4 binding relative to MD-2, although the 
E92V mutation yielded a lower level of increase (Figure 4.14). The maximum MFU as 
determined with biotin-LPS/CD14 and TLR4 for the double mutant E92V/S118P was 
improved compared to either mutation individually, indicating these acted synergistically. 
The predominant effect of these mutations was on surface stability and I was unable to 
determine if there was a significant impact on binding affinities.  
 
Discussion 
In studies to date, MD-2 has been examined by selective mutagenesis using 
predominantly single-site alanine mutations at several residues, followed by expression 
and purification of the soluble mutants. In order to develop a more rapid, higher 
throughput system for analysis of MD-2, I used yeast display of the human MD-2 as a 
fusion protein. This system allowed me to survey the contribution of residues in single 
positions, or a group of residues, to ligand binding. I engineered MD-2 mutants from 
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degenerate libraries by random mutagenesis throughout the protein and in selected 
regions of MD-2 predicted to be involved in ligand binding, targeting primarily the F119-
K132 loop (324-326). The results provided insight into the role of specific residues in 
MD-2 stability and ligand binding, and they showed that yeast-displayed MD-2 could 
serve as a system for further engineering. 
Proline mutations at positions S118 and K122 suggested that these conferred 
stability to the protein, or to that region of the protein. The strong preference for these 
prolines was also indicated by the observation that different degenerate codons for 
proline were present among the clones isolated from the various libraries. The S118 
residue is present at the start of a loop in MD-2 that connects two beta sheets and is 
located at the opening of the MD-2 pocket where the LPS acyl chains enter (Figure 4.15). 
The position is adjacent to the loop region (F119-K132) identified by previous studies as 
important for interactions with LPS (324-326). The wild-type serine at this position forms 
a hydrogen bond with one of the phosphate groups of LPS based on the crystal structure 
(7). Although proline at this position eliminates this potential interaction, it likely 
decreases the conformational entropy within this region and this could lead to an increase 
in the stability of the protein (329). The proline substitutions at positions S118 and K122 
could increase the rigidity in and around the LPS-binding loop (F119-K132), and may 
position the other selected residues such as S120R and G123R to engage the ligands more 
effectively (Figure 4.16).  
In addition to the proline mutations S118P and K122P in the LPS-selected library 
(S118/S120/K122/G123), all mutants contained positive-charged residues at the nearby 
residues, S120R/K and G123K/R. I propose that positive charges at positions 120 and 
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123 promotes a charge interaction with the negative-charged LPS phosphate groups 
(Figure 4.16). The lysine at position 122 of the wild-type MD-2 may serve a similar role, 
but the proline mutation at this position could provide a strong requirement that either 
lysine or arginine be present at the adjacent position 123 in order to compensate. It is also 
worth noting that the lysine or arginine at position 123 could potentially form a hydrogen 
bond with the Ser415 of TLR4 (Figure 4.16). 
It was striking that while a positive charged residue was predominant at position 
120 with LPS-selection, a negative charged residue was predominant at position 120 
(S120D) when the library was selected with TLR4 (Figure 4.11). Furthermore, position 
123 in the TLR4-selected clones either retained the wild-type glycine, or they also 
contained a negative-charged residue (as opposed to the positive charge observed with 
LPS-selection). Lee et al have shown that the backbone of G123 forms a hydrogen bond 
with TLR4 (7), consistent with the retention of glycine in most of the mutants. However, 
it is difficult to predict how the negative charged mutations operate to improve the 
binding to TLR4. The distinct LPS-binding curve of this mutant (TLR4selected in Figure 
4.13) may indicate that the negative charged side chains reduce the binding to LPS, as 
might be predicted due to repulsion of the phosphate groups in LPS.  
It is also of interest that residues F119 and F121 were highly restricted to wild-
type or conserved (Tyr or Trp) residues, indicating a strong preference for aromatic 
residues. I suggest that the hydrophobic, space-filling properties of these side chains 
facilitates the creating of a pocket for insertion of the hydrophobic LPS acyl chains. Two 
other mutations, S118P and E92V, identified using an error prone library, appear to 
operate primarily by stabilizing the protein on the surface of yeast. Such single-site 
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mutations have been observed using random mutagenesis approaches in other proteins 
engineered by yeast display. While the mechanistic basis of their stabilizing effects are 
often not clear, the mutations can be of use in expressing the protein at higher levels in 
secretion systems (283).   
In summary, I show that it is possible to express MD-2 on the surface of yeast, 
allowing the more rapid analysis of single-site mutants. Through both alanine single-site 
mutagenesis and library approaches, the system allowed me to determine the critical role 
of aromatic residues at position 119 (F119) and position 121 (F121) for LPS binding. In 
addition the selection of prolines at several positions (118 and 122) stabilized the protein, 
and opposite charged mutations at positions 120 and 123 provided a ‘toggle’ that yielded 
improved binding to LPS or TLR4. Finally, there is the possibility that mutants with 
increased affinity for LPS and decreased affinity for TLR4 (or vice versa) could be 
potentially used as ‘dominant negative’ inhibitors of the LPS reactions. Accordingly, 
directed evolution of MD-2 using yeast display may be of further use in developing such 
MD-2 reagents. 
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Figure 4.2 Yeast displayed MD-2 binds to biotin-LPS & CD14 reduces 
nonspecific biotin-LPS signal. (A) Histogram of biotin-LPS binding to 
yeast displayed MD-2 (solid line) and negative control L3 (dotted line) 
relative  to  secondary only  background (grey filled histogram).  (B)  The 
nonspecific  negative  control  signal  is  reduced  when  biotin-LPS  is 
incubated with CD14 prior  to titration with yeast  displayed MD-2.  (C) 
Biotin-LPS was incubated with CD14 after which, MD-2 was titrated with 
the biotin-LPS/CD14 complex. The MFU for histograms were determined 
at each concentration of LPS, and the background MFU was subtracted 
from these values. This MFU was plotted against concentration of biotin-
LPS/CD14 to generate the binding curve. Insets of histograms at indicated 
concentrations are shown. The error bars represent SEM. (n=3)!
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Figure 4.2 (cont.) Yeast displayed MD-2 binds to biotin-LPS & CD14 
reduces  nonspecific  biotin-LPS  signal.  (A)  Histogram  of  biotin-LPS 
binding  to  yeast  displayed  MD-2  (solid  line)  and  negative  control  L3 
(dotted line) relative to secondary only background (grey filled histogram). 
(B) The nonspecific negative control signal is reduced when biotin-LPS is 
incubated with CD14 prior  to titration with yeast  displayed MD-2.  (C) 
Biotin-LPS was incubated with CD14 after which, MD-2 was titrated with 
the biotin-LPS/CD14 complex. The MFU for histograms were determined 
at each concentration of LPS, and the background MFU was subtracted 
from these values. This MFU was plotted against concentration of biotin-
LPS/CD14 to generate the binding curve. Insets of histograms at indicated 
concentrations are shown. The error bars represent SEM. (n=3)!
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Figure  4.3  Yeast  displayed  MD-2  binds  to  TLR4.  (A)  Histogram of 
TLR4 binding to yeast displayed MD-2 (solid line) and negative control L3 
(dotted line) relative to secondary only background (grey filled histogram). 
(B)  Yeast  displayed  MD-2  was  titrated  with  TLR4.  The  MFU  for 
histograms  were  determined  at  each  concentration  of  TLR4,  and  the 
background MFU was subtracted from these values. This MFU was plotted 
against the concentration of TLR4 to generate the binding curve. Insets of 
histograms at indicated concentrations are shown. The error bars represent 
SEM. (n=3)!
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Figure 4.4 MD-2 crystal structure and alanine mutants. Structure of 
LPS (yellow) binding to MD-2 (red) and TLR4 (green). Selected residues 
are shown in blue in MD-2 and magenta in TLR4. Alanine mutants that 
were engineered are shown in blue and listed. Residues used in library 
engineering are also listed. Structure based on RCSB PDB accession code 
3FXI.!
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Figure 4.5 Yeast displayed MD-2 alanine mutants. (A) Yeast displayed 
MD-2 and MD-2 alanine mutants were titrated with biotin-LPS after CD14 
incubation. Mutations Y131A and F126A show no change in stability or 
binding affinity relative to MD-2, whereas F121A and F119A show the 
greatest  changes  (n=1 per  mutant,  experiment  was  repeated at  different 
concentrations and showed the same trends for all mutants). MFU=Mean 
Fluorescence Units. !
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Figure  4.7  MD-2  alanine  mutants  D100A and  D101A.  (A)  MD-2, 
D100A, and D101A were titrated with TLR4 and (B) biotin-LPS/CD14. 
Mutants D100A and D101A show reduced binding affinity to TLR4 and 
retain  binding affinity  and stability  to  biotin-LPS/CD14.  The error  bars 
represent SEM. MFU=Mean Fluorescence Units. The error bars represent 
SEM (n=2 per mutant). !
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Figure  4.9  Residues  selected  in  each  of  the  three  codon  libraries 
constructed. The three residue libraries that were pooled prior to FACS are 
shown above. MD-2 is shown in red, LPS in yellow, and TLR4 in green. 
The  residues  selected  for  mutation  are  shown  in  blue.  When  possible, 
residues  were  labeled  for  clarity.  Underlined  residues  indicate  alanine 
mutant  residues.  Crystal  structure  based on RCSB PDB accession code 
3FXI.!
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Figure 4.10 Pre-soe and soe products. Construction of the error-prone 
library and six libraries with site-directed mutagenesis. Top panel shows 
pre-soe products containing overlapping primers and the 0.5% error-prone 
constructed library. Expected sizes of products are listed to the right of the 
gel. The lower panel indicates the soe products of the 6 libraries and all at 
the  appropriate  size  of  957  bp.  0.8% agarose  gels.  NT= No  Template 
negative control. Kb=Kilobases. Bp=base pairs.!
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Figure 4.12 Library clone preliminary analysis. Unique sequences from 
each  of  the  libraries  were  analyzed  for  binding  to  biotin-LPS/CD14 at 
three different concentration 100 (solid black), 20 (diagonal fill), and 4nM 
(white) for A and B. 50 (solid black), 15 (diagonal fill), and 5nM (white) 
for C and D. The error bars represent SEM (n=2 per group).!
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Figure  4.12  (cont.)  Library  clone  preliminary  analysis.  Unique 
sequences from each of the libraries were analyzed for binding to biotin-
LPS/CD14 at three different concentration 100 (solid black), 20 (diagonal 
fill), and 4nM (white) for A and B. 50 (solid black), 15 (diagonal fill), and 
5nM (white) for C and D. The error bars represent SEM (n=2 per group).!
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Figure 4.13 Clone analysis for biotin-LPS/CD14 and TLR4 binding. 
(A) Clones were titrated with biotin-LPS/CD14, and (B) also titrated with 
TLR4. Stability was most improved in LPS-EP mutants, followed by LPS-
II, and least for LPS-I mutants in biotin-LPS/CD14 studies in comparison 
to MD-2, with a similar trend for TLR4 studies with the exception of the 
TLR4 selected mutant showing the greatest improvement. Mutant LPS-EP-
a (E92V/D101A/S118P) had the most  improved stability  in  biotin-LPS/
CD14 studies, while mutant TLR4 selected (T84N/D101A/S118A/S120D/
K122P) showed the greatest improvements in stability in TLR4 studies. 
There was no significant differences in binding affinity from MD-2, except 
for  TLR4  selected  binding  to  biotin-LPS/CD14.  (n=1  per  mutant 
experiment was repeated at different concentrations and showed the same 
trends). !
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Figure  4.13  (cont.)  Clone  analysis  for  biotin-LPS/CD14  and  TLR4 
binding.  (A)  Clones  were  titrated  with  biotin-LPS/CD14,  and  (B)  also 
titrated  with  TLR4.  Stability  was  most  improved  in  LPS-EP mutants, 
followed  by  LPS-II,  and  least  for  LPS-I  mutants  in  biotin-LPS/CD14 
studies in comparison to MD-2, with a similar trend for TLR4 studies with 
the  exception  of  the  TLR4  selected  mutant  showing  the  greatest 
improvement.  Mutant  LPS-EP-a  (E92V/D101A/S118P)  had  the  most 
improved  stability  in  biotin-LPS/CD14  studies,  while  mutant  TLR4 
selected  (T84N/D101A/S118A/S120D/K122P)  showed  the  greatest 
improvements  in  stability  in  TLR4  studies.  There  was  no  significant 
differences  in  binding  affinity  from  MD-2,  except  for  TLR4  selected 
binding to biotin-LPS/CD14. (n=1 per mutant experiment was repeated at 
different concentrations and showed the same trends). !
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Figure  4.14  Select  clone  analysis  for  biotin-LPS/CD14  and  TLR4 
binding.  (A)  Clones  E92V,  S118P,  and  E92V/S118P were  titrated  with 
biotin-LPS/CD14, and (B) also titrated with TLR4. The maximum MFU as 
determined with biotin-LPS/CD14 and TLR4 for the double mutant E92V/
S118P was improved compared to either mutation individually. Error bars 
represent SEM (n=2 per group). !
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MD-2 mutant E92V/A101D/S118P!
Figure 4.15 Model of MD-2 clone EP-3:A101D binding LPS. Top-down 
model of LPS (yellow) binding to MD-2 error-prone library mutant E92V/
A101D/S118P  (red).  The  mutation  D101A was  introduced  into  MD-2 
before  construction  of  of  the  library.  Selected  mutations  from  sorting, 
E92V  and  S118P,  are  shown  in  blue.  Model  based  on  RCSB  PDB 
accession code 3FXI.!
S118P!
A101D!
E92V!
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